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Cancer remains a global epidemic, with millions affected by the Non-Communicable Disease 
(NCD) annually. While cisplatin and its platinum(II) derivatives remain widely used 
chemotherapeutic agents, the undesirable side effects associated with the use of these 
metallodrugs and the evolution of resistance by cancers limit the scope of use of these 
platinum(II) complexes. Working towards addressing these issues, research has focused on 
the development of chemotherapeutic agents based on alternate platinum-group metals 
(PGMs), with ruthenium metallodrugs being among the most successful in this category. The 
combination of pharmacophores onto dendritic scaffolds and the combination of these 
scaffolds with PGMs, yielding multinuclear organometallic complexes is a strategy that has 
been widely used in rational drug design. However, there is limited research into multinuclear 
ruthenium compounds, specifically trimetallic ruthenium compounds. With this in mind, the 
purpose of this study was to synthesize and characterize a series of 2,5-disubstituted 
benzimidazole-based trimeric compounds and related trinuclear complexes bearing 
ruthenium(II) metal centers at the periphery. All of the synthesized compounds were 
screened for their in vitro cytotoxicity against the MCF-7 and MDA-MB-231 breast cancer cell 
lines and the 501 melanoma cell line. 
A series of 2,5-disubstituted benzimidazole trimeric ligands were prepared from the cyclo-
condensation reaction of trimeric o-phenylenediamines with either benzaldehyde or  
2-pyridinecarboxaldehyde. Complexation of these 2,5-disubstituted tris-benzimidazole 
ligands with [RuCl(µ-Cl)(p-cymene)]2 afforded the respective trinuclear neutral C^N-chelated 
and cationic N^N-chelated ruthenium(II) complexes. In addition to this, a series of  
2-ferrocenyl benzimidazole trimeric compounds were synthesized as non-planar bioisosteres 
of the 2-aryl 5-substituted benzimidazole trimeric ligands. All of the synthesized compounds 
were fully characterized using an array of spectroscopic (1H, 13C{1H}, 31P{1H} and 19F{1H} NMR, 
FT-IR spectroscopy) and analytical (mass spectrometry and elemental analysis) techniques.  
Preliminary cytotoxic screening of all of the synthesized compounds against the MCF-7 breast 
adenocarcinoma cell line was done. This preliminary investigation revealed that the 2-pyridyl 





trimeric ligands and the corresponding trinuclear cationic complexes show superior activity 
relative to their respective 2-phenyl trimeric ligand counterparts and the corresponding 
neutral cyclometallated complexes. Consequently, the 2-pyridyl tris-benzimidazole ligands 
and their corresponding cationic complexes were selected for cytotoxic evaluation against 
additional cancer cell lines (the MDA-MB-231 breast cancer and the 501mel cancer cell lines). 
Overall, a 2-pyridyl tris-benzimidazole ligand and two trimetallic cationic complexes showed 
anticancer activity either comparable or superior to that of cisplatin against the  
MCF-7 breast cancer cell line (IC50 ≤ 35 µM). Additionally, a 2-pyridyl trimeric benzimidazole 
ligand and a trimetallic cationic N^N-ruthenium(II) complex showed mild activity against the 
MDA-MB-231 and 501mel cancer cell lines, respectively (IC50 < 35 µM in both cell lines). 
Selectivity studies based on the non-tumorigenic MCF-12A breast epithelial cell line indicated 
that selected compounds had low cytotoxicity towards non-tumorigenic cells and showed 
enhanced selectivity towards the MCF-7 cancerous cells relative to cisplatin. Solvent stability 
studies of the cationic N^N-ruthenium(II) complexes show that these compounds are stable 
in DMSO for 48 hours under physiological conditions. Additionally, preliminary mechanistic 
studies of the most active complex indicate that the complex does not interact with guanosine  
5’-monophosphate (5’-GMP), suggesting that this complex elicits cytotoxicity via an 
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A2780 Human ovarian cancer cells  
A2780cisR Cisplatin-resistant Human ovarian cancer cells  
ATP Adenosine triphosphate  
ATR Attenuated total reflection 
br s Broad singlet 
cisplatin cis-dichloridodiammineplatinum(II) 
COSY Homonuclear correlation spectroscopy 
CSC Cancer stem cell 
d Doublet 
DCM  Dichloromethane 
DMF Dimethylformamide 
DMSO (d6) Deuterated dimethylsulfoxide 
DNA Deoxyribonucleic acid 
EPR Enhanced permeability and retention 
eq. Equivalent 
ESI-MS Electrospray ionization mass spectrometry  
EtOAc Ethyl acetate 
EtOH Ethanol 
FT-IR Fourier-transform infrared spectroscopy 
HCT116 Human colorectal cancer cells  
HeLa Human cervical cancer cells  





HepG2 Human liver cancer cells  
HMBC Heteronuclear multiple-bond correlation spectroscopy 
HMLER Human breast cancer stem cells 
HPLC High-performance liquid chromatography  
h Hours 
HSQC Heteronuclear single-quantum correlation spectroscopy 
IC50 50% cell viability concentration 
J Coupling constant 
LNCap Human prostate cancer cells  
m Multiplet 
MCF-12A Human breast epithelial cells 
MCF-7 Human breast adenocarcinoma cells 





MP Melting point 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium 
bromide 
NAMI-A New anti-tumour metastasis inhibitor 
NMR  Nuclear magnetic resonance  
PC3 Human epithelial teratocarcinoma cells  
PDT Photodynamic therapy 
Pet. Ether Petroleum ether 
PGM Platinum group metal 
ppm Parts per million 
PT Proton transfer 
PTA 1,3,5-triaza-7-phospaadamantane 
RAED Ruthenium arene ethylenediamine 
RAPTA Ruthenium arene PTA 
VIII 
 
ROS Reactive oxygen species 
RT Room temperature 
s Singlet (NMR), Strong (IR) 
S.I. Selectivity index 
sept. Septet 
t Triplet 
TFA Trifluoroacetic acid 
TLC Thin layer chromatography 
TMS Tetramethylsilane 
TNBC Triple negative breast cancer  
tR Retention time (minutes) 
v/v% Volume percentage  
WHCO1 Human oesophageal cancer cells  








Conference/ Symposia Contributions ………………………………………………….……………………………III 
Abstract …………………………………….……………………………………………………………………………………IV 
Abbreviations, Symbols and Units …………………………………………………………………………………..VI 
Chapter 1 
Advances in the development of multinuclear organometallic complexes as anticancer 
agents 
1.1 Introduction ......................................................................................................................... 1 
       1.1.1 Cancer Prevalence and Mortality ............................................................................... 1 
       1.1.2 Cell cycle and the Biology of Cancer ........................................................................... 1 
       1.1.3 Cancer therapies ......................................................................................................... 2 
       1.1.4 Chemoresistance ......................................................................................................... 4 
1.2 Benzimidazoles .................................................................................................................... 5 
       1.2.1 Chemical Structure ...................................................................................................... 5 
       1.2.2 Anticancer activity ...................................................................................................... 5 
1.3 Metals in medicine ............................................................................................................... 7 
       1.3.1 Platinum-based anticancer complexes ....................................................................... 7 
       1.3.2 Ruthenium(III) anticancer agents ............................................................................. 10 
       1.3.3 Ruthenium(II) anticancer agents .............................................................................. 12 
1.4 Transition-metal based benzimidazoles ............................................................................ 15 
       1.4.1 Benzimidazole-based anticancer agents .................................................................. 15 
1.5 Multinuclear Organometallic Anticancer Agents .............................................................. 16 
 
 
1.6 Trinuclear Ruthenium Arene Complexes as Anticancer Agents ............................... 19 
1.7 Rationale for the Current Study ................................................................................ 22 
1.8 Aims and Objectives .................................................................................................. 23 
       1.8.1 General aims ...................................................................................................... 23 
       1.8.2 Specific Objectives ..................................................................................................... 23 
1.9 References ................................................................................................................. 25 
Chapter 2 
Synthesis and characterization of tris(2-aminoethyl)amine-based 
2,5-disubstituted benzimidazoles 
2.1 Introduction ....................................................................................................................... 31 
2.2 Synthesis of 2,5-disubstituted tris-benzimidazole compounds (7 – 15) and their   
       corresponding intermediates ............................................................................................ 32 
   2.2.1  The synthesis of tris-nitrobenzenes (1 – 3) .................................................................. 34 
          2.2.1.1 Synthesis …………………………………………………………….…………………………………………34 
        2.2.1.2 Characterization ................................................................................................... 36 
2.2.2 The synthesis of tris-1,2-benzenediamines (4 – 6) ......................................................... 37 
       2.2.2.1 Synthesis ................................................................................................................ 37 
       2.2.2.2 Characterization .................................................................................................... 38 
   2.2.3 Synthesis of 2,5-disubstituted tris-benzimidazoles (7 – 15) ........................................ 39 
       2.2.3.1 Synthesis ................................................................................................................ 39 
       2.2.3.2 Characterization .................................................................................................... 42 
2.3 Synthesis of the monomeric 2-pyridylbenzimidazole ligand (18) ..................................... 48 
       2.3.1 Synthesis ................................................................................................................... 48 
       2.3.2 Characterization ....................................................................................................... 49 
2.4 Summary ............................................................................................................................ 51 




Synthesis and characterization of neutral C^N-Ru(II) and cationic N^N-Ru(II) trimetallic 
complexes  
3.1 Introduction ....................................................................................................................... 55 
3.2 Synthesis of the neutral cyclometallated trimetallic C^N-Ruthenium(II)-p-cymene   
           complexes (19 – 21) ....................................................................................................... 57 
       3.2.1 Synthesis ................................................................................................................... 57 
       3.2.2 Characterization ....................................................................................................... 59 
3.3 Synthesis of the cationic trimetallic N^N-Ruthenium(II)-p-cymene 
        complexes (22 – 24) ...................................................................................................... ….63 
       3.3.1 Synthesis ................................................................................................................... 63 
       3.3.2 Characterization ....................................................................................................... 64 
3.4 Synthesis of the cationic mononuclear N^N-Ruthenium(II)-p-cymene complex (25)…….67 
       3.4.1 Synthesis ................................................................................................................... 67 
       3.4.2 Characterization ....................................................................................................... 67 
3.5 Summary ............................................................................................................................ 69 
3.6 References ......................................................................................................................... 69 
Chapter 4 
In vitro biological evaluation of trinuclear ruthenium(II)-p-cymene complexes of  
2,5-disubstituted benzimidazole-based trimeric ligands  
4.1 Introduction ....................................................................................................................... 73 
4.2 In vitro single dose pre-screen ........................................................................................... 76 
       4.2.1 In vitro cytotoxicity of the 2,5-disubstituted trimeric ligands  (7 – 12) and their  
               trinuclear Ru(II) complexes (19 – 24) in the MCF-7 breast cancer cell line ................ 77 
       4.2.2 In vitro pre-screen of the anticancer activity of 2-ferrocenyl tris-benzimidazole  
                compounds (13 – 15) in the MCF-7 breast cancer cell line ........................................ 80 
 
 
       4.2.3 In vitro pre-screen of the cytotoxicity of the 2-pyridyl trimeric ligands (10 – 12) and 
                the cationic complexes (22 – 24) against the MDA-MB-231 cell line ........................ 83 
       4.2.4 In vitro cytotoxic evaluation of the 2-pyridyl trimeric ligands (10 - 11) and the 
                cationic Ru(II) complexes (22 – 23) in the 501 melanoma cells ................................ 84 
4.3 In vitro multidose screening .............................................................................................. 86 
       4.3.1 IC50 concentrations obtained in MCF-7 breast cancer cells ...................................... 86 
       4.3.2 IC50 concentrations obtained in MDA-MB-231 TNBC cells ....................................... 88 
       4.3.3 Cytotoxic evaluation of the 5-trifluoromethyl 2-pyridyl ligand (11) and complex (23)  
                 against the 501mel cell line ...................................................................................... 90 
4.4 In vitro cytotoxicity studies ................................................................................................ 91 
4.5 Solution stability and mechanistic insights ........................................................................ 93 
       4.5.1 Solvent stability......................................................................................................... 94 
       4.5.2 Mechanistic insight: 5’-GMP binding ........................................................................ 95 
4.6 Summary ............................................................................................................................ 96 
4.7 References ......................................................................................................................... 98 
Chapter 5 
Conclusions and future outlook 
5.1 Overall Summary and Conclusions .................................................................................. 103 
5.2 Future Outlook ................................................................................................................. 105 
       5.2.1 Mechanistic Studies ................................................................................................ 105 
       5.2.2 Structural Alterations to Enhance Biological Activity ............................................. 106 
5.3 References ....................................................................................................................... 108 
Chapter 6 
Experimental 
6.1 General Details ................................................................................................................. 109 
6.2 The General Procedure for the Synthesis of Tris-nitrobenzenes (1 – 3) ......................... 110 
 
 
       6.2.1 The synthesis of N1-(2-nitrophenyl)-N2,N2-bis(2-((2nitrophenyl)amino)ethyl)ethane- 
                1,2 -diamine2 (1) ...................................................................................................... 110 
       6.2.2 Synthesis of N1-(2-nitro-4-(trifluoromethyl)phenyl)-N2,N2-bis(2-((2-nitro-4- 
                (trifluoromethyl)phenyl)amino)ethyl)ethane-1,2-diamine (2) ................................ 111 
       6.2.3 The synthesis of N1-(4-methyl-2-nitrophenyl)-N2,N2-bis(2-((4-methyl-2- 
                nitrophenyl)amino)ethyl)ethane-1,2-diamine (3) ................................................... 111 
6.3 The Synthesis of the Tris-1,2-benzenediamines (4 – 6) ................................................... 112 
       6.3.1 Synthesis of N1-(2-(bis(2-((2-aminophenyl)amino)ethyl)amino)ethyl)benzene-1,2- 
                diamine2 (4) ............................................................................................................. 112 
       6.3.2 The synthesis of N1-(2-(bis(2-((2-amino-4- 
               (trifluoromethyl)phenyl)amino)ethyl)amino)ethyl)-4-(trifluoromethyl)benzene-1,2 
              -diamine (5) ........................................................................................................... ….113 
       6.3.3 Synthesis of N1-(2-(bis(2-((2-amino-4-methylphenyl)amino)ethyl)amino)ethyl)-4 
                -methylbenzene-1,2-diamine (6) ............................................................................. 114 
6.4 The General Synthetic Procedure for the 2,5-Disubstituted Benzimidazole-Based Trimeric 
       Ligands (7 – 12) ................................................................................................................ 114 
       6.4.1 Synthesis of tris(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl)amine (7) ............... 115 
       6.4.2 Synthesis of tris(2-(2-phenyl-5-(trifluoromethyl)-1H-benzo[d]imidazol-1- 
                 yl)ethyl)amine (8).................................................................................................... 116 
       6.4.3 Synthesis of tris(2-(5-methyl-2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl) 
                 amine (9) ............................................................................................................. ….117 
       6.4.4 Synthesis of tris(2-(2-(pyridin-2-yl)-1H-benzo[d]imidazol-1-yl)ethyl)amine (10) ….118 
       6.4.5 Synthesis of tris(2-(2-(pyridin-2-yl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-1- 
               yl)ethyl)amine (11) ................................................................................................... 119 
6.4.6 Synthesis of tris(2-(5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazol-1-yl)ethyl) 
         amine (12) ...................................................................................................................... 120 
6.5 The General Synthesis of the  2-ferrocenyl Tris-benzimidazole compounds (13 – 15) ... 121 
 
 
       6.5.1 The synthesis of tris(2-(2-ferrocenyl-1H-benzo[d]imidazol-1-yl)ethyl) 
              amine (13) ............................................................................................................. ….121 
       6.5.2 Synthesis of tris(2-(2-ferrocenyl-5-(trifluoromethyl)-1H-benzo[d]imidazol-1- 
                 yl)ethyl)amine (14) ................................................................................................. 122 
       6.5.3 Synthesis of tris(2-(5-methyl-2-ferrocenyl-1H-benzo[d]imidazol-1-yl)ethyl) 
                  amine (15) .............................................................................................................. 123 
6.6 The synthesis of N-ethyl-2-nitroaniline3 (16) ................................................................... 124 
6.7 Synthesis of N1-ethylbenzene-1,2-diamine3 (17) ............................................................. 124 
6.8 The synthesis of 1-ethyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole4 (18) ............................ 125 
6.9 The Synthesis of the cyclometallated C,N-Ru(II)-p-cymene metal  
       complexes (19 – 21) ..................................................................................................... ….126 
       6.9.1 Synthesis of cyclometallated Ru(II)-p-cymene metal complex (19) ........................ 126 
       6.9.2 Synthesis of the trifluoromethyl substituted Ru(II) cyclometallated 
               complex (20) ......................................................................................................... ….127 
       6.9.3 Synthesis of the methyl substituted Ru(II) cyclometallated complex (21) .............. 128 
6.10 General synthetic procedure for the cationic N,N-Ru(II)-p-cymene metal  
         complexes (22 – 24) ………………………………………………………………………………………..………129 
       6.10.1 Synthesis of the cationic N,N-Ru(II)-p-cymene metal complex (22) ..................... 130 
       6.10.3 Synthesis of the cationic N,N-Ru(II)-p-cymene metal complex (23) ..................... 131   
        6.10.2 Synthesis of the cationic N,N-Ru(II)-p-cymene metal complex (24) .................... 132 
       6.10.4 Mononuclear cationic N,N-Ru(II)-p-cymene complex (25) .................................. 133 
6.11 Single crystal X-ray Crystallography ............................................................................... 134 
6.12 Cell culture ..................................................................................................................... 134 
6.13 Cytotoxicity studies ........................................................................................................ 135 
6.14 Solution Stability and 5’-GMP Binding Study ................................................................. 135 








Chapter 1                                                          Literature Review  
 
 
1.1 Introduction  
1.1.1 Cancer prevalence and mortality  
Cancer remains one of the major causes of death both in developed and developing countries, 
including South Africa. The non-contagious disease affects approximately 600 000 people and 
accounts for approximately 41 000 deaths annually in South Africa alone.1,2 The term cancer 
is used to describe a large group of diseases that affect any part of the body. The main defining 
characteristic of cancer is the abrupt evolution of abnormal cells which overgrow and may 
spread to other organs using either the lymphatic or bloodstream systems.3 Due to cancer 
being one of the leading causes of mortality globally,4 a thorough understanding of its biology 
is of utmost importance for effective drug development.   
1.1.2 Cell cycle and the biology of cancer  
Cancer cells are a result of an accumulation of mutations of various genes that control cell 
proliferation, thus, allowing the cancerous cell to grow, divide, and become increasingly 
independent of controls that maintain normal cells.5 These mutated cells divide and replicate 
faster than their non-cancerous counterparts and congregate to form a tumour; which can 
either be benign or malignant. Benign tumours are tumours which are localised within tissue 
boundaries, and they are the easiest to treat. On the other hand, malignant tumours comprise 
of cancerous cells that can migrate from the primary tumour, via either the lymphatic or the 
bloodstream systems, to other parts of the body or organs (called secondary sites) to form 
secondary tumours.6,7 This process of migration is termed metastasis (Figure 1.1)7 and is the 
most fearsome aspect of cancer, as majority of cancer-related mortalities are due to 
To God Be The Gl ory  
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metastatic cancer cells which may be resistant to conventional therapies. There are several 
conventional therapies that have been developed to manage and treat cancer, these include 
radiation therapy, immunotherapy, surgery and chemotherapy. However, each cancer 
therapy option is accompanied by several specific side effects which may range in severity 
from slight headaches to nephrotoxicity.8 
 
1.1.3 Cancer therapies   
In the early stages of cancer, the disease can be treated by one or more therapies, including 
surgery, radiotherapy or systemic chemotherapy. Surgery and radiotherapy are the primary 
therapies used to treat cancers that are localized in tissue (benign tumours).9 To reduce the 
chances of the development of recurring localized tumours and the development of 
secondary tumours, these primary therapies are used in tandem with cytotoxic 
chemotherapeutic agents.9,10 This is when chemotherapy is applied in combination with 
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surgery or radiotherapy as either an adjuvant (chemotherapy used after curative surgery) or 
a neoadjuvant (chemotherapy used as treatment before planned curative surgery).10 
In the unfortunate case of the tumour advancing to its metastatic stage, combination 
chemotherapy is the recommended treatment. This is whereby several agents from different 
chemotherapy classes are used in combination (Figure 1.2). The main rationale behind this 
treatment is that the combined chemotherapy drugs have differing mechanisms of action and  
dose-limiting toxicities, which allow for additive anticancer effects with minimal toxic side 
effects.  
Chemotherapeutic agents may be cell cycle-specific (such as anti-tumour antibiotics) or cell 
cycle non-specific (such as alkylating agents), as shown in Figure 1.2; but they all induce 
apoptosis by damaging DNA and/or preventing mitotic division.11 The currently available 
chemotherapeutic agents, however, entail considerable adverse effects, with the most 
common immediate side effects being myelosuppression (bone marrow suppression),  
hair loss, and chemotherapy-induced-nausea and vomiting (CINV).12 These undesirable side 
effects arise from the non-selective killing of rapidly growing cells by chemotherapeutic 
 agents.9–11  
These therapies do not always provide a curative treatment for cancer, as tumours often 
develop resistance to chemotherapy through a combination of mechanisms. This  
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chemoresistance is the main reason for the failure in the treatment and management of 
cancer.  
1.1.4 Chemoresistance  
Despite chemotherapy being an important treatment option, and the several classes of 
chemotherapeutic agents available, chemotherapeutic agents frequently miscue slow-
dividing and non-dividing cancer cells.13 Although these pharmacological factors may 
contribute to the development of chemoresistance, cellular factors play a major role in 
chemoresistance.14 Resistance to chemotherapy, or chemoresistance, accounts for 
approximately 90% of drug failures in the treatment of metastatic cancers.15 
Chemoresistance is multifactorial and is caused by multiple interconnected or independent 
mechanisms.13–15 Chemoresistance manifests itself in two primary forms; acquired resistance 
and intrinsic (natural) resistance. In both cases, cancer cells tend to show resistance to 
numerous chemotherapeutic agents from different classes. The main mechanisms for 
chemoresistance can be grouped into three main categories: 
• Decrease of chemotherapeutic drug concentration at the target cancer cells, due to 
the activation of transporter proteins and/or detoxifying agents (such as the activation 
of ATP-dependant transporter domains on cancer cell membranes). 
• Alterations affecting the drug-target interactions (such as the altering of the structure 
of DNA polymerase in cancer cells). 
• Factors influencing cellular response that affect tumour cell survival (such as the 
upregulation of DNA repair mechanisms in cancer cells).14 
Chemoresistance remains a major challenge in the treatment of metastatic cancers. The 
benzimidazole pharmacophore is extensively investigated for its potential as an anticancer 
agent and researcher’s interests in this pharmacophore are further cultivated by the 





Chapter 1                                                          Literature Review  
1.2 Benzimidazoles  
1.2.1 Chemical structure   
The benzimidazole ring system has been of interest to researchers since the 1950s when it 
was established that 5,6-dimethyl-1-(α-D-ribofuranosyl) benzimidazole is an integral part of 
the vitamin B12 structure.16 This spawned interest and extensive studies on the benzimidazole 
core as a potential therapeutic agent.  
A benzimidazole is a heterocyclic aromatic ring system formed by the fusion of a benzene ring 
onto the 4- and 5-positions of an imidazole ring (Figure 1.3).17 Studies have shown that 
modifications of the 2- and 5-position of the benzimidazole scaffold yields a number of 
biologically active compounds. 16 
The prevalence of the benzimidazole core in biologically active molecules has stimulated 
systematic investigations of this class of heterocyclic compounds. It is well established in 
literature that benzimidazole derivatives show an array of biological activity, including 
antiviral, antihistaminic, antiparasitic, antimalarial and anticancer activity.18 Due to their vast 
medicinal value, research into benzimidazole-based compounds as potential anticancer 
agents is an active and attractive field in medicinal chemistry. 
1.2.2 Anticancer activity  
Despite improvements in chemotherapy treatments, the development of resistance remains 
a major hurdle in the treatment of cancer. The success of clinically approved benzimidazole 
derivatives, such as omeprazole, lansoprazole and albendazole, has resulted in increased 
interest into the medicinal use of benzimidazoles as chemotherapeutic agents.19 
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In a study, Wu et al.19 assayed a series of benzimidazole-2-substituted phenyl or pyridine 
propyl ketenes for their in vitro antiproliferative activity against the colon cancer (HCT116), 
breast cancer (MCF-7) and liver cancer (HepG2) cell lines. It was observed that the 
antiproliferative activities of compounds 1 and 2  (Figure 1.4) were in the ranges of  0.06 – 
1.53 µM and 0.04  – 9.80 µM, respectively, against all the tested cancer  cell lines. This activity 
is significantly better than that of 5-fluorouracil (IC50 = 56.96 – 174.50 µM) and close to the 
anticancer activity of carboplatin (IC50 = 0.026 – 1.53 µM). Furthermore, it was shown that 
these compounds also inhibit tumour growth in BALB/c mice with HCT116 colon carcinoma.19  
In a more recent study, Sun and co-workers20 conducted a structure-activity relationship 
study on novel water-soluble benzimidazole carbamates. All the compounds synthesized in 
the study were screened for in vitro anticancer activity at 1 and 10 µM concentrations against 
the non-small cell lung cancer (A549) and prostate cancer cell lines (PC3 and PC3MLN4). The 
study led to the identification of a novel oxetane-containing benzimidazole derivative (Figure 
1.5), which shows potent cytotoxic activity in the range 23.19 – 50.19 µM in the tested 
concentrations across the assayed cell lines.20 
The evaluation of benzimidazole derivatives for their anticancer activity is an ever-growing 
field in medicinal chemistry. This field continues to show great promise in addressing the 
 
Figure 1.5: The novel oxetane-containing benzimidazole derivative potential lead identified by Sun and 
co-workers.20 
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looming threat of chemoresistance. However, another strategy that may be useful in 
combating chemoresistance is the investigation of organometallic complexes.   
1.3 Metals in medicine  
Metal-based drugs have played a pivotal role in the diverse history of medicine, especially as  
anti-infective agents.21 The main concept in the rational design of organometallic drug 
candidates is the use of the metal-organic drug synergism; through binding a potentially 
pharmacologically active organic compound to a metal center.22 The complexation of a 
potentially biologically active compound to a metal center presents two distinct advantages: 
firstly, the enhancement of the biological activity of the organic compound; possibly by 
increasing solubility and bioavailability. Secondly, the reduction of the risk of toxicity of the 
metal center, as the metal is not available to promote and/ or undergo undesirable 
reactions.23  
Organometallic complexes present the unique advantage of vast synthetic diversity for 
rational drug design. As the metal ion, the oxidation state of the metal ion, and the ligands 
coordinated to the metal center can be varied; thus allowing various characteristics of the 
metal complex to be altered and fine-tuned to best suit the desired biological activity.22 This 
diversity may also be the key to combating drug resistance, which remains a major hurdle in 
the treatment of cancer.   
1.3.1 Platinum-based anticancer complexes  
The fortuitous discovery of cis-diamminedichloridoplatinum(II), commonly known as 
cisplatin, by Rosenberg in 1967 has cemented the path for the development of metal-based 
complexes as an alternative class of chemotherapeutic agents. Today, platinum-based drugs 
(well-known examples include cisplatin, carboplatin and oxaliplatin; Figure 1.6) constitute as 
much as 70% of cancer treatment regimens.24 Cisplatin is commonly used to treat testicular 
and ovarian cancers and is increasingly being used for the treatment of other tumours like 
bladder and cervical tumours. Cisplatin and other platinum-based compounds are known to 
primarily target DNA, disrupting DNA replication by forming inter- and/ or intra-strand 
crosslinks.11,25 This prevents DNA replication, RNA and protein synthesis in cancer cells, 
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Several derivatives of cisplatin have been developed in a bid to improve efficacy and minimize 
side effects. Derivatives with the same cis-PtX2(amine)2 structure (where X = leaving anionic 
group; amine = any primary or secondary amine group) have been developed and some 
display similar or even improved anticancer activity relative to cisplatin.25 However, due to 
the numerous side effects of cisplatin and its derivatives, strategies to lower toxicity of 
platinum-based chemotherapeutics have been employed. These strategies include the 






Cisplatin use is accompanied by severe side effects, including kidney toxicity, loss of sensation 
in extremities and nausea, have been major issues for cancer treatment;24,25 and this is how 
platinum(IV) complexes came into the medicinal chemistry stage. The general scientific 
consensus is that these octahedral platinum(IV) complexes are kinetically more inert in the 
bloodstream and can be activated upon entry into cells, by biological reducing agents, to the 
cytotoxic platinum(II) species. This offers potential advantages over platinum(II) complexes 
regarding oral availability, reduced drug resistance and lower toxicity.26 Two best-known 
examples of Pt(IV) pro-drugs are satraplatin and LA-12 (Figure 1.7). Satraplatin is currently in 
clinical trials for the treatment of ovarian, prostate and lung cancers.27 The complex LA-12 is 
an analogue of satraplatin and contains an adamantylamine ligand, which may improve the 
complex’s cellular uptake. The compound LA-12 displayed improved anticancer activity 
against cisplatin-sensitive (A2780) and cisplatin-resistant (A2780cisR) human ovarian 
carcinoma cells relative to cisplatin, with equitoxic concentrations that were 6-  (A2780) or 
18-fold (A2780cisR) lower.28 
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The success of mononuclear chemotherapeutic agents also fuelled the investigation of 
multinuclear platinum(II) complexes as potential drug candidates. The most successful 
candidate in this category is BBR3464 (Figure 1.8), which comprises of three platinum(II) 
metal centres bridged by naturally occurring polyamines. The polyamine scaffold, and 
multinuclearity of the complex results in a slightly different mechanism when interacting with 
DNA; as the complex spans a long distance along DNA strands.25 The trinuclear complex 
showed promising activity in pancreatic, non-small cell lung and ovarian cancers in Phase I 
clinical trials. However, in Phase II clinical trials, no significant responses were noted in 
patients treated with small cell lung, gastric and gastroesophageal cancers after treatment 
with BBR3464.27 
Platinum-based agents still constitute most of the currently used chemotherapeutic 
treatments. Nevertheless, their high toxicity and resistance of cancers towards these 
metallodrugs has prompted interest in other platinum group metals for cancer treatment.  
 
Figure 1.7: The structures of satraplatin  and LA-12.27 
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1.3.2 Ruthenium(III) anticancer agents 
Unlike platinum compounds, which display reasonably predictable biological behaviour, 
ruthenium complexes are known to show diverse toxicity and mechanisms of action. This 
diversity is even observed in very structurally similar compounds, which often display 
strikingly different biological properties. This diversity in biological activity is one of the 
factors cultivating interest into the investigation of ruthenium complexes for anticancer 
activity.29 To date, the most successful ruthenium complexes are the New Anti-tumour 
Metastatic Inhibitor-A (NAMI-A) and NKP1339 (Figure 1.9); which have entered clinical 
trials.24,30 NAMI-A possesses anti-metastatic properties,  can reduce metastases mass and 
prevents the formation of secondary tumours. However, NAMI-A has minimal effects on 
primary tumour growth.31 In Phase II clinical studies, NAMI-A was investigated in combination 
with gemcitabine (2’,2’-difluoro-2-deoxycytidine) for the treatment of non-small cell lung 
cancer. The combination was noted to be less effective than gemcitabine alone, and the use 
of the combination was accompanied by gastrointestinal disturbances and neutropenia. As a 
result, the combination was deemed ineffective for further use.32,33  
On the other hand, the Phase I clinical trials of NKP1339 were deemed a success, as the 
complex was noted to show effective activity against neuroendocrine tumours and colorectal 
tumours.30 Furthermore, mild side effects were noted from the trial participants after 
treatment with NKP1339.34 This low side effect profile may be accounted for by the metal-
protein adduct formed by NKP1339 and serum albumin, as this adduct may selectively 
accumulate in tumour cells by exploiting the Enhanced Permeability and Retention (EPR) 
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The aforementioned ruthenium(III) complexes are widely considered as pro-drugs, in that 
they are administered in their inactive form and are converted to the cytotoxic species in 
situ.31 Similar to the reduction of platinum(IV) complexes, such as satraplatin as previously 
discussed (Section 1.3.1, vide supra), the reduction of ruthenium(III) complexes is carried out 
by biological reductants such as glutathione, ascorbate or nicotinamide adenine dinucleotide 
(NADH). The reduction from ruthenium(III) to ruthenium(II) results in a decrease of the  
π-acceptor properties of the metal center, subsequently leading to the increased lability of 
π-donor ligands, such as chlorides. Thus, resulting in the facilitation of hydrolysis, yielding the 
active species.33 The interaction with actin-type proteins on cancer cell surfaces or with 
collagens of the extracellular matrix, leading to reduced mobility of metastatic cells, have 
been implicated for the possible mechanism of action of these ruthenium(III) complexes.31 
Although NAMI-A and NKP1339 are known to show appreciable activity towards metastases, 
these complexes lack appreciable activity towards primary tumours.36 The negligible activity 
of these ruthenium(III) complexes towards primary tumours has prompted the investigation 
of ruthenium(II) complexes which may be active against both metastases and primary 
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1.3.3 Ruthenium(II) anticancer agents 
The activation by reduction hypothesis, which states that the active ruthenium(II) species is 
generated in situ by the reduction of ruthenium(III), was one of the motivations behind the 
direct preparation of potential anticancer ruthenium(II)-arene complexes. These 
ruthenium(II) complexes do not require the activation step and are relatively more stable. 
One class of these ruthenium(II)-arene complexes is the Ruthenium-Arene PTA (RAPTA) 
complexes (where PTA is the 1,3,5-triaza-7-phospaadamantane ligand). RAPTA complexes are 
characterized by a monodentate PTA ligand and an η6-arene which are bound to the metal 
center.37 The most widely known examples of this class of compounds are the prototype 
RAPTA-C and the η6-toluene derivative, RAPTA-T (Figure 1.10). In vivo studies revealed that 
both of the aforementioned RAPTA complexes are inhibitors of lung metastasis in mice 
bearing MCa mammary carcinoma, inhibit tumour growth and halt the growth of solid 
metastatic tumours.38,39 Due to the lability of the Ru(II)-Cl bond in RAPTA-C and RAPTA-T, 
these complexes were initially hypothesized to primarily target DNA.37 However, these RAPTA 
complexes have been observed to target several proteins, including histidine protein cores in 
chromatin,24 cathepsin B and thioxin reductase.40 The primary targeting of proteins, instead 
of DNA, by these piano-stool ruthenium(II) complexes is an advantage as this characteristic 
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Another well-explored class of ruthenium(II)-arene complexes is the Ruthenium(II)-Arene 
Ethylenediamine (RAED) complexes. These pseudo-octahedral complexes, pioneered by the 
Sadler group, are characterized by the general formula [Ru(II)-η6-arene(en)Cl]+, where en is 
ethylenediamine.41 Numerous derivatives of the prototype RAED-C complex have been 
developed, with the aims of fine-tuning the biological activity while minimizing off-target 
effects. The most widely known examples of this RAED family of complexes include RAED-C, 
the η6-biphenyl derivative RM175 and the η6-tetrahydroanthracene derivative HC11  
(Figure 1.11).42 In vitro evaluation of these complexes against the A2780 and A2780cisR 
human ovarian cancer cell lines (cisplatin-sensitive and -resistant, respectively) revealed that 
these complexes show antiproliferative activity either comparable or superior to that of 
carboplatin (2 µM < IC50 < 10 µM for the RAED complexes).43 Additionally, the anticancer 
activity was noted to increase with the increase in the size of the arene: p-cymene< biphenyl< 
tetrahydroanthracene.43  
RAED complexes are known to primarily target DNA, with a mechanism of action drawing 
similarities to that of cisplatin.32 Although these complexes are known to bind to guanine 
nucleotides in DNA to form covalently bonded adducts, it is thought that the arene system in 
these complexes enables hydrophobic interactions with DNA, via intercalation between base 
pairs.44 This intercalation may be used to account for the observed dependence of the 
anticancer activity of RAED complexes on the size of the arene moiety.  
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Another strategy that has become of recent interest is the use of  ruthenium(II) complexes as 
photosensitizers for Photodynamic Therapy (PDT). The flagship complex in this class is 
TLD1443 (Figure 1.12), which is a ruthenium(II) polypyridyl  complex developed by the 
McFarland group in 2011.45 TLD1443 is currently in Phase IB clinical trials as a PDT agent for 
the treatment of non-muscle invasive bladder cancer, and is proving to be a new, alternative 
and non-invasive therapy.33,46  
 
Figure 1.12:  The structures of the ruthenium(II) complex in clinical trials as a PDT agent.45  
The success of ruthenium-based complexes and their alternate mechanisms of action 
suggests that they may facilitate the development and discovery of new combination 
chemotherapy agents. This further entices research into ruthenium-based complexes with 
pharmacologically active scaffolds in a bid to exploit synergism between the metal and the 
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1.4 Transition-metal based benzimidazoles 
The contribution of metal complexation to the enhancement of the biological activity of 
known pharmacologically active organic scaffolds is well established in literature and is 
highlighted by the development of ferrocifens.47 This phenomenon is also observed when 
benzimidazoles are complexed to transition metal centers. 
1.4.1 Benzimidazole-based anticancer agents 
 The design of ligands that have stand-alone therapeutic effects has proven to be beneficial 
and may also provide a quicker optimization of organometallic complexes.48 This was one of 
the main rationales behind the study of semaxininb-inspired bispyrazole-benzimidazole 
ligands complexed to ruthenium(II) by Mukherjee and co-workers48 for antiproliferative 
activity. Semaxinib ((3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-
2-one) inhibits the vascular endothelial growth factor receptor (VEGFR), which is imperative 
for the angiogenesis of cancer cells.49 In the study, all the investigated complexes (Figure 1.13) 
showed potent cytotoxic activity (with IC50 values <15 µM) against the breast cancer (MCF-7), 
human hepato-carcinoma (HepG2) and the human metastatic prostate cancer (LNCaP) cell 
lines. Moreover, it was established that these compounds show excellent anti-cell migratory 
properties at almost non-toxic in vitro doses.49  
 
Figure 1.13:  The general structure of Ru(II)-based benzimidazole complexes that display potent 
antitumour activity.49 
In another recent study, a series of iridium(III) complexed benzimidazoles were assayed for 
anticancer activity against the cisplatin-sensitive (A2780) and resistant (A2780cisR) human 
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complexes all showed potent antitumour activity against the assayed cell lines, with the 
complexes with a butyl functionality attached to the benzimidazole ligand showing the 
highest cytotoxicity. The compounds 3 and 4 (Figure 1.14), displayed approximately 7- and 
100-fold more cytotoxic activity than cisplatin, against the A2780 and MDA-MB-231 cancer 
cell lines, respectively. Additionally, all the complexes were found to be significantly less toxic 
to healthy kidney cell line (BGM) relative to cisplatin. This may contribute to overcoming the 
debilitating nephrotoxicity associated with cisplatin chemotherapy.50 
  
Figure 1.14: The most active Ir(III)-based benzimidazole complexes screened for antitumour activity by 
Yellol et al.50 
The investigation of antitumour activity of transition metal complexed benzimidazoles 
remains fruitful, with numerous studies on the potent activity of benzimidazole based 
organometallic complexes. However, the development of benzimidazole-based multinuclear 
anticancer agents remains relatively unexplored.  
 
1.5 Multinuclear organometallic anticancer agents  
With the need for the development of novel drugs in efforts to overcome increasing 
resistance of cancers to current chemotherapeutic agents, organometallic complexes are 
seen as a potential solution to this, as they offer a broad spectrum of biological activity. More 
recently, however, there has been a growing interest in the development of multinuclear 
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bearing more than one metal center possess improved biological activities relative to their 
mononuclear counterparts.51,52  
As previously discussed, one of the factors impeding the clinical success of cisplatin and its 
platinum-based derivatives are the debilitating side effects and the development of 
resistance. To overcome these factors, numerous polynuclear platinum-based drug 
candidates have been investigated, with the most successful and widely known example 
being Farrell’s cationic complex BBR3464 (Figure 1.8, vide supra).53 Despite the limited 
success of BBR3464 in Phase II clinical trials due to trial participant reports of adverse side 
effects including chemotherapy-induced nausea and vomiting (CNIV) and neutropenia,54–56 
this trinuclear complex is exemplary in illustrating the concept of exploiting multinuclear 
organometallic complexes as anticancer agents.   
More recently, the Suntharalingam group investigated a novel triangular trinuclear platinum 
complex, Pt-3 (Figure 1.15) for cytotoxicity against breast cancer stem cells (CSCs). The 
trinuclear complex Pt-3 exhibited potent anticancer activity against the HMLER and HMLER-
shEcad cells ( 1.26 µM < IC50 < 2.24 µM in both cell lines).57 Furthermore, the activity of Pt-3 
is superior to that of cisplatin and carboplatin against the aforementioned cell lines. In 
addition, the trinuclear complex Pt-3 was noted to show activity more potent than that of 
salinomycin, an established breast CSC agent, on the three-dimensional tumour-like 
spheroids of the HMLER-shEcad cell line. Notably, the trinuclear Pt-3 displayed approximately 
3-fold greater activity relative to its corresponding mononuclear (Pt-1a) and dinuclear (Pt-2) 
analogues.57  This trend reinforces the therapeutic potential of multinuclear complexes as 
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Figure 1.15: The novel triangular trinuclear platinum-based complex investigated by the  
Suntharalingam group for anticancer activity against breast CSC, along with the mononuclear and the 
dinuclear counterparts  
The investigation of multinuclear complexes as potential anticancer agents has also been 
extended to other transition metals such as rhodium, ruthenium and iridium. These PGMs 
have several stable oxidation states and possess an octahedral geometry; thus offering two 
more coordination sites relative to platinum(II).58 
In a recent study, Burgoyne et al.59 screened salicylaldiminato-sulfonate based iridium(III) and 
rhodium(III) mono- and trinuclear complexes (Figure 1.16) for anticancer activity against the 
WHCO1 oesophageal cancer cell line. A general trend was reported, in which the trinuclear 
complexes displayed enhanced antitumour activity (43.87 – 200 µM) relative to their 
corresponding monomeric complexes (with IC50 values ranging from 169.1 µM to  >300 µM).59  
 
Figure 1.16: The novel rhodium(III) and iridium(III) half-sandwich complexes investigated by 
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Motivated by the encouraging results obtained from a previous study of the dinuclear 
ruthenium(II) tppz complex [(Ru(phen)2)2(tpphz)]4+ (where phen = 1,10-phenanthroline , and 
tpphz = tetrapyrido[3,2-a:2’,3’-c:3”,2”-h:2’’’,3’’’-j]phenazine), complex 5, Gill et al.60 
investigated the lipophilic derivative of 5, [(Ru(DIP)2)2(tpphz)]4+ (where DIP is 4,7-diphenyl-
1,10-phenanthroline), 6. From the study, it was observed that complex 6 (Figure 1.17) 
displayed approximately 2-fold higher cytotoxicity relative to the cisplatin standard, against 
the breast cancer (MCF-7) and HeLa human cervical cancer cell lines. Moreover, it was 
established that this complex (6) displays a localization profile that is consistent with targeting 
the endomembrane system, which comprises of the endoplasmic reticulum, nuclear envelope 
and vacuole structures.60 
1.6 Trinuclear ruthenium arene complexes as anticancer agents 
 
Trinuclear ruthenium arene organometallic complexes are significantly less developed and 
considerably less investigated relative to their dinuclear and tetranuclear counterparts.61 An 
approach that is widely used in the rational design of trinuclear ruthenium complexes for 
application as anticancer agents is the use of branched and flexible linkers to connect three 
ruthenium moieties, yielding trinuclear dendritic complexes. This approach is commonly used 
as it confers flexibility and conformational adjustment of each ruthenium unit.61 
The effects of different flexible linker ligands to the anticancer activity of trinuclear 
organoruthenium complexes have been extensively studied by the Smith group.62–65 In a 
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study, Burgoyne et al. investigated a series of trinuclear polyester-bridged ruthenium(II)-
arene complexes (Figure 1.18 a) as potential anticancer agents against human ovarian cancer 
cell lines (A2780 and A2780cisR).64 This class of trinuclear ruthenium complexes showed 
promising antiproliferative activity against both the A2780 and A2780cisR cell lines  
(33.38 µM < IC50 < 60.50 µM), with selectivity towards these cancerous cell lines over  
non-tumorigenic human fibroblast cells (KMST-1).64 Additionally, the trinuclear complexes 
were noted to have 2 – 4 fold enhanced activity relative to their respective mononuclear 
counterparts in the A2780 and A2780cisR cell lines. 
In another study, the Smith group investigated a series of trinuclear ruthenium(II) complexes 
based on the tris-2-(salicylaldimine ethyl)amine and tris-2-(2-pyridine ethyl)amine scaffolds 
(Figure 1.18 b) for their potential anticancer activity.65 Generally, it was noted that there is a 
correlation between the number of ruthenium centers and the cytotoxicity of the complexes. 
This is evidenced by the enhanced antiproliferative activity noted for the trinuclear complexes 
relative to their mononuclear analogues on the human osteosarcoma (MG63) and the 
cisplatin-resistant human ovarian cancer (A2780cisR) cell lines. However, the trinuclear 
complexes were noted not to be selective for cancer cells, when evaluated for cytotoxicity 
against non-tumorigenic human fibroblast cells (KMST-1).65  
 
Figure 1.18: Some of the trinuclear ruthenium(II)-arene complexes based on either the polyester (a) or 
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More recently, Beckford et al. investigated a discrete series of trinuclear ruthenium 
complexes based on a 2,4,6-tris(di-2-pyridylamino)-1,3,5-triazine core (Figure 1.19).66 The 
investigated complexes showed very mild activity against the triple-negative HCC-1937 breast 
cancer cell line, with all IC50 values >100 µM. All the trinuclear complexes were only observed 
to show an appreciable reduction of HCC-1937 cell viability at 1 mM, reducing cell viability to 
a range between 20% and 80%. Furthermore, these complexes were noted to have 
stimulatory effects on the viability of MCF-10A non-tumorigenic breast epithelial cells.66 
Additional mechanistic studies suggest that  DNA is the primary target of these complexes, 
with the trinuclear complexes either binding to DNA grooves or electrostatically interacting 
with DNA. 
  
Figure 1.19: The trinuclear ruthenium(II)-arene complexes based on a 1,3,5-triazine core investigated 
by Beckford and co-workers.  
The improved cytotoxicity of multinuclear macromolecules, relative to their mononuclear 
analogues, may also be attributed to the enhanced permeability and retention (EPR) effect.51 
This is a phenomenon in which solid tumours have defective and permeable blood vessels; 
this is to ensure a sufficient supply of nutrients and oxygen to tumour tissues for rapid growth 
(Figure 1.20). Macromolecules, such as polynuclear complexes exploit this EPR effect and 
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Figure 1.20: An illustration of the Enhanced Permeability and Retention (EPR) effect.68 
 
1.7 Rationale for the current Study 
The field of bioorganometallic chemistry presents favourable biological results which cultivate 
interest into further development of organometallic compounds as biological agents. The 
incorporation of two or more metal centers onto an organic scaffold has been shown to yield 
multinuclear organometallic complexes with novel mechanisms of action as potential 
anticancer agents. These novel mechanisms of action may assist in overcoming resistance 
displayed by tumours to clinically used chemotherapeutic agents and improve the selectivity 
of metallodrugs. The incorporation of pharmacophores onto dendritic scaffolds and the 
combination of these dendritic ligands with PGMs, to form trinuclear complexes, is a widely 
used strategy in rational anticancer drug design. However, whilst interest in the development 
of multinuclear organometallic complexes as anticancer agents is growing, exploration into 
ruthenium arene trinuclear complexes remains in infancy.  
As previously discussed, the benzimidazole moiety is well-documented for its appreciable 
anticancer activity. Moreover,  the study of benzimidazole-based organometallic biological 
agents is ever-growing and continues to provide encouraging results, especially as anticancer 
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complexes remains slow developing. As a result, the development of multinuclear 
benzimidazole-based organometallic complexes and their use as potential anticancer agents 
have not been systematically investigated, and thus prompts further investigation into this 
field. 
1.8 Aims and objectives  
1.8.1 General aims 
As discussed in this chapter, the investigation of the less-developed trinuclear ruthenium 
arene benzimidazole-based organometallic complexes may result in an interesting study. As 
a result, the aims of the project were to: 
• Synthesize a series of trimeric 2,5-disubstituted benzimidazole ligands and 
corresponding 2-ferrocenyl bioisosteres based on the tris(2-aminoethyl)amine 
scaffold. 
• Complex the respective ligands to ruthenium to afford the corresponding trinuclear 
N^N-ruthenium(II) cationic and C^N-ruthenium(II) cyclometallated complexes bearing 
the ruthenium centers at the periphery.  
• The evaluation of the synthesized compounds for their biological activity as potential 
anticancer agents.  
1.8.2 Specific objectives  
1. The synthesis of a series of 2,5-disubstituted trimeric benzimidazole ligands and the 
corresponding 2-ferrocenyl compounds as non-planar bioisosteres of the 2-aryl 
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Figure 1.21: The general structures of the trimeric 2,5-disubstituted benzimidazole compounds 
synthesized in this study.  
2. The preparation of the corresponding trinuclear ruthenium(II) arene complexes as 
either the neutral C^N-Ru(II) or cationic N^N-Ru(II) complexes (Figure 1.22). 
 
Figure 1.22: The general structures of the neutral cyclometallated and cationic N^N-chelated 
trinuclear ruthenium(II)-p-cymene complexes synthesized in this study.  
3. To characterize all of the compounds using an array of analytical and spectroscopic 
techniques, including Nuclear Magnetic Resonance spectroscopy (NMR), Elemental 
Analysis, Fourier Transform-Infrared spectroscopy (FT-IR) and Electrospray Ionisation 
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analysis was used on single crystals to provide further evidence of the molecular 
structure for a ligand.  
4. The investigation of the anticancer activity of the synthesized ligands and complexes 
against breast cancer (MCF-7 and MDA-MB-231) and skin cancer (501mel) cell lines 
using the MTT assay. Additionally, to conduct NMR studies to determine a potential 
intercellular target for the most active complex.  
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Chapter 2                                    Synthesis of Benzimidazole Compounds  
 
 
2.1  Introduction 
Over the years of active research, the benzimidazole nucleus has evolved to be an important 
privileged heterocyclic structure in medicinal chemistry. There are several examples of 
benzimidazole-containing compounds that show appreciable antiparasitic, antiviral, 
antimalarial and anticancer activity.1, 2 It is well documented that modification at the   2- and 
5-position of the benzimidazole scaffold yields a number of biologically active compounds 
with varying cellular targets.3  The wide range of pharmacological activities of benzimidazole-
containing drugs is attributed to the unique fused benzene and imidazole rings which form 
the benzimidazole core. These fused rings may interact with an array of biological targets in 
a non-covalent manner, which may be attributed to the electron-rich nature of the 
benzimidazole heterocyclic system.4 
Several benzimidazole-based compounds have been approved for clinical use for the 
treatment of various ailments.5,6 The most commonly known examples include the 
anthelmintic drugs albendazole (methyl [5-(propylthio)-1H-benzoimidazol-2-yl]carbamate) 
and mebendazole (methyl N-(6-benzoyl-1H-benzimidazol-2-yl)carbamate), and the antiulcer 
drug lansoprazole (2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-
benzimidazole).5 Despite the great success of the benzimidazole system in the clinical 
treatment of various diseases, the accomplishments of the heterocyclic system are not 
reflected in the treatment of cancer. There is only a single benzimidazole-containing drug that 
is currently approved for the clinical treatment of cancer, bendamustine (4-[5-[bis(2-
chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid) (Figure 2.1 a), which used to 
treat chronic lymphocytic leukemia and myeloma.7 Additionally, there are two compounds in 
Phase III clinical trials that contain the benzimidazole nucleus, selumetinib8  (6-(4-bromo-2-
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chloroanilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methylbenzimidazole-5-carboxamide) and 
galeterone9 ((3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-
2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol) (Figure 2.1 b and c, 
respectively).  
 
Figure 2.1: The chemical structures of benzimidazole-based drugs in clinical use (a) and in clinical trials 
(b and c).7 - 9 
Numerous trimeric benzimidazoles have been reported for their potential biological 
applications, including Hoechst 33258 DNA stain-inspired trinuclear benzimidazoles,10 RNA-
cleaving tris(2-aminobenzimidazoles),11 citric acid-based antibacterial tris-benzimidazoles12 
and antimicrobial triazine-based tripodal tris-benzimidazoles.13 However, there have been no 
reports of tris(2-aminoethyl) based benzimidazoles. The prevalence of the benzimidazole core 
in biological molecules and the applications of the scaffold as synthons for various biologically 
important compounds has stimulated the need for the development of simple and efficient 
methods to synthesize this heterocyclic system. To this end, the synthesis and 
characterization of a series of 2,5-disubstituted trimeric benzimidazole compounds, and their 
intermediates is reported in this chapter. 
2.2  Synthesis of 2,5-disubstituted tris-benzimidazole compounds (7 – 15) and their 
corresponding intermediates  
The synthesis of the 2,5-disubstituted tris-benzimidazoles (7 – 15) involved three steps:  
i) A nucleophilic aromatic substitution reaction (SNAr) of tris(2-aminoethyl)amine with either 
ortho-substituted fluoro- or chloro- nitrobenzenes ii) the reduction of the nitro- 
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either benzaldehyde, 2-pyridinecarboxaldehyde or ferrocenecarboxaldehyde to afford the 




Scheme 2.1: Synthesis of the intermediates and the 2,5-disubstituted tris-benzimidazoles. Reagents 
and conditions: i) DMF/ RT/ 24 h; ii) Zn/ NH4Cl/ MeOH/ RT/ 1 h; iii) Benzaldehyde,  
2-pyridinecarboxaldehyde or ferrocenecarboxaldehyde / TFA/ EtOH/ MgSO4/ 80 °C or RT/ 24 h.  
 
There are several reported methods in which the synthesis of 2-aryl substituted 
benzimidazoles is described.14–18 The reaction of o-phenyldiamenes with aromatic aldehydes 
in the presence of an acid catalyst remains one of the popular methods due to the one-pot 
nature and simplicity of procedures in yielding benzimidazoles.19 The first step towards the 
synthesis of the tris-benzimidazole compounds reported in this chapter entails the synthesis 
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2.2.1 The synthesis of tris-nitrobenzenes (1 – 3) 
2.2.1.1 Synthesis 
The first step towards the synthesis of the tris-benzimidazole compounds is a SNAr reaction, 
in which an excess of a commercially available ortho-halogenated nitrobenzene is reacted 
with one molar equivalent of tris(2-aminoethyl)amine (Scheme 2.2).  
 
 
Scheme 2.2: The general synthetic route for the tris-nitrobenzenes (1 – 3). Reagents and conditions: 
DMF/ RT/ 24 h. 
  
A SNAr reaction is described as a reaction in which a nucleophile displaces a good leaving 
group, commonly a halogen, on an aromatic ring. The core prerequisite of a SNAr reaction is 
that a strong electron-withdrawing group is present  in either the ortho- or para- positions 
relative to the nucleofuge. The electron-withdrawing group serves to stabilize the 
Meisenheimer complex, which is formed as an intermediate as the reaction proceeds, via a 
negative resonance effect (Scheme 2.3). The Meisenheimer complex is formed as a result of 
the nucleophilic addition of the tris(2-aminoethyl)amine nucleophile onto the aromatic ring. 
The subsequent elimination of the halogen from the aromatic ring and successive proton 
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Scheme 2.3: The proposed general mechanism of the Nucleophilic Aromatic Substitution (SNAr) 
reaction  to yield the tris-nitrobenzene compounds. 
Generally, the synthesis of the tris-nitrobenzenes proceeded with ease, with the conversion 
of starting materials occurring under mild conditions. After 24 hours, TLC analysis showed the 
near-complete conversion of the starting materials to a new, more polar product. The desired 
compounds were isolated via column chromatography as bright yellow solids (1 and 2) or a 
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2.2.1.2 Characterization 
Analysis of the 1H NMR spectra of compounds 1 – 3 (Figure 2.2) confirmed the successful 
synthesis of the desired tris-nitrobenzenes. The presence of a triplet between δH 8.08 and  
δH 8.45 ppm (H-g for 1 and H-h for 2 and 3), integrating for three protons corresponding to 
the secondary amine protons, and the two distinct aliphatic signals at δH  ~3.50 ppm and  
δH  ~2.90 ppm (H-h and H-i for 1, H-i and H-j for 2 and 3) individually integrating for six protons 
corresponding to the methylene protons of the tris- core, are all indicative of introduction of 
the tris- core onto the aromatic rings. Additionally, in the aromatic region of the spectra, 
either three (for 2 and 3) or four (for 1) distinct aromatic signals are observed and these 
signals collectively integrate for nine and twelve protons, respectively, and are assigned to 
the protons on the aromatic rings of the tris-nitrobenzenes.  
Figure 2.2: The stacked 1H NMR spectra of the tris-nitrobenzene compounds (1 – 3) in DMSO (d6). 
The splitting of these aromatic signals is consistent with a splitting pattern associated with a 
1,2,4-trisubstituted aromatic ring (apart from 1, as this compound is 1,2-disubstituted) with 
three electronically distinct functional groups. Furthermore, in the 13C{1H}-NMR spectra of the 
tris-nitrobenzenes (1 – 3), the expected eight (for 1) or nine (for 2 and 3) signals are observed, 
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2.2.2 The synthesis of tris-1,2-benzenediamines (4 – 6) 
2.2.2.1 Synthesis 
The synthesis of the tris-1,2-benzenediamines (4 – 6) from the corresponding  
tris-nitrobenzenes (1 – 3) involved the reduction of the nitro- groups to primary amine 
functionalities. This was achieved by the reaction of the tris-nitrobenzenes with thirty molar 
equivalents of ammonium chloride and sixty molar equivalents of zinc powder. This method 
gave the highest yields of the desired products under mild conditions (Scheme 2.4).  
 
 
Scheme 2.4: The general synthesis of the tris-1,2-benzenediamines (4 – 6). Reagents and conditions: 
Zn/ NH4Cl/ MeOH/ RT/ 1 h. 
After an hour, TLC analysis showed the complete conversion of the tris-nitrobenzene limiting 
reagent (1 – 3) to a new more polar product. Purification by column chromatography, with 
ethyl acetate as the eluent in each instance, afforded the desired products as either dark 
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2.2.2.2 Characterization 
Upon comparison of the 1H NMR spectra of the tris-1,2-benzenediamines (4 – 6)  (Figure 2.3) 
with the 1H NMR spectra of the corresponding precursor tris-nitrobenzenes (1 – 3)  
(Figure 2.2, vide supra), there are several indicators of successful reduction of the nitro- 
functionalities to primary arylamine moieties. Firstly, in the aromatic region of the spectra, an 
interesting trend was observed in which the aromatic protons of the tris-1,2-
benzenediamines (4 – 6) converge and some coalesce, relative to the aromatic protons of the 
corresponding tris-nitrobenzene (1 – 3). This is attributed to the similar electronic effects that 
the primary and secondary amine functionalities exert on the aromatic ring. Secondly, the 
presence of an additional signal which corresponds to the primary amine protons, at δH 4.40, 
δH 4.84 and δH 4.32 ppm for 4, 5 and 6, respectively, validates the reduction of all the aryl 
nitro- moieties to primary amine functionalities. However,  when comparing the aliphatic 
regions of the spectra on the tris-1,2-benzenediamines (4 – 6) with the 1H NMR spectra of the 
corresponding tris-nitrobenzene (1 – 3), no significant changes were observed, as two 
aliphatic signals with individual integrations of six are observed. These aliphatic signals 
correspond to the methylene protons of the tris- core. 
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Comparison of the 13C{1H}-NMR spectra of the tris-1,2-benzenediamines (4 – 6) to the  
13C{1H}-NMR spectra of the corresponding  tris-nitrobenzene precursors (1 – 3) revealed a 
general upfield shift of the aromatic carbon signals of the tris-1,2-benzenediamines (4 – 6)  is 
observed, shifting from δC 147 – 115 ppm in the tris-nitrobenzenes to δC 139 – 108 ppm in the  
tris-1,2-benzenediamines. This shift may be attributed to the electron-donating nature of the 
primary amine moiety on each aromatic ring resulting in increased electron density in the 
aromatic rings of the tris-1,2-benzenediamines, further attesting to the successful reduction 
of the nitro- functionalities to primary amine moieties.  
 Infrared spectroscopic analysis of the compounds 4 – 6 revealed two absorption bands 
between 3306 and 3373 cm-1 in each spectrum (summarized in Table 2.1). These absorption 
bands are diagnostic of the symmetrical and asymmetrical stretches of primary amine 
functionalities and are thus indicative of the presence of the primary aryl amine groups. This 
further corroborates the successful synthesis of the tris-1,2-benzenediamines.  
 Table 2.1: Summarised Infrared spectroscopic data for the tris-1,2-benzenediamine compounds (4 – 
6) 
Compound 1° AmineR-NH2 (cm-1) 
4 3366 and 3299 
5 3342 and 3306 
6 3373 and 3318 
 
Combined, these spectroscopic analyses all attest to the successful synthesis of the  
tris-1,2-benzenediamine compounds (4 – 6) from their respective tris-nitrobenzene (1 – 3) 
precursors. 
2.2.3 Synthesis of 2,5-disubstituted tris-benzimidazoles (7 – 15) 
2.2.3.1 Synthesis 
The synthesis of the 2,5-disubstituted benzimidazole compounds entailed a cyclization-
condensation reaction of the synthesized  tris-1,2-benzenediamines (4 – 6) with 3.6 molar 
equivalents of either benzaldehyde, 2-pyridinecarboxaldehyde or ferrocenencarboxaldehyde 
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Scheme 2.5: The general synthesis of 2,5-disubstituted tris-benzimidazole compounds (7 – 15). 
Reagents and conditions: Benzaldehyde, 2-pyridinecarboxaldehyde or ferrocenecarboxaldehyde / TFA/ 
EtOH/ MgSO4/ 80 °C or RT/ 24 h. 
There are numerous methods describing the synthesis of benzimidazoles from  
o-phenylenediamines and the various biological applications of these benzimidazoles.15,20,21 
However, mechanistic insights into the acid-catalyzed synthesis of  
2-arylsubstituted benzimidazoles from o-phenylenediamines and aryl aldehydes are very 
limited. Recent mechanistic studies propose that the reaction occurs via a sequence of steps 
that are catalyzed by hydrochloric acid, oxalic acid or tosylic acid.22–24 The proposed 
mechanism for the cyclization-condensation reactions performed in this study (Scheme 2.6) 
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Scheme 2.6: The proposed mechanism of the cyclization-condensation reaction for benzimidazole 
synthesis. 
In all the reported mechanisms,22–24 the first step is the acid-catalyzed nucleophilic attack of 
the aldehyde. Here, trifluoroacetic acid plays the crucial role of protonating the carbonyl 
oxygen of the aldehyde, resulting in the increased electrophilicity of the carbonyl carbon, 
making the carbonyl carbon more susceptible to nucleophilic attack. The secondary amine of 
the synthesized tris-1,2-benzenediamines acts as the nucleophile in this step. This can be 
attributed to the inductively electron-donating methylene carbon adjacent to the secondary 
amine nitrogen, which results in an increased abundance of electron density on the secondary 
amine nitrogen relative to the primary amine nitrogen. Due to the well-reported correlation 
between basicity and nucleophilicity,25–27 the secondary amine nitrogen has more 
nucleophilic character relative to the primary amine. Thus, the secondary amine acts as the 
nucleophile in the first addition (AN) step. Furthermore, it is only the nucleophilic attack by 
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which forms after the elimination of water (Scheme 2.6). This is subsequently followed by 
intramolecular nucleophilic attack of the iminium carbon by the primary amine moiety, 
yielding the hydrobenzimidazole which is aerobically oxidized to afford the benzimidazole.28 
Therefore, the reactions in which the tris-benzimidazoles were synthesized were allowed to 
progress in air, to ensure optimal oxidation of the hydrobenzimidazole.  
 After 24 hours, TLC analysis showed the complete conversion of the limiting reagents  
(4 – 6) to a new more polar product. The pure products were isolated using column 
chromatography as various coloured solids in moderate to good yields, ranging between  
33% and 71%.  
2.2.3.2 Characterization 
2.2.3.2.1 Characterization of the 2-phenyl and 2-pyridyl ligands (7 – 12) 
Analysis of the 1H NMR spectra of 2-aryl tris-benzimidazole ligands 9 – 12 (Figures 2.4 and 2.5) 
correlates with the proposed structures of these ligands. Comparison of the spectra 
corresponding previously synthesized tris-1,2-benzenediamines (4 – 6)  
(Figure 2.3, vide supra), the 1H NMR spectra of the tris-benzimidazole ligands (9 – 12) did not 
show any significant changes in the aliphatic region, as two aliphatic signals, integrating for 
six protons each, are observed and correspond to the methylene protons (H-a and H-b) on 
the tris- core. However, in the aromatic region, additional aromatic signals collectively 
integrating for either fifteen (for 7 - 9) or twelve protons (for 10 - 12) are observed. These 
additional aromatic signals correspond to the protons of the phenyl or 2-pyridyl 
functionalities on the 2-positions of the benzimidazole cores and are indicative of the 
successful synthesis of the benzimidazole cores.  
Furthermore, an additional five (for 7 - 9) or six (for 10 - 12) aromatic signals are observed in 
the 13C{1H}-NMR spectra of the tris-benzimidazole ligands (9 – 12) relative to their respective 
tris-benzenediamines (4 – 6). These additional carbons are indicative of the formation of the 
benzimidazole motif and corroborate the introduction of the phenyl or the 2-pyridyl 
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Figure 2.4: The stacked 1H NMR spectra of the 2-phenyl tris-benzimidazole ligands (7 – 9) in DMSO (d6). 
Infrared spectral analysis of the tris-benzimidazole ligands (7 – 12) revealed a general trend. 
In the IR spectra of the 2-phenyl benzimidazoles (7 - 9), an absorption band between  
1695 - 1625 cm-1 was observed and this absorption band corresponds to the imine (C=N) 
moiety. The IR spectra of the 2-pyridyl tris-benzimidazole ligands (10 – 12) revealed two 
absorption bands, one in the range 1592 - 1733 cm-1 and another in the range  
1489 - 1587 cm-1. These absorption bands correspond to imine (C=N) bond stretch on the 
benzimidazole core and the C=N bond stretch of 2-pyridyl functionality, respectively.  This 
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Figure 2.5: The stacked 1H NMR spectra of the 2-pyridyl tris-benzimidazole ligands (10 – 12) in DMSO 
(d6). 
In addition, the purity of the tris-benzimidazole ligands (7 – 12) was attested to by  
High-Performance Liquid Chromatography (HPLC). From the data attained, the compounds 
were 94 – 99% pure, and thus sufficiently pure for in vitro anticancer evaluation (Chapter 4, 
vide infra).  
Single crystal X-ray Diffraction (XRD) is a valuable tool in confirming the molecular structures 
of compounds. Single crystal XRD was used to confirm the molecular structure of compound 
9 in the solid-state. Single crystals of 9 were obtained by slow diffusion of a concentrated 
solution of 9 in dichloromethane layered with ethyl acetate, at room temperature. The 
molecular structure of 9 is depicted in Figure 2.6 and further crystallographic data is available 
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Compound 9 crystallized in the triclinic crystal system and P-1 space group, with two molecules 
present per cell unit. The fluorine atoms of two, of the three, trifluoromethyl groups C9A and 
C9C are disordered over two sites, with refined site occupancy factors of 0.615(15) for F1A, 
F2A and F3A, 0.315(15) for F4A, F5A and F6A; 0.778(9) for F1C, F2C and F3C, 0.222(9) for F4C, 
F5C and F6C. The imine (C=N) bond lengths in the benzimidazole core range from 1.317 Å to 
1.320 Å, which are comparable to imine bond lengths reported in literature for 2-phenyl 
benzimidazole compounds.29,30  
Figure 2.6: The ORTEP drawing of the molecular structure of compound 9, hydrogen atoms have been 
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Table 2.2: Selected crystallographic data for compound  9 
 
 Compound 9 
Empirical formula C48H36F9N7 
Formula weight 881.85 
Temperature (K) 173(2) 
Crystal system Triclinic 
Space group P-1 
a (Å) 12.9590(8) 
b (Å) 13.5286(10) 
c (Å) 14.2464(10) 
α (°) 70.930(2) 
β (°) 64.023(2) 
γ (°) 81.799(2) 
Volume (Å3) 2122.1(3) 
Z 2 
ρcalc (g/cm3) 1.380 
μ (mm-1) 0.111 
F(000) 908.6 
Crystal size(mm3) 0.18 × 0.18 × 0.12 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 3.18 to 56.62 
Index ranges -17 ≤ h ≤ 17, -18 ≤ k ≤ 18, -18 ≤ l ≤ 18 
Reflections collected 55275 
Independent reflections 10545 [Rint = 0.0656, Rsigma = 0.0528] 
Data/restraints/parameters 10545/15/633 
Goodness-of-fit on F2 1.030 
Final R indexes [I>=2σ (I)] R1 = 0.0504, wR2 = 0.1011 
Final R indexes [all data] R1 = 0.0907, wR2 = 0.1215 
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2.2.3.2.2 Characterization of  the 2-ferrocenyl compounds (13 – 15) 
In the  1H NMR spectra for the 2-ferrocenyl tris-benzimidazole compounds (13 – 15)  
(Figure 2.7) there are several indicators of the successful synthesis of the 2-ferrocenyl  
tris-benzimidazole compounds. Upon comparison of the 1H NMR spectra of 13 – 15 to the 
spectra of the respective tris-1,2-benzenediamines (4 – 6) (Figure 2.3, vide supra), three 
additional signals at δH ~4.75 ppm (H-l for 14 and 15, H-k for 13), δH ~4.50 ppm (H-m for 14 and 
15, H-l for 13) and δH ~4.15 (H-Cp) ppm are observed. These additional signals correspond to 
the protons on the substituted and unsubstituted cyclopentadienyl (Cp) rings, respectively. 
This is the first indicator of the successful introduction of the ferrocenyl entity onto the 2-
positions of the benzimidazole motifs.  Furthermore, when comparing the 13C{1H}-NMR 
spectra of 13 – 15 to their corresponding tris-1,2-benzenediamines (4 – 6), five additional 
signals are observed, which are also indicative of the formation of the benzimidazole cores 
and indicate the incorporation of the ferrocenyl moiety onto the 2-positions of the 
benzimidazole scaffolds. 
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Analysis of the 2-ferrocenyl tris-benzimidazole compounds (13 – 15) using IR spectroscopy 
revealed an absorption band in the range 1611 – 1620 cm-1 corresponding to the imine (C=N) 
functional group (Table 2.3). This is indicative of the successful synthesis of the benzimidazole 
motifs present in the compounds.  
High-Resolution Electrospray Ionisation (HR-ESI) mass spectrometry data was obtained for 
the 2-ferrocenyl tris-benzimidazole compounds (13 – 15). Generally, a base peak 
corresponding to the protonated molecular ion, [M+H]+, was observed. The ESI-MS data for 
13 – 15 is summarized in Table 2.3 and attests to the integrity of the compounds.  
Table 2.3: A summary of the ESI-MS and the IR spectroscopy data obtained for the 2-ferrocenyl tris-
benzimidazole compounds (13 – 15) 
 
The correlation between the proposed structures and the spectroscopic and analytical results 
concludes that the desired 2,5-disubstituted tris-benzimidazole compounds (7 – 15) were 
indeed synthesized from their respective precursors.  
2.3  Synthesis of the monomeric 2-pyridylbenzimidazole ligand (18) 
2.3.1 Synthesis  
The monomeric 2-pyridylbenzimidazole ligand (18) was synthesized after the in vitro 
anticancer evaluation of the 2,5-disubstituted tris-benzimidazole compounds (9 – 15), later 
discussed in Chapter 4 (vide infra). From the in vitro anticancer results attained, the  
5-unsubstituted 2-pyridyl tris-benzimidazole ligand (10) was observed to show superior 
anticancer activity against the tested cancer cell lines (Chapter 4, Sections 4.2 and 4.3, vide 
infra). Consequentially, the mononuclear counterpart (18) of the trimeric ligand 10 was 
synthesized. 
Compound Calculated [m/z] Found [m/z] IR (C=N)Imine (cm-1) 
13 1002.6270 1002.2359 [M+H]+ 1611 
14 1206.1956 1206.1980 [M+H]+ 1613 
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The synthesis of the 1-ethyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole ligand (18) was carried out 
using the same three-step procedure as previously described in Section 2.2, for the synthesis 
of the 2,5-disubstituted tris-benzimidazole compounds (vide supra), using the relevant molar 
equivalents (Scheme 2.7). 
 
Scheme 2.7: The synthesis of the synthons and the monomeric 2-pyridylbenzimidazole ligand (18). 
Reagents and conditions: i) DMF/ RT/ 24 h; ii) Zn/ NH4Cl/ MeOH/ RT/ 1 h; 
 iii) 2-Pyridinecarboxaldehyde / TFA/ EtOH/ MgSO4/ RT/ 24 h. 
The synthesis of the nitroaniline precursor (16) involved a SNAr reaction of 1-chloro-2-
nitrobenzene with ethylamine. After 24 hours, the presence of a more polar product was 
observed on TLC. The nitroaniline 16 was isolated in a moderate yield of 37% as a bright yellow 
oil.  
The nitroaniline (16), was successively reduced to the benzene-1,2-diamine (17). The 
benzene-1,2-diamine (17) was subsequently reacted with 2-pyridinecarboxaldehyde to yield 
the 2-pyridylbenzimidazole (18). The benzene-1,2-diamine precursor (17) and the 
benzimidazole ligand (18) were isolated in good yields of 83% and 42%, respectively. 
2.3.2 Characterization  
In the 1H NMR spectrum of the nitroaniline (16) (Figure 2.8), resonances diagnostic of the 
formation of the desired products are observed. Firstly, in the aromatic region of the 
spectrum (δH 6.50 – 8.50 ppm), aromatic protons with a collective integration of four protons, 
assigned to the aromatic protons of the nitroaniline (16), are observed. The splitting pattern 
of these aromatic signals correlates to a 1,2-disubstituted aromatic, with two electronically 
different functionalities. Additionally, the two aliphatic signals at δH 3.34 ppm (H-h) and  
δH 1.37 ppm (H-i), integrating for two and three protons respectively, corresponding to the 
methylene and methyl protons of the ethyl functionality is indicative of the formation of the 
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As previously discussed, the comparison of the aromatic regions of the 1H NMR of the  
benzene-1,2-diamine (17) (Figure 2.8) to that of the nitroaniline (16) reveals the successful 
reduction of the nitro- moiety to a primary amine functionality. Upon reduction of the nitro- 
group, the aromatic protons of the desired benzene-1,2-diamine (17) are observed to shift 
relatively upfield (from δH 6.50 – 8.50 ppm in 16, to δH 6.60 – 6.90 ppm in 17) and converge.  
This convergence of the aromatic protons of the benzene-1,2-diamine (17) is indicative of the 
similar electronic effects that the primary and secondary amine moieties exert on the 
aromatic ring. Additionally, a new broad signal is observed at δH 3.25 ppm (H-a), with an 
integration of two protons, corresponding to the protons of the primary amine functionality.  
The successful cyclization of the benzene-1,2-diamine (17) to yield the desired  
2-pyridylbenzimidazole (18) is evidenced by the presence of additional aromatic signals in the 
1H NMR spectrum of 18 relative to that of 17 (Figure 2.8). These additional aromatic protons 
collectively integrate for four protons and are assigned to the protons of the 2-pyridyl 
functionality on the benzimidazole core (H-i, H-j, H-k and H-l).  
 
Figure 2.8: The stacked 1H NMR spectra of the nitroaniline (16) and benzene-1,2-diamine (17) 
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The observed chemical shifts and signal multiplicities observed in the 1H NMR spectra of the 
nitroaniline (16) precursor, the benzene-1,2-diamine (17) synthon and the monomeric  
2-pyridylbenzimidazole ligand (18) are comparable to those reported in literature.31–33 
2.4  Summary  
A series of new 5-substituted 2-phenyl (7 - 9) and 2-pyridyl (10 - 12) tris-benzimidazole ligands 
were successfully synthesized. Additionally, a series of 5-substituted 2-ferrocenyl  
tris-benzimidazole trinuclear compounds (13 – 15) were synthesized. The synthesized 
compounds were characterized using an array of spectroscopic and analytic techniques such 
as 1H, 13C{1H}, COSY, HSQC NMR spectroscopy, Infrared spectroscopy, HPLC and mass 
spectrometry. Single crystal XRD was used as a tool to confirm the molecular structure of 
compound 9 in the solid-state. The imine bond length was consistent with structurally similar 
to 2-phenyl benzimidazole ligands reported in literature.29,30  Furthermore, the mononuclear  
2-pyridylbenzimidazole (18), was synthesized. The 1H NMR spectral data of this mononuclear  
2-pyridyl ligand (18), and the precursors (16 and 17), all correlate to the 1H NMR spectra 
reported in literature.31–33  
The three-step procedure reported in this Chapter provides an efficient and facile procedure 
for the synthesis of the benzimidazole scaffold from relatively inexpensive starting materials. 
Additionally, the benzimidazole compounds reported in this Chapter may contribute towards 
the ever-growing field of the synthesis of potentially biological applications multimeric 
benzimidazoles. The synthesis of the 2-pyridylbenzimidazole (18), the monomeric 
counterpart of the 2-pyridyl tris-benzimidazole ligand 10, may offer insight into the 
advantages that trimeric benzimidazoles have relative to monomeric benzimidazoles. These 
advantages may be highlighted by a comparison of the biological activity and mechanisms of 
action of the trimeric ligand 10 relative to that of the monomeric ligand 18.  
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3.1  Introduction 
Metal-based complexes have been at the forefront of the rational design of cytotoxic agents 
in recent years. This was catalyzed by the fortuitous discovery of  
cis-dichloridodiammineplatinum(II), commonly known as cisplatin, by Rosenberg and  
co-workers in 1967.1 Today, platinum-based drugs constitute as much as 70% of cancer 
chemotherapeutic regimens.2 However, the dose-dependent side effects accompanied by the 
use of Pt(II)-based anticancer drugs has sparked the development of a new generation of 
metallodrugs based on alternative Platinum Group Metals (PGMs).3 This is mainly aimed at 
developing PGM-based complexes that show improved selectivity while maintaining 
appreciable anticancer activity across a variety of malignancies, and unique mechanisms of 
action. From this category, ruthenium-based metallodrugs are by far the most successful, as 
they offer great potential as cytostatic and cytotoxic agents.4 Ruthenium-based complexes 
have gained significant prominence as potential anticancer agents, as these metal complexes 
display diverse and non-conventional mechanisms of action.5 Additionally, the ruthenium 
metal center offers the unique advantage of having Ru(II), Ru(III) and Ru(IV) oxidation states 
accessible under physiological conditions.6 This distinctive feature presents a unique 
advantage in the rational design of metallodrugs, as the anticancer activity and mechanisms 
of action of most metal-based compounds are dependent on the oxidation state of the metal 
center.7–11  
To date, the most successful ruthenium complexes are the New Anti-tumour Metastatic 
Inhibitor-A (NAMI-A) and IT-139 (Figure 3.1) which have entered clinical trials.2,12 NAMI-A 
possesses anti-metastatic properties, reduces metastases mass and prevents the formation 
of secondary tumours. However, NAMI-A has minimal effects on primary tumour growth.13 
On the other hand, IT-139 is a cytotoxic agent that is effective against advanced solid tumours, 
showing promising activity against non-small lung cancer, neuroendocrine and sarcoma 
God i s great  
Chapter 3 
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tumours.12,14 The success of ruthenium-based complexes and their alternate mechanisms of 
action suggests that these complexes may facilitate the discovery of new combination 
chemotherapy agents. This is due to several reports of half-sandwich ruthenium(II)-arene 
complexes (where the arene is either η6-p-cymene or η5-C5H5) having several intracellular 
targets, including but not limited to DNA interaction and binding,15 and induction of 
apoptosis.16,17 
Furthermore, ruthenium(II)-arene complexes have been reported to show potent inhibition 
of enzymes that are overexpressed in human cancers and play vital roles in the growth and 
progression of tumours, including the PARP-1,18 the CDK1,19 and cathepsin B enzymes.20  
The incorporation of pharmacophores onto dendritic scaffolds and the combination of these 
dendritic ligands with PGMs, to form multinuclear organometallic complexes, is a prolific area 
of research which has been explored substantially as a strategy in anticancer drug  
design.21–30 The interest in these multinuclear complexes is cultivated by the reported 
enhanced anticancer activity and selectivity observed for these multinuclear complexes, 
relative to their mononuclear counterparts.26,28,31 To the best of our knowledge, no work has 
been reported on the synthesis of trinuclear benzimidazole-based complexes with 
ruthenium(II) nuclei at the periphery. This Chapter describes the synthesis and 
characterization of a series of benzimidazole-based ruthenium(II) organometallic compounds.  
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3.2  Synthesis of the neutral cyclometallated trimetallic C^N-Ruthenium(II)-p-
cymene complexes (19 – 21) 
3.2.1 Synthesis 
The synthesis of the cyclometallated trimeric C^N-Ru(II)-p-cymene complexes (19 – 21) 
involved two reactions. Firstly, the preparation of the [RuCl(µ-Cl)(p-cymene)]2 dimer was 
achieved following a literature procedure.32 This was subsequently followed by 
cyclometallation of the 2-phenyl tris-benzimidazole ligands (7 – 9) to yield the trinuclear 
neutral complexes (19 – 21) via a sodium acetate assisted C-H activation reaction  (Scheme 
3.1). In this reaction, the appropriate  2-phenyl tris-benzimidazole ligand (7 – 9) was reacted 
with 1.5 molar equivalents of the [RuCl(µ-Cl)(p-cymene)]2 dimer.  
 
Scheme 3.1: The general synthesis of the cyclometallated trimetallic Ru(II) complexes  (19 – 21). 
Reagents and conditions: i) MeCN or DCM: EtOH (1:1 v/v%)/ NaOAc/ RT/ 24 h. 
The application of cyclometallated complexes as biological agents has been an area of great 
interest in recent literature.33–35 However, until recently, cyclometallation reactions typically 
required a strong base, 36 strong acid, 37 mercury reagent, 38 or borate salts39,40 to provide the 
driving force in the activation of the C-H bond. However, an efficient and facile method of 
cyclometallation was discovered by Davies and co-workers.41 This reported method entailed 
the sodium acetate-catalyzed cyclometallation of [MCp*Cl2]2 (where M is Rh or Ir) or  
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Mechanistic insights of the reaction were briefly provided by Davies and co-workers, primarily 
through Density Functional Theory computational calculations, which shed light on the 
possible transition state.42,43 More recently, Jones and co-workers undertook a more rigorous 
kinetic, mechanistic and computational study into the sodium acetate-promoted 
cyclometallation of phenyl imines and 2-phenyl pyridines with [MCp*Cl2]2 (where M is Rh or 
Ir).42 The proposed mechanism of the cyclometallation of 2-phenyl tris-benzimidazoles with 
the [Ru(p-cymene)Cl2]2 dimer reported in this study (Scheme 3.2) is based on the mechanisms 
provided by Davies and co-workers41  and Jones and co-workers.42 
Although the role of sodium acetate in the cleavage of the [RuCl(µ-Cl)(p-cymene)]2 dimer to 
form the intermediate A has not been clearly elucidated, in reported kinetic studies it was 
observed that the intermediates A and B are formed rapidly and are in a dynamic 
equilibrium.42 From A and B, a vacant site is required for the formation of the transition state 
(D).  As a result, A and B undergo dissociation of either the chloride or acetate anions, 
respectively, to form the key intermediate C. This is followed by the formation of the agostic 
transition state D, with the cleavage of the C-H bond being the rate-determining step in the 
formation of D. The proton from the cleavage of the C-H bond is transferred to acetate moiety 
to form intermediate E. The protonated acetate is subsequently substituted by an acetate ion 
to form the acetate intermediate F. The acetate coordinated F is rapidly converted to the 
corresponding cyclometallated complex by the dissociation of the κ1-acetate by a chloride 
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Scheme 3.2: The proposed mechanism of the C-H activation reaction yielding the cyclometallated 
trimetallic C^N-Ruthenium(II)-p-cymene complexes. 
The neutral trinuclear cyclometallated Ru(II) complexes (19 – 21) were isolated in excellent 
yields (84 – 88%) as either green (19) or dark yellow powders (20 and 21) that are air- and  
moisture-stable, and are soluble in dimethylsulfoxide, acetonitrile or acetone.  
3.2.2 Characterization 
The 1H NMR spectra (Figure 3.2) of the cyclometallated complexes (19 – 21) correlates to the 
proposed structures of these complexes. In the obtained 1H NMR spectra (Figure 3.2), the 
appearance of four (for 19) or five (for 20 and 21) signals between δH 5.00 and δH 6.00 ppm 
which collectively integrate for twelve protons, corresponding to the aromatic protons of the 
p-cymene ring (H-q, H-r, H-s and H-t), are the first indicator of cyclometallation. Additionally, 
the two multiplets observed in the range δH 0.51 – 1.00 ppm, integrating for eighteen protons, 
correspond to the methyl protons of the iso-propyl functionality of the p-cymene ancillary 
ligand (H-u and H-v for 19, and H-v and H-x for 20 and 21) and support the formation of the 
complex. These signals are observed as two multiplets due to the methyl groups of the  
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planar symmetry of the p-cymene ring, due to the chelation of the Ru(II) metal center to the 
2-phenyl tris-benzimidazoles. 
However, in the aromatic regions (in the range δH  6.50 – 8.50 ppm) of the 1H NMR spectra of 
20 and 21, an intricate aromatic spectrum was observed for each of the complexes. As a 
result, additional analytical techniques were used to further attest to the integrity of the 
complexes 20 and 21.  
Figure 3.2: The stacked 1H NMR spectra of the trimeric cyclometallated C^N-Ru(II) complexes 19, 21, 
and 20, in DMSO (d6) and CDCl3, respectively. 
High-Resolution Electrospray Ionization Mass Spectrometry (HR ESI-MS) analysis of 21 
revealed a molecular ion peak at m/z = 1494.3296 that corresponds to the [M – Cl]+ ion and 
confirms the formation of the neutral complex 21 (Figure 3.3 a), and cyclometallation of all 
three benzimidazole cores. Additionally, upon analysis of the high-resolution mass spectrum 
of 20, a molecular ion fragment at m/z = 1157.3227 that corresponds to [M + Na+ - 
C26H25ClF3N2Ru]+ was observed and this further substantiates metal complexation and 
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Figure 3.3: The High-Resolution ESI Mass Spectra of 21 a) and 20 b) recorded in the positive-ion mode 
(+ve), with assigned characteristic fragments observed. 
In addition to the NMR and high-resolution mass spectrometry, IR spectroscopy was also 
useful in validating metal complexation. Generally, it was noted that the absorption band 
corresponding to the imine (C=N) functional group in the Ru(II) complexes (19 – 21) is 
observed at a lower wavenumber relative to the corresponding 2-phenyl tris-benzimidazole 
ligands (7 – 9), shifting from a range of 1625 – 1695 cm-1 in the ligands to 1578 – 1581 cm-1 in 
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Figure 3.4: The stacked Infrared spectra of the 5-trifluoromethyl substituted 2-phenyl tris-
benzimidazole ligand (8) and its corresponding cyclometallated complex (20). 
This observed lowering in wavenumber of the absorption band correlating to the imine 
moiety in the cyclometallated complexes (19 – 21), relative to their respective ligands (7 – 9), 
confirms successful coordination of the Ru(II) metal center to the imine nitrogen. The 
resultant lowering of the wavenumber is attributed to π-backbonding between the imine 
nitrogen atom and the Ru(II) metal center (Scheme 3.3). This is a synergistic phenomenon in 
which there is a sigma donation of electron density from the imine nitrogen atom to a vacant 
bonding orbital of the Ru(II) center. Concurrently, there is back-donation of electron density 
from the filled d-orbitals of the Ru(II) center to the unoccupied π*-antibonding orbitals of the 
imine. This results in the strengthening of the Ru(II)-N bond, which is accompanied by the 
synergistic decrease in the bond order of the imine C=N bond, yielding the consequential 
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Scheme 3.3: A schematic representation of π-backbonding interactions in the cyclometallated 
benzimidazole complexes. With the C=N:       Ru σ-donation (top) and the Ru       N=C back-donation 
(bottom).  
Additionally, to attest to the purity of the cyclometallated complexes 20 and 21, these 
complexes were analyzed using CHN elemental analysis. The entrapment of solvent molecules 
was anticipated, as the arms of the tris-core tend to fold back on one another.44 This may be 
the cause of the inclusion of three water molecules with each molecule of either complex 20 
or 21. The presence of water molecules correlates with the peaks observed in both the  
1H NMR spectra of 20 and 21 (Figure 3.2, vide supra) which correspond to water (the broad 
signal at δH 1.56 ppm in the 1H NMR spectra of 20, and the signal at δH  3.33 ppm in the  
1H NMR spectra of 21). 
3.3  Synthesis of the cationic trimetallic N^N-Ruthenium(II)-p-cymene complexes 
(22 – 24) 
3.3.1 Synthesis 
The synthesis of the cationic N^N-Ruthenium(II)-p-cymene complexes was achieved by two 
steps: i) firstly, the bridge splitting reaction of the [RuCl(µ-Cl)(p-cymene)]2 dimer with the 
appropriate 2-pyridyl tris-benzimidazole ligand (10 – 12) in a mixture of DCM: EtOH  
(1: 1 v/v%) at room temperature. This was followed by, ii) a salt metathesis reaction using 
ammonium hexafluorophosphate to yield the appropriate complex as a hexafluorophosphate 
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Scheme 3.4: The general synthetic route of the cationic N^N-Ruthenium(II)-p-cymene complexes  
(22 – 24). Reagents and conditions: i) EtOH: DCM (1:1 v/v%)/ RT/ 24 h; ii) ) EtOH: DCM (1:1 v/v%)/ 
NH4PF6/ RT/ 1 h.  
After 24 hours, TLC analysis revealed that the limiting reagent (the 2-pyridyl  
tris-benzimidazole ligands 10 – 12) had completely reacted. This suggested that the reaction 
had reached completion, and thereafter the crude reaction product was reacted with NH4PF6 
in DCM: EtOH (1: 1 v/v%). The cationic complexes were isolated in moderate to good between 
51% and 75%, as yellow hexafluorophosphate salts that are air- and moisture-stable, and are 
soluble in dimethylsulfoxide, dichloromethane or acetone.   
3.3.2 Characterization 
Analysis and comparison of the 1H NMR spectra of the cationic Ru(II) complexes 22 – 24 
(Figure 3.5) to that of the corresponding 2-pyridyl tris-benzimidazole ligands (10 – 12, in 
Figure 2.5, vide supra) reveals resonances characteristic of successful complex formation. 
Firstly, the signal corresponding to the proton bonded to the carbon adjacent to the pyridyl 
nitrogen (H-n for 10 and 22, H-o for 11, 12, 23 and 24) was observed at a significantly higher 
chemical shift in the ruthenium(II) complexes 22 – 24 (from δH 8.25 – 8.50 ppm in the ligands, 
to δH ~9.6 ppm in the metal complexes). This is due to the bonding of the pyridyl nitrogen to 
the ruthenium metal center resulting in π-backbonding, which consequentially results in the 
reduction of electron density on the carbon adjacent to the pyridyl nitrogen. Additionally, 
three (for 22) or four (for 23 and 24) signals were observed  in the range δH 6.00 – 6.50 ppm 
which collectively integrate for twelve protons, corresponding to the aromatic protons of the 
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These resonances confirm the bidentate coordination of the ruthenium(II) center to both the 
imine and the pyridyl nitrogen atoms, as these signals are indicative of the stereogenicity 
introduced by the chelation of the Ru(II) metal center to the imine and the 2-pyridyl nitrogen 
atoms. 
On comparing the 13C{1H}-NMR spectra of  complexes (22 – 24) to that of the corresponding  
2-pyridyl ligands (10 – 12), it was generally noted that the signal corresponding to the carbon 
adjacent to the pyridyl nitrogen in the complexes was observed at a significantly higher 
chemical shift relative to that of the corresponding ligand (from δC 148.52 – 149.37 ppm in 
the ligands, to δC 157.89 – 158.85 ppm in the metal complexes). This is consistent with the 
same trend which was observed in the 1H NMR spectra, and further corroborates the bonding 
of the pyridyl nitrogen to the ruthenium metal center, which results in the reduction of 
electron density on the pyridyl carbon through π-backbonding.  
The 31P{1H}-NMR spectra of the cationic complexes (22 – 24) revealed a high field septet at  
δP ~-114 ppm. This signal correlates to the phosphorus atom of the PF6 counter-ions, which 
couples to the six fluorine atoms with 1JP-F = 711 Hz. This further attesting to the successful 
counter-ion exchange and confirms the presence of one phosphorus salt.  
Figure 3.5: The stacked 1H NMR spectra of the cationic N^N-Ruthenium(II)-p-cymene complexes (22 – 
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In addition to the 1H NMR and 13C{1H}-NMR spectral analyses, the Ru(II) complexes (22 – 24) 
were analyzed using IR spectroscopy, and the results obtained are summarised in Table 3.1. 
Generally, the IR spectra revealed absorption bands corresponding to the imine (C=N) moiety 
of the benzimidazole cores and the pyridyl C=N bond at lower wavenumbers in the complexes 
(22 – 24), relative to their respective 2-pyridyl tris-benzimidazole ligands (10 – 12). The 
observed lowering of the absorption bands corresponding to the abovementioned C=N bonds 
can be explained by the π-backbonding interactions of the Ru(II) metal center and the 
nitrogen atoms of the imine and pyridyl functionalities (Scheme 3.3, vide supra). The observed 
lowering of both the imine C=N and pyridyl C=N stretching frequencies in the cationic 
complexes (22 – 24), relative to their respective 2-pyridyl ligands (10 – 12), confirms the 
chelation of the Ru(II) centers to both the imine and pyridyl nitrogen atoms.  
Table 3.1: The wavenumber (cm-1) of the C=N bonds of the cationic ruthenium(II) complexes 22 – 24 
and their corresponding ligands 10 – 12. 
 
The correlation of the analytical data and the proposed structures leads to the conclusion that 
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3.4  Synthesis of the cationic mononuclear N^N-Ruthenium(II)-p-cymene complex 
(25) 
3.4.1 Synthesis 
The synthesis of the cationic mononuclear complex (25) was achieved using the same  
two-step procedure as reported in Section 3.3.1 (vide supra), for the synthesis of the 
trimetallic cationic N^N-Ru(II) complexes (22 – 24), using the appropriate molar equivalents 
(Scheme 3.5).  
 
Scheme 3.5: Synthesis of the cationic N^N-Ru(II)-p-cymene complex (25). Reagents and conditions: 
 i) EtOH: DCM (1:1 v/v%)/ RT/ 24 h; ii) ) EtOH: DCM (1:1 v/v%)/ NH4PF6/ RT/ 1 h. 
After 24 hours, TLC analysis revealed that the 2-pyridylbenzimidazole ligand (18) had 
completely reacted. This suggested that the reaction had reached completion, and thereafter 
the crude reaction product was reacted with NH4PF6 in DCM: EtOH (1: 1 v/v%). The cationic 
complex (25) was isolated in a good yield of 81%, as a yellow hexafluorophosphate salt that 
is air- and moisture-stable and is soluble in dimethylsulfoxide, dichloromethane or acetone.   
3.4.2 Characterization 
Upon comparison of the 1H NMR spectra of the cationic complex (25) to that of the  
2-pyridylbenzimidazole ligand (18), numerous resonances that are diagnostic of complex 
formation are present (Figure 3.6). The first indicator of successful complex formation is the 
splitting of the signal corresponding to the methylene protons of the ethyl functionality from 
a distinct quartet (at δH 4.85 ppm), in the ligand (18), to an intricate multiplet, in the complex 
25 (at δH 4.90 ppm). This splitting is due to the introduction of stereogenicity by the Ru(II) 
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Additionally, three signals between δH 6.00 and δH 6.50 ppm, collectively integrating for four 
protons, correlate with the aromatic protons of the p-cymene auxiliary ligand.  
The 13C{1H}-NMR spectrum of the mononuclear complex (25) revealed a signal corresponding 
to the carbon adjacent to the pyridyl nitrogen (C-i) at δC 157.91 ppm. This observed chemical 
shift is comparable to that of the carbon signal corresponding to the carbon adjacent to the 
pyridyl nitrogen (C-o, at δC 157.98 ppm) in the 13C{1H}-NMR spectrum of the trinuclear cationic 
complex (22), and support successful complex formation. Additionally, the signals 
corresponding to the methyl carbons on the iso-propyl functionality of the p-cymene ancillary 
ligand are observed at δC 22.13 (C-r) and δC 22.10 (C-p) in the spectrum of the mononuclear 
complex (25). These signals are comparable to those observed for the same iso-propyl 
functionality of the p-cymene auxiliary ligand (C-t and C-v, at δC 22.25 ppm and 22.13 ppm, 
respectively) in the trinuclear cationic complex (22). These signals corroborate the successful 
synthesis of the mononuclear cationic complex (25). 
 
Figure 3.6: The stacked 1H NMR spectra of the mononuclear cationic N^N-Ruthenium(II)-p-cymene 
complex (25) in DMSO (d6) and the 2-pyridylbenzimidazole ligand (18) in CDCl3. 
 
Further complementing spectroscopic and analytical data, was the ESI mass spectrometry 
data for the mononuclear cationic complex (25), which showed a molecular ion base peak at 
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3.5  Summary  
A series of neutral cyclometallated C^N-Ru(II)-p-cymene (19 – 21) and cationic N^N-Ru(II)-p-
cymene (22 – 24) trinuclear complexes were successfully synthesized. The complexes were 
afforded in moderate to excellent yields (51 – 88%). Additionally, the mononuclear cationic 
N^N-Ru(II)-p-cymene complex (25) was synthesized and isolated in an excellent yield  
(81%). All the complexes were fully characterized using a range of spectroscopic and analytic 
techniques including NMR (1H, 13C{1H}, 31P{1H}, HSQC and COSY) spectroscopy, IR 
spectroscopy, elemental analysis and mass spectrometry (electrospray ionization), which all 
attest to the integrity of the complexes. The attained analytical and spectroscopic data 
correlate well with the proposed structures (19 – 25). 
The small library of novel ruthenium(II) complexes reported in this Chapter may contribute to 
the ever-growing field of the biological applications of multinuclear organometallic 
complexes. These complexes will be evaluated for their anticancer activity against an array of 
malignant cells and mechanistic studies will be conducted on the most promising complexes 
from this series. Additionally, the synthesis of the mononuclear counterpart of the trinuclear 
cationic complex 22 may highlight the merit in the investigation of multinuclear complexes 
relative to their mononuclear counterparts. The anticancer evaluation of the trinuclear 
complex 22 and its mononuclear counterpart 25 may highlight the unique advantage that 
multinuclear complexes have of exploiting the Enhanced Permeability and Retention (EPR) 
effect, thus potentially resulting in superior anticancer activity and selectivity.  
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4.1  Introduction 
Classical platinum(II)-based metallodrugs with the cis-[PtX2(amine)2] general chemotype 
(where X = leaving group; amine = neutral or carrier group) have been in clinical use for the 
treatment of cancer for over thirty years, with the most commonly known example being 
cisplatin.1 However, these platinum anticancer agents lack specificity for cancer cells and 
target all rapidly dividing cells including those in the hair follicles, bone marrow and the 
gastrointestinal tract.2 This lack of selectivity often leads to the development of severe 
adverse side effects including hair loss, vomiting and neurotoxicity.3 Additionally, the 
prevalence of resistance towards clinically used platinum drugs displayed by various cancers 
is a growing concern, as platinum drugs constitute the majority of current combination 
chemotherapy regimens.4,5 Overcoming the aforementioned challenges has thus been of 
great interest to cancer researchers. 
One approach that can be used to reduce the side effects caused by platinum-based 
metallodrugs is to replace the platinum metal center with an alternative Platinum-Group 
Metal (PGM). Motivated by the promising results of the ruthenium drug candidates,  
NAMI-A, IT-139 and TLD-1433, ruthenium-based organometallic complexes have been of 
great interest.6 Indeed, numerous ruthenium(II)-arene complexes which show promising 
anticancer activity have been developed.7–9 For example, RM179 (Figure 4.1 a) which was 
developed by the Sadler group in 2001, is one of the first ruthenium(II)-arene complexes to 
be investigated for anticancer activity.10 This ruthenium complex was reported to be a potent 
inhibitor of MDA-MB-231 and MCF-7 breast cancer cell metastasis in vitro, through its ability 
to inhibit the matrix metalloprotease-2 (MMP-2) enzyme.2 Furthermore, the complex was 
also observed to reduce murine mammary carcinoma (MCa) tumours in vivo. RAPTA-C (Figure 
4.1 b), was the second notable ruthenium(II)-arene complex developed by the Dyson group. 
To God Be The Gl ory  
Chapter 4 
In Vitro Biological Evaluation of Trinuclear Ruthenium(II)-p-cymene complexes 
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RAPTA-C exhibits selectivity towards the TS/A mouse mammary adenocarcinoma cell line as 
opposed to non-tumorigenic mammary epithelial cells (HBL-100).11 Additionally, it was noted 
that RAPTA-C shows activity similar to that of NAMI-A in the reduction of the growth of lung 
metastases in mice bearing the MCa tumours. Despite the promising strides in the 
development of organometallic complexes with enhanced selectivity, the threat of either 
intrinsic or developed resistance of cancer cells to chemotherapeutic agents remains a major 
hurdle in rational anticancer metallodrug design. 
A strategy that may be used to overcome intrinsic or developed resistance of cancer cells to 
clinically used metal-based anticancer agents is to develop multinuclear organometallic 
complexes with novel mechanisms of action. This concept was used in the development of 
BBR3464 (Figure 4.1 c), a complex comprised of three trans-configured platinum moieties 
linked by diaminoalkanes. The BBR3464 trinuclear complex has been reported to show a 
higher degree of DNA interstrand crosslinking compared to cisplatin.12 Furthermore, it was 
reported to show enhanced activity two to three times the magnitude of that noted for 
cisplatin in the cisplatin-resistant A2780cisR, 41McisR and the CH1cisR human ovarian cancer 
cell lines.13 Despite the limited success of BBR3464 in Phase II clinical trials for the treatment 
of patients with small-cell lung carcinoma, gastric and gastroesophageal cancers,14–16 the 
trinuclear complex provides additional credibility for the concept that multinuclearity may 
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Figure 4.1: The structures of the ruthenium(II)-arene complexes RM175 a) and RAPTA-C b), and the 
trans-platinum(II)-based complex BBR3464 c).  
The enhanced potency of multinuclear systems, relative to their mononuclear analogues, may 
be attributed to the Enhanced Permeability and Retention (EPR) effect.17,18 The EPR effect 
refers to the preferential accumulation of multinuclear complexes in solid tumours, over 
normal tissues, due to tumours having porous vasculature. Once inside the tumour cells, the 
multinuclear complexes are retained at a high concentration due to poor lymphatic drainage 
of tumours. This results in enhanced cytotoxicity specifically towards tumour cells and thus 
minimize side effects.19  
The development of trinuclear complexes has been mainly focused on the platinum metal 
center. Analogous trinuclear ruthenium complexes have been less studied for their anticancer 
properties with only a handful of examples in the literature.20–24 This chapter therefore 
explores the in vitro anticancer activity of the 2,5-disubstituted tris-benzimidazole 
compounds (7 – 15) and their respective triruthenium(II) complexes (19 – 24) that were 
synthesized in this study. Furthermore, the interaction of the most active trinuclear 
ruthenium(II) complex with Guanosine 5’-monophosphate disodium (5’-GMP) was also 
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4.2  In vitro single dose pre-screen 
To identify compounds with potential anticancer activity, the 2,5-disubstituted  
tris-benzimidazole compounds (7 – 15) and their corresponding ruthenium(II) complexes  
(19 – 24) synthesized in this study were pre-screened for their in vitro cytotoxicity against the 
MCF-7 and MDA-MB-231 breast cancer cell lines and the 501 melanoma skin carcinoma cell 
line. The compounds were firstly tested for their cytotoxicity at 10 µM using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) assay.26 This concentration was 
selected based on the approach by the National Cancer Institute (NCI, USA) which conducts a 
pre-screen of putative anticancer drug candidates at 10 µM.25 MTT  is a yellow tetrazolium 
salt that gets reduced to purple water-insoluble formazan crystals (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenylformazan) by dehydrogenase enzymes in viable cells, using NADH and NADPH 
as co-substrates (Scheme 4.1).27 After solubilization of the formazan crystals, the number of 
viable cells can be quantified colorimetrically by measuring the absorbance at 600 nm. In all 
the biological assays, cisplatin was used as a positive control. Due to the compounds showing 
mild to no activity at 10 µM, their cytotoxicity was subsequently tested at 20 µM.  
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4.2.1 In vitro cytotoxicity of the 2,5-disubstituted trimeric ligands  
(7 – 12) and their trinuclear Ru(II) complexes (19 – 24) in the MCF-7 breast 
cancer cell line  
The data obtained for the in vitro anticancer evaluation of the 2-phenyl tris-benzimidazole 
ligands (7 – 9) and their corresponding cyclometallated complexes (19 – 21) against the  
MCF-7 breast cancer cell line is summarized in Figure 4.2. At 10 µM, all the tested compounds 
from this series showed mild to no activity, as they were only able to reduce cancer cell 
viability by 3% to 19%. Upon doubling the concentration to 20 µM, the 2-phenyl  
tris-benzimidazole ligands (7 – 9) and their respective complexes (19 – 21) reduced MCF-7 cell 
viability by 14% to 22%. There was therefore only a slight increase in their activity at 20 µM. 
The most active compound from this series was the 5-unsubstituted ligand 7 which inhibits 
MCF-7 cell viability by 19% and 22% at 10 and 20 µM, respectively. Additionally, with the 
exception of ligand 7 and its corresponding cyclometallated complex 19, there was a 
significant enhancement of the anticancer activity of the 2-phenyl tris-benzimidazole ligands 
(8 and 9) upon complexation with the ruthenium(II) metal centers to yield the corresponding  
complexes (20 and 21, respectively). For example, when comparing the activity of ligand 8 
and its corresponding cyclometallated complex (20), the complex (20) shows 4% and 16% 
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Figure 4.2: The percentage cell viability as measured by MTT assays in MCF-7 breast cancer cells 
exposed to either vehicle (0.1% DMSO) or the 2-phenyl ligands (7 - 9) and their corresponding neutral 
C^N-Ru(II) complexes (19 - 21) at 10 and 20 µM concentrations for 48 hours. 35 µM cisplatin (the IC50 
of cisplatin in MCF-7 cells treated for 48 hours28) was included as a positive control. 
The 2-pyridyl tris-benzimidazole ligands (10 – 12) and their corresponding cationic complexes 
(22 – 24) showed appreciable cytotoxic activity in the MCF-7 breast cancer cell line (Figure 
4.3). Indeed, at 10 µM they reduced MCF-7 cancer cell viability by 5% to 31% and this was 
improved by 12% to 57% at 20 µM. The most active compound from this series is the  
5-unsubstituted  ligand 10 which inhibits MCF-7 breast cancer cell viability to 69% at 10 µM 
and to 43% at 20 µM. Importantly, ligand 10 at 20 µM has comparable cytotoxicity to cisplatin 
at 35 µM which suggests that ligand 10 may be more cytotoxic to MCF-7 cells at equivalent 
concentrations of cisplatin. Furthermore, with the exception of the trimeric ligand 10 and its 
corresponding cationic complex 22, at 10 µM the ruthenium(II) complexes (23 and 24) show 
enhanced activity relative to their corresponding 2-pyridyl tris-benzimidazole ligands (11 and 
12, respectively). For example, the cationic ruthenium(II) complex 23 was observed to show 
15% greater inhibition of cancer cell viability relative to its corresponding 5-methyl 
substituted 2-pyridyl ligand (12). With the exception of ligand 11 and its corresponding 
complex 23, which both reduced MCF-7 cell viability to 73%, the same trend was observed at 
20 µM for the other compounds tested. This general trend observed highlights the synergistic 
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Figure 4.3: The percentage cell viability as measured by MTT assays in MCF-7 breast cancer cells 
exposed to either vehicle (0.1% DMSO) or the 2-pyridyl trimeric ligands (10 – 12) and corresponding 
trinuclear N^N-Ru(II) cationic complexes (22 - 24) at 10 and 20 µM concentrations for 48 hours. 35 µM 
cisplatin (the IC50 of cisplatin in MCF-7 cells treated for 48 hours28) was included as a positive control. 
A comparison of the in vitro anticancer activity obtained for the 2-phenyl tris-benzimidazole 
ligands (7 - 9) and their corresponding neutral C^N-Ru(II) complexes (19 – 21) shown in Figure 
4.2, to that of the 2-pyridyl tris-benzimidazole ligands (10 – 12) and their respective cationic 
N^N-Ru(II) complexes (22 – 24) as shown in Figure 4.3, reveals a number of trends. Firstly, at 
10 and 20 µM, the 5-unsubstituted trimeric ligands (7 and 10) show greater activity than the 
corresponding ruthenium(II) complexes (19 and 22, respectively). Additionally, the 2-pyridyl 
tris-benzimidazole ligands (10 – 12) show activity superior to that of their respective 2-phenyl 
tris-benzimidazole ligands (7 – 9). This is exemplified by the 5-unsubstituted 2-pyridyl ligand 
(10) showing 12% and 35% greater MCF-7 cell inhibition, at 10 and 20 µM respectively, 
compared to the 5-unsubstituted 2-phenyl ligand (7). 
Furthermore, the cationic trimetallic complexes (22 – 24) show enhanced cytotoxicity relative 
to their respective neutral cyclometallated complexes (19 – 21). This is evidenced by the 
cationic complex 22 showing 12% to 15% greater inhibition of MCF-7 cancer cell viability, 
relative to the neutral complex 19, at both 10 and 20 µM. A similar trend was previously 
reported, in which cationic organometallic complexes showed significantly enhanced 
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intracellular accumulation of the cationic compounds relative to their neutral conjugates, as 
it has been noted that the ability of cationic complexes to cross the cellular membrane may 
be equal and even superior to that of neutral complexes.33–35 
4.2.2 In vitro pre-screen of the anticancer activity of 2-ferrocenyl tris-
benzimidazole compounds (13 – 15) in the MCF-7 breast cancer cell line  
The use of the ferrocenyl moiety as a non-planar bioisostere for aryl and heteroaryl rings was 
first introduced in the 1970s.36 However, the medicinal applications of these compounds have 
only been fully appreciated in the last two decades. This resulted from the independent 
discoveries that ferroquine and ferrocifens showed enhanced antimalarial and anticancer 
activity, respectively, relative to their organic counterparts.37 The aqueous stability and 
favorable electrochemical properties have made the ferrocenyl functionality an ideal 
candidate for biological applications and conjugation to biomolecules.38 This prompted the 
evaluation of the anticancer activity in the MCF-7 breast cancer cell line of 10 and 20 µM  
2-ferrocenyl tris-benzimidazoles (13 – 15) which were synthesized in this study.  
The biological data obtained from the in vitro pre-screening of the 2-ferrocenyl  
tris-benzimidazole compounds (13 – 15) are summarized in Figure 4.4. Interestingly, all the  
2-ferrocenyl compounds (13 – 15) screened did not show any appreciable reduction in  
MCF-7 cancer cell viability at both concentrations tested. This was unexpected as ferrocenyl-
conjugated molecules are known to promote the production of Reactive Oxygen Species 
(ROS) via Fenton-type processes, which generally trigger cell death. An example of 
compounds that are known to use this mechanism of action to elicit anticancer effects is the 
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Figure 4.4: The percentage cell viability as measured by MTT assays in MCF-7 breast cancer cells 
exposed to either vehicle (0.1% DMSO) or the 2-ferrocenyl compounds (13 – 15) at 10 and 20 µM 
concentrations for 48 hours. 35 µM cisplatin (the IC50 of cisplatin in MCF-7 cells treated for 48 hours28) 
was included as a positive control. 
Upon closer inspection, precipitation was observed in the medium of cells treated after 3 to 
5 hours with 10 and 20 μM compounds 13 – 15 (red arrows in Figure 4.5 a, b and c). This may 
explain the inactivity of the 2-ferrocenyl compounds (13 – 15) in the MTT assays. Because the 
tested compounds were initially dissolved in DMSO, this observation prompted the change to 
another Generally Regarded as Safe (GRAS) solvent, Ethanol.  
 
Figure 4.5: Microscopic images of the MCF-7 breast cancer cells in culture after treatment with the  
2-ferrocenyl compounds 13 (a), 14 (b) and 15 (c), showing extensive precipitation of these compounds 
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However, this change in solvent did not prevent the precipitation of the 2-ferrocenyl 
compounds (13 – 15). Indeed, microscopic inspection of the cells treated for 3 – 5 hours with 
20 μM of the 2-ferrocenyl tris-benzimidazoles (13 – 15) dissolved in Ethanol (Figure 4.6 a, b 
and c) revealed more extensive precipitation than when DMSO was used as the solvent 
(Figure 4.5 a, b and c, vide supra).  
 
Figure 4.6: Microscopic images of the MCF-7 breast cancer cells in culture after treatment for 3 – 5 
hours with the 2-ferrocenyl compounds 13 (a), 14 (b) and 15 (c) dissolved in Ethanol. Extensive 
precipitation is shown with red arrows. 
The observed precipitation of the 2-ferrocenyl tris-benzimidazoles (13 – 15) out of growth 
media, correlated with them not exhibiting any cytotoxic effects in MCF-7 breast cancer cells 
(Figure 4.7).  
Figure 4.7: The percentage cell viability as measured by MTT assays in MCF-7 breast cancer cells 
exposed to either vehicle (0.1% EtOH) or the 2-ferrocenyl compounds (13 – 15) at 20 µM for 48 hours. 
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4.2.3 In vitro pre-screen of the cytotoxicity of the 2-pyridyl trimeric ligands (10 – 
12) and the cationic complexes (22 – 24) against the MDA-MB-231 cell line  
Due to the promising cytotoxic activity observed for the 2-pyridyl tris-benzimidazole ligands 
(10 – 12) and their corresponding trinuclear cationic complexes (22 - 24) in the MCF-7 breast 
cancer cell line, they were evaluated for their cytotoxic activity in the MDA-MB-231 breast 
cancer cell line. The MDA-MB-231 cell line is a triple-negative (oestrogen, progesterone and 
human epidermal growth factor 2 receptor-negative) and highly invasive breast cancer cell 
subtype41,42 which is notoriously hard to treat.43  
The data obtained from the in vitro pre-screening of the 2-pyridyl ligands (10 – 12) and their 
corresponding cationic complexes (22 – 24) against the MDA-MB-231 cell line at 20 µM are 
summarized in Figure 4.8. When these results are compared with those obtained for the MCF-
7 breast cancer cell line at 20 µM (Figure 4.3 vide supra), the 2-pyridyl tris-benzimidazole 
ligands (10 – 12) and their corresponding trinuclear cationic complexes (22 - 24) were 
significantly less active. Indeed, these compounds inhibited MCF-7 cell viability by 11% to 23% 
more than in the MDA-MB-231 breast cancer cells. An exception was the 5-methyl substituted 
cationic complex (24) which was 5% more potent in the MDA-MB-231 cell line than in the 
MCF-7 cell line.  
When the activity of the 2-pyridyl tris-benzimidazole ligands (10 – 12) was compared to that 
of their corresponding trimetallic cationic complexes (22 – 24) in the MDA-MB-231 cell line,  
similar trends were observed as in the MCF-7 breast cancer cell line. Firstly, the activity of the 
5-unsubstituted 2-pyridyl ligand (10) is superior to that of the corresponding ruthenium(II) 
complex (22). Additionally, the general enhanced activity of the cationic complexes (23 and 
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Figure 4.8: The percentage cell viability as measured by MTT assays in MDA-MB-231 breast cancer 
cells exposed to either vehicle (0.1% DMSO) or the 2-pyridyl ligands (10 – 12) and their corresponding 
trinuclear N^N-Ru(II) chelated complexes (22 - 24) at 20 µM for 48 hours. 23 µM cisplatin (the IC50 of 
cisplatin in MDA-MB-231 cells treated for 48 hours44) was included as the positive control. 
Owing to their promising activity in the pre-screens in the MCF-7 and the MDA-MB-231 breast 
cancer cell lines, the promising 2-pyridyl ligands (10 and 11), and their respective cationic 
trimetallic complexes (22 and 23), were selected for further multidose screening. The 
multidose experiments were aimed at determining the IC50 values of the selected compounds 
against the MCF-7 and MDA-MB-231 breast cancer cell lines and are discussed in Section 4.3, 
vide infra.  
4.2.4 In vitro cytotoxic evaluation of the 2-pyridyl trimeric ligands (10 - 11) and the 
cationic Ru(II) complexes (22 – 23) in the 501 melanoma cells  
The threat of malignant melanoma continues to loom over the global population, as the 
incidence of this aggressive cancer is increasing rapidly more than any other solid tumour.45 
This is exacerbated by the limited success of current chemotherapeutic strategies in the 
treatment of malignant melanomas, and the ability of melanoma cells to metastasize rapidly 
to other organs.46,47 To this end, the promising 2-pyridyl tris-benzimidazole ligands (10 and 
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pre-screened for their in vitro anticancer activity against the metastatic 501 melanoma 
(501mel) cell line at 10 and 20 µM (Figure 4.9). 
Generally, at 10 µM the 2-pyridyl ligands (10 and 11) and their respective trinuclear cationic 
complexes (22 and 23) were observed to show mild to no activity. However, except for the  
5-trifluoromethyl substituted ligand (11), all the compounds tested show slightly enhanced 
activity at 20 µM. An example of this is the ruthenium(II) complex 22 which at 20 µM inhibited 
501mel cell viability by 19% more relative to at 10 µM. Additionally, in general the cationic 
complexes (22 and 23) were more cytotoxic compared to their respective 2-pyridyl ligands 
(10 and 11). This suggests that incorporation of the ruthenium(II) metal centers onto the 
trimeric 2-pyridylbenzimidazole scaffold results in the enhancement of anticancer activity due 
to the synergism of the organic scaffold and the metal centers.   
 
Figure 4.9: The percentage cell viability as measured by MTT assays in 501 melanoma cells exposed to 
either vehicle (0.1% DMSO) or the 2-pyridyl ligands (10 and 11) and their respective N^N-Ru(II) chelated 
complexes (22 and 23) at 10 and 20 µM concentrations for 48 hours. Cisplatin (at 10 and 20 µM) was 
included as the positive control. 
Interestingly, at 10 and 20 µM, the 5-trifluoromethyl cationic complex (23) and cisplatin 
showed comparable activity. However, the rest of the compounds tested showed significantly 
less potent cytotoxic activity relative to cisplatin at both the concentrations tested. As a result, 
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for multidose experiments to determine the IC50 values of these compounds in the 501 
melanoma cell line (Section 4.3.2, vide infra). 
4.3  In vitro multidose screening 
The IC50 values of the selected 2-pyridyl ligands (10 and 11) and their corresponding cationic 
complexes (22 and 23, respectively) were next determined in the MCF-7 and MDA-MB-231 
breast cancer cell lines, and the 501 melanoma cell line. In these experiments, the cancer cells 
were treated with the test compounds (10, 11, 22 and 23) at concentrations ranging from  
5 to 35 µM, and cisplatin was included as a positive control. These multidose experiments 
were performed in quadruplicate on two different occasions and the dose-response data and 
IC50 values obtained from the experiments are discussed in Sections 4.3.1 – 4.3.3, vide infra.  
4.3.1 IC50 concentrations obtained in MCF-7 breast cancer cells 
When the compounds were tested in MCF-7 breast cancer cells, the 5-unsubstituted 2-pyridyl 
ligand (10) was the most active compound, with an IC50 of 28.65 µM, which was closely 
followed by its 5-unsubstituted cationic complex (22), which had an IC50 of 33.87 µM (Figure 
4.10). These findings are consistent with the data from the pre-screen (Figure 4.3, vide supra). 
It is also worth noting that ligand 10 and complex 22 show cytotoxic activity superior to that 
of cisplatin (IC50 = 35 µM for cisplatin). 
The IC50 value of the 5-trifluoromethyl substituted 2-pyridyl trimeric ligand (11) could not be 
determined because none of the concentrations tested inhibited MCF-7 cell viability (Figure 
4.10). However, the 5-trifluoromethyl substituted cationic complex (23) had an IC50 of 35.06 
µM which is comparable to the IC50 for cisplatin in MCF-7 cells. As previously observed in the 
pre-screen, enhanced activity against the MCF-7 cell line is observed for the 5-trifluoromethyl 
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Figure 4.10: Percentage cell viability as measured by MTT assays in MCF-7 breast cancer cells treated 
for 48 hours with increasing concentrations of the 2-pyridyl trimeric ligands (10 and 11) and the 
respective trinuclear N^N-Ru(II) chelated complexes (22 and 23) or cisplatin at 35 µM28. Cells treated 
with 0.1% DMSO were included as a vehicle control. The table shows the concentration of each tested 
compound required to kill 50% of the cancer cells (IC50) which was calculated from sigmoidal plots with 
GraphPad Prism V5.01. 
As previously discussed, the monomeric 5-unsubstituted 2-pyridylbenzimidazole ligand (18) 
and its corresponding mononuclear cationic ruthenium(II) complex (25), were synthesized to 
compare their anticancer activity to that of their trimeric counterparts 10 and 22, 
respectively. Multidose screening experiments were thus performed for ligand (18) and 
complex (25) but their IC50 values could not be determined because none of the 
concentrations tested were able to inhibit MCF-7 cell viability to 50% (Figure 4.11). However, 
a comparison of the cytotoxic activity of the monomeric ligand (18) (Figure 4.11) to that of its 
respective trimeric counterpart (10) (Figure 4.10, vide supra) at 35 µM in MCF-7 cells reveals 
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In addition, at 35 µM concentrations, the trinuclear complex (22) (Figure 4.10, vide supra) is 
also approximately twice as active as its mononuclear conjugate (25) (Figure 4.11).  
 
Figure 4.11: Percentage cell viability as measured by MTT assays in MCF-7 breast cancer cells exposed 
for 48 hours to increasing concentrations of the monomeric 2-pyridylbenzimidazole ligand (18) and the 
respective mononuclear N^N-Ru(II) chelated complex (25) or cisplatin at 35 µM28. Cells treated with 
0.1% DMSO were included as a vehicle control. 
The observations that the trimeric ligand (10) and the trinuclear complex (22) have a two-fold 
increased potency compared to their respective monomeric counterparts are consistent with 
reports in the literature and highlight the merit for further investigating multimeric systems 
as potential anticancer agents.48–50   
4.3.2 IC50 concentrations obtained in MDA-MB-231 TNBC cells  
When tested against the more aggressive MDA-MB-231 TNBC cell line, only the  
5-unsubstituted trimeric 2-pyridyl ligand (10) showed mild cytotoxic activity, with an IC50 of 
33.53 µM (Figure 4.12). The ligand 10 was however less potent than cisplatin (IC50 = 23 µM). 
The IC50 values of all the other compounds tested (the 5-trifluoromethyl ligand 11, and the 
cationic complexes 22 and 23) could not be determined because none of the concentrations 
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Figure 4.12: Percentage cell viability as measured by MTT assays in MDA-MB-231 breast cancer cells 
treated for 48 hours with increasing concentrations of the 2-pyridyl ligands (10 and 11) and 
corresponding trinuclear N^N-Ru(II) chelated complexes (22 and 23) or cisplatin at 23 µM44. Cells 
treated with 0.1% DMSO were included as a vehicle control. The table illustrates the concentration of 
the tested compounds required to reduce cell viability to 50% (IC50) which was calculated from 
sigmoidal curves with GraphPad Prism V5.01.  
It is worth noting that the MDA-MB-231 TNBC cell line is known to be resistant to an array of 
anticancer chemotherapeutic agents.51 Therefore, the activity of the trimeric ligand (10) in 
the MDA-MB-231 cell line, albeit moderate, presents a promising scaffold for the rational 
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4.3.3 Cytotoxic evaluation of the 5-trifluoromethyl 2-pyridyl ligand (11) and 
complex (23) against the 501mel cell line 
The anticancer data obtained for the 5-trifluoromethyl substituted ligand (11) and its 
corresponding trinuclear cationic ruthenium(II) complex (23) in the 501mel cell line is 
summarized in Figure 4.13. The results show that none of the concentrations tested for the 
5-trifluoromethyl ligand (11) were able to inhibit 501mel cell viability (Figure 4.13). 
Consequently, the IC50 for ligand 11 in these cells could not be determined. However, the 
cationic complex (23) showed significant, albeit moderate, cytotoxic activity in 501mel cells 
with an IC50 of 34.67 µM. When the 501mel cells were treated with cisplatin an IC50 of 21 µM 
was obtained and thus cisplatin exhibits increased potency relative to complex 23. 
 
Figure 4.13: The percentage of 501mel cell viability as measured by MTT assays after 48 hour 
treatment with varying concentrations of the 2-pyridyl 5-trifluoromethyl ligand (11), the respective 
N^N-Ru(II) chelated complex (23) and cisplatin. Vehicle (0.1% DMSO) treated cells were included as a 
vehicle control. The table shows the concentration of each of the tested compounds required to reduce 
cell viability to 50% (IC50) which was calculated from sigmoidal plots with GraphPad Prism V5.01. 
The relatively moderate activity of the 5-trifluoromethyl cationic ruthenium(II) complex (23) 
in 501mel cancer cells suggests that complex 23 may present a novel scaffold for the 




Chapter 4                                                  Biological Evaluation  
4.4  In vitro cytotoxicity studies  
One of the main challenges with current chemotherapeutic drugs is their non-specificity 
which is often accompanied by numerous undesirable side-effects. A pertinent example is 
cisplatin, and its second and third-generation derivatives, carboplatin and oxaliplatin.2 Thus, 
understanding the selectivity of potential anticancer agents for cancer cells is imperative for 
drug development. The selected 2-pyridyl trimeric ligands (10 and 11) and their corresponding 
trinuclear cationic ruthenium(II) complexes (22 and 23, respectively) were therefore 
investigated for their cytotoxicity against the non-tumorigenic MCF-12A breast epithelial cell 
line. Briefly, the cells were treated with the test compounds at concentrations varying from 5 
to 35 µM for 48 hours and cell viability was assessed using the colorimetric MTT assay.  
From the results obtained it is evident that IC50 values could not be experimentally 
determined for the compounds tested (the ligands 10 and 11, and their respective complexes 
22 and 23) which suggested that they were more selective for breast cancer cells relative to 
cisplatin (Figure 4.14). Therefore, IC50 values for the compounds tested were predicted by the 
GraphPad Prism V5.01 software and a comparison with cisplatin show that cisplatin was more 
cytotoxic to the normal MCF-12A cells (Table 4.1).  
 
Figure 4.14: Percentage non-tumorigenic  MCF-12A breast epithelial cell viability as measured by MTT 
assays following 48 hour treatment with varying concentrations of either the 2-pyridyl ligands (10 and 
11) or the respective N^N-Ru(II) chelated complexes (22 and 23) or cisplatin. Vehicle (0.1% DMSO) 
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Compared to cisplatin, the 5-unsubstituted 2-pyridyl tris-benzimidazole ligand (10) and its 
respective cationic complex (22) showed less cytotoxicity towards the non-tumorigenic  
MCF-12A breast epithelial cell line (IC50 = 38.72 µM and 82.42 µM for 10 and 22, respectively, 
and IC50 = 36.32 µM for cisplatin). Importantly, the 5-trifluoromethyl substituted ligand (11) 
showed no significant reduction in MCF-12A cell viability at any of the concentrations tested 
and its corresponding cationic complex (23) was three-fold less cytotoxic towards MCF-12A 
cells relative to cisplatin (IC50 = 122.20 µM for 23 and IC50 = 36.32 µM for cisplatin).  
The selectivity indices (S.I.) of the compounds tested (10, 11, 22 and 23) were calculated by 
dividing their IC50 in the non-tumorigenic MCF-12A breast epithelial cell line by their IC50 in 
each of the breast cancer cell lines and are summarized in Table 4.1. The S.I. is a useful 
indicator of the selectivity of an anticancer drug for cancer cells and the larger the S.I. value 
the more selectively cytotoxic a compound is towards cancer cells as opposed to the non-
tumorigenic cells.  
The S.I. values obtained for the 5-unsubstituted 2-pyridyl tris-benzimidazole ligand (10) and 
its respective cationic complex (22) in MCF-7 cells were 1.35 and 2.43, respectively, which 
were significantly higher than the S.I. value of 1.04 obtained for cisplatin. Thus, compounds 
10 and 22 showed greater cytotoxicity and selectivity towards the MCF-7 breast cancer cells 
(Section 4.3.1, vide supra) than cisplatin. While the 5-trifluoromethyl triruthenium(II) complex 
23 and cisplatin showed comparable cytotoxic activity in MCF-7 cells (Section 4.3.1, vide 
supra), complex 23 was more selective for MCF-7 breast cancer cells relative to cisplatin (S.I. 
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 Table 4.1: The IC50 concentrations and the selectivity indices of the selected trimeric 2-pyridyl ligands 
(10 and 11) and their corresponding trinuclear cationic complexes (22 and 23, respectively), and the 
mononuclear conjugate of the most active ligand and complex.  
The larger S.I. values obtained for the trinuclear ruthenium(II) complexes (22 and 23), relative 
to cisplatin, suggests that these compounds may present a potent class of organometallic 
complexes with either enhanced or comparable activity respectively to cisplatin with minimal 
side effects.  
4.5  Solution stability and mechanistic insights 
The determination of the stability of compounds in solution, aqueous media and blood 
plasma is important in the identification of viable drug leads.52 The aforementioned stability 
studies are usually conducted in the presence of DMSO, which is arguably one of the most 
widely used organic solvents in the in vitro biological screening of compounds. However, 
reports of the platinum(II)-based metallodrugs cisplatin, carboplatin and oxaliplatin reacting 
with DMSO have prompted the question of stability of metal complexes in DMSO.53,54 The 
reaction of platinum(II) metallodrugs with DMSO is attributed to the affinity of the Pt(II) 
center to the nucleophilic sulfur donor atom of the DMSO molecule.55 Additionally, the 
Compound R-group 
IC50 (µM) ± SD     Selectivity     
        Indicesa, b MCF-7 MDA-MB-231 501mel  MCF-12A 
10 H 28.65 ± 1.08 33.53 ± 1.03 - 38.72 ± 1.10 ⱡ 1.35a 1.15b 
22 (Ru) H 33.87 ± 1.16 N/A* - 82.42 ± 2.29 ⱡ 2.43a - b 
11 CF3 N/A* N/A* N/A* N/A* - a - b 
23 (Ru) CF3 35.06 ± 1.07 N/A* 34.67 ± 1.13 122.20 ± 2.62 ⱡ 3.49a - b 
18 H N/A* - - - -  -  
25 (Ru) H N/A* - - - -  -  
Cisplatin - 3528 2344 21.00 ± 1.05 36.32 ± 1.09 1.04a 1.58b 
* N/A Not active at tested concentrations 
 ⱡ Predicted by GraphPad Prism V5.01 
a (IC50 MCF-12A/ IC50 MCF-7) 
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reported significant lowering of the cytotoxicity of these platinum(II)-based drugs, upon being 
dissolved in DMSO, in various cell lines has stimulated interest in investigating the effects of 
DMSO coordination to the cytotoxic  activity of organometallic complexes.53 With this in mind, 
the stability of the triruthenium(II) complexes (22 - 24) was monitored using Ultraviolet-
Visible (UV/ Vis) spectroscopy at 37 °C over 48 hours. Owing to reports of ruthenium(II) 
complexes undergoing rapid chloride/ aqua ligand exchanges forming aquated complexes 
which may form adducts with DNA,56,57 the potential interaction of the most active complex 
(22) with guanosine 5’-monophosphate disodium salt hydrate (5’-GMP) was monitored by 1H 
NMR spectroscopy.  
4.5.1 Solvent stability  
The stability of the trimetallic cationic ruthenium(II) complexes (22 – 24) was investigated 
using UV/ Vis spectroscopy at 37 °C to simulate the chemical environment prior to cell viability 
studies. In the obtained UV/ Vis spectra of the cationic complexes 22 – 24 (Figure 4.15 a - c), 
no significant changes are noted after 24 and 48 hours of incubating the compounds at  
37 °C.  
 
Figure 4.15: The UV/ Vis spectra of the trimetallic N^N-Ru(II) chelated complexes 22 (a), 23 (b) and  
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The results obtained in this study suggest that these ruthenium(II) complexes do not undergo 
solvation and further suggest that the complexes by themselves are eliciting cytotoxic effects. 
Additionally, the compounds remaining intact in DMSO suggest that they do not interact with 
DMSO, which may influence their cytotoxic activity.  
4.5.2 Mechanistic insight: 5’-GMP binding 
DNA is regarded as a potential target for metal complexes in the treatment of cancer, as metal 
complexes have been reported to form various interactions with  DNA. The most widely 
known example of a complex that forms these metal complex-DNA interaction phenomenon 
is cisplatin, which has been reported to interact in a covalent manner with purine nucleotides 
in DNA (adenine and guanine).58 As a result, the interaction of the most active ruthenium(II) 
complex (22) synthesized in this study was studied for its interactions with Guanosine 5’-
monophosphate disodium (5’-GMP) by 1H NMR spectroscopy in a 1:1 v/v% mixture of H2O 
and DMSO (d6) incubated at 37 °C over 24 hours. 5’-GMP is a simplistic model used to study 
possible nucleotide interactions.  
Free 5’-GMP was studied at 37 °C in the same conditions over 24 hours and no significant 
changes were observed in the 1H NMR spectra over 24 hours. Ruthenium complexes have 
been reported to bind to single-stranded DNA via the N-7 nitrogen of the guanosine 
nucleotide.24,59 In the model used, this binding to the N-7 nitrogen atom of the 5’-GMP will 
be reflected by the downfield shift of the signal corresponding to H-8 from δH 8.0 ppm in the 
1H NMR spectrum of free 5’-GMP to a higher chemical shift in the ruthenium-5’-GMP adduct. 
This shift may be attributed to the π-backbonding of the N-7 nitrogen atom to the 
ruthenium(II) metal center, resulting in reduced electron density on the H-8 proton, thus 
causing the signal to be observed at a higher chemical shift.  
Inspection of the obtained initial 1H NMR spectrum of the 5’-GMP and complex 22 mixture 
(Figure 4.16 c) reveals resonances that correspond to signals noted for the free 5’-GMP  
(Figure 4.16 a) and the complex 22 (Figure 4.16 b) in an approximately 1:1 ratio. After 
incubation of the mixture at 37 °C for 24 hours, the obtained 1H NMR spectrum (Figure 4.16 
d) signals corresponding to free 5’-GMP and broadened signals corresponding to the complex 
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signal from δH 8.0 ppm, thus suggesting that the ruthenium(II) metal centers of complex 22 
do not interact with the N-7 nitrogen atom of 5’-GMP after 24 hours of incubation.  
 
Figure 4.16: The stacked 1H NMR spectra of 5’-GMP (a), the cationic complex 22 (b) and the mixture of 
22 and 5’-GMP before incubation (c) and after incubation at 37 °C for 24 hours (d) in a mixture of H2O: 
DMSO (d6) 1:1 v/v%.  
The results obtained from this binding study suggests that DNA may not be the primary target 
of the complex 22, thus suggesting that complex 22 may elicit anticancer activity via an 
alternative mechanism of action. 
4.6  Summary 
The cytotoxicity of the 2,5-disubstituted tris-benzimidazole ligands (7 – 12)  and their 
respective cyclometallated (19 – 21) and cationic (22 – 24) triruthenium(II) complexes was 
investigated in pre-screen experiments against the MCF-7 breast cancer cell line at 10 and 20 
µM. The 2-pyridyl ligands (10 – 12) showed significantly enhanced anticancer activity relative 
to their respective 2-phenyl counterparts (7 – 9) at both tested concentrations on the MCF-7 
breast cancer cell line. The same trend was observed upon the comparison of the cytotoxic  
activity of the cationic trimetallic complexes (22 – 24) to that of the respective neutral 
cyclometallated complexes (19 – 21). The 2-ferrocenyl tris-benzimidazole compounds (13 – 
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However, all the 2-ferrocenyl compounds (13 – 15) were not observed to significantly reduce 
MCF-7 cell viability. This observed inactivity was attributed to the precipitation of the  
2-ferrocenyl compounds (13 – 15) in growth media. 
The promising activity noted for the 2-pyridyl ligands (10 – 12) and their respective trimetallic 
cationic complexes (22 – 24) against the MCF-7 cancer cell line prompted further cytotoxic 
evaluation of these compounds against the MDA-MB-231 breast cancer and the 501mel cell 
lines. In the MCF-7 cell line, the 5-unsubstituted ligand (10) and the corresponding complex 
(22), were observed to show enhanced cytotoxicity relative to cisplatin, and the  
5-trifluoromethyl complex (23) showed activity comparable to cisplatin (IC50 = 28.65 µM, 
33.87 µM and 35.06 µM for 10, 22 and 23, respectively). Against the MDA-MB-231 breast 
cancer cell line, only the ligand 10 showed mild activity (IC50 = 33.53 µM). Cytotoxic data 
obtained for the ligand (11) and its respective complex (23), against the 501mel cell line, 
revealed that the complex 23 showed mild activity which is less potent relative to cisplatin. 
When screened against the non-tumorigenic MCF-12A breast epithelial cell line, the 2-pyridyl 
ligands (11 and 12) and their corresponding complexes (22 and 23) were noted to be less 
cytotoxic relative to cisplatin on the non-tumorigenic MCF-12A cell line.  
The most active complex (22) was investigated for nucleotide binding as a possible 
mechanism of action. This was achieved by studying the interaction of 22 with 5’-GMP using 
1H NMR spectroscopy. The complex 22 was not observed to interact with 5’-GMP to form an 
adduct. Thus, suggesting that 22 elicits anticancer activity via an alternate mechanism, that is 
yet to be investigated. The possibility of the complex 22 having an alternate mechanism of 
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5.1  Overall summary and conclusions  
A series of trimeric 2,5-disubstituted benzimidazole ligands (7 – 12)  and their respective  
2-ferrocenyl bioisosteres (13 – 15) were synthesized in this study. The respective trimetallic 
ruthenium(II)-p-cymene complexes (19 – 24) were successfully synthesized. All the 
synthesized compounds were characterized using various spectroscopic and analytical 
techniques including one (1H, 13C{1H}, 19F{1H}, 31P{1H}) and two (HSQC, COSY, HMBC) 
dimensional NMR spectroscopy, mass spectrometry (electrospray ionization) and FT-IR 
spectroscopy. Additionally, the molecular structure of the 5-trifluoromethyl 2-phenyl  
tris-benzimidazole ligand (10) in the solid-state was confirmed via single crystal X-ray 
diffraction. To the best of our knowledge, most of the target compounds and synthons 
reported in this study are new.  
The trimeric 2,5-disubstituted benzimidazole-based compounds (9 – 15) were prepared via a 
three-step procedure from commercially available reagents. Characterization data obtained 
validates the synthesis of the desired compounds (9 – 15). The 2,5-disubstituted ligands  
(9 - 12) were reacted with the [RuCl(µ-Cl)(p-cymene)]2 dimer in either a C-H activation 
reaction or a bridge-splitting reaction to afford the respective trinuclear neutral C^N-Ru(II) 
complexes (19 - 21) and the cationic N^N-Ru(II) complexes (22 – 24). The isolated complexes 
were novel and were fully characterized. The obtained characterization data correlates to the 
proposed structures of the novel ruthenium(II) complexes (19 – 24).  
The 2,5-disubstituted tris-benzimidazole ligands (7 – 12)  and their respective cyclometallated 
(19 – 21) and cationic (22 – 24) trimetallic ruthenium(II) complexes synthesized were 
 pre-screened for their anticancer activity at fixed concentrations of 10 and 20 µM against the 
MCF-7 breast cancer cell line. The pre-screen studies revealed that the 2-pyridyl ligands  
(9 – 12) and the corresponding cationic complexes (22 – 24) showed superior activity relative 
to their 2-phenyl (7 – 9) and cyclometallated (19 – 21) counterparts. This prompted the study 
To God Be The Gl ory  
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of the 2-pyridyl ligands (9 – 12) and their corresponding cationic complexes (22 – 24) in the 
MDA-MB-231 TNBC and the 501mel cancer cell lines at either 10 or 20 µM. In the  
MDA-MB-231 breast cancer cell line, the 5-unsubstituted ligand (10)  was the most active, 
inhibiting cancer cell viability by 43% at 20 µM. In the 501mel cell line, the 5-trifluoromethyl 
substituted cationic complex showed activity comparable to that of cisplatin at 10 and 20 µM.  
In the MCF-7 cell line, the 5-unsubstituted ligand (10) and the corresponding complex (22), 
showed cytotoxicity more potent than that of cisplatin (IC50 < 35 µM for 10 and 22, 
respectively). In addition,  the 5-trifluoromethyl complex (23) showed activity comparable to 
cisplatin (and IC50 ≈ 35 µM for 23). Against the MDA-MB-231 breast cancer cell line, the ligand 
11 and both the cationic complexes 22 and 23, were all inactive at the concentrations tested. 
Cytotoxic data obtained for the ligand (11) and its respective complex (23), in the 501mel cell 
line, revealed that the complex 23 showed mild activity which is less potent relative to 
cisplatin. The 2-pyridyl ligands (11 and 12) and their corresponding complexes (22 and 23) 
were screened in non-tumorigenic MCF-12A breast epithelial cells to gain insight on the 
selectivity of these compounds. All the compounds tested were noted to be less cytotoxic 
relative to cisplatin in the non-tumorigenic MCF-12A cell line and more selective for MCF-7 
breast cancer cells relative to cisplatin (1.35 < S.I. < 2.43 for 11, 12, 23 and 24, and S.I. = 1.04 
for cisplatin).  
The possible interaction of 22 with a purine nucleotide was studied as a possible mode of 
action. The complex 22 was not observed to interact with 5’-GMP to form an adduct. Thus, 
suggesting that 22 possibly does not interact with DNA and elicits anticancer activity via an 
alternate mechanism, that is yet to be investigated. The possibility of the complex 22 having 
an alternate mechanism of action may be a contributing factor towards the enhanced 
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5.2  Future outlook   
Based on the results obtained in this study, the synthesized series of trimeric benzimidazole-
based compounds show promising anticancer activity. Further mechanistic studies and 
structural modifications could be made to fine-tune the activity of the compounds and gain 
further insight into the mechanism(s) of action in which these compounds elicit anticancer 
activity.   
5.2.1 Mechanistic studies  
The cationic complex 20 was the most active ruthenium(II) complex from the series. However, 
preliminary mechanistic studies revealed that the complex does not interact with the 
guanosine nucleotide, suggesting that the complex  does not target DNA. Therefore, the 
interaction of the complex 20 with Calf Thymus DNA could be studied via UV/ Vis 
spectroscopy to fully ascertain that 20 does not interact with DNA. Further electrochemical 
characterization of the complex may assist in characterizing the redox activity of the complex 
and this may be supplemented with the DCFDA ROS detection assay to determine whether 
the complex may generate ROS intracellularly. In addition, Western Blot studies may be 
conducted to investigate the potential protein targets that the complex may interact with. 
Furthermore, exploring the mechanism of cell death by flow cytometry and measuring the 
level of expression of pro- and anti-apoptotic molecular markers, assessing for autophagy and 
investigating the role of the compounds in DNA damage, could be done to understand the 
mechanisms in which the complex exerts anticancer effects. Evaluation of the anticancer 
activity of the promising complexes in this study against additional cell lines (for example 
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5.2.2 Structural alterations to enhance biological activity  
The biological evaluation of the 2-ferrocenyl tris-benzimidazole compounds revealed that 
these compounds precipitate out of aqueous growth media. Thus, the aqueous solubility of 
these ferrocenyl bioisosteres may be improved by oxidation of the iron centers and isolation 
of the corresponding ferrocenium salts (Figure 5.1). These ferrocenium salts could then be 
investigated for their anticancer activity, as the improved aqueous solubility of the 
ferrocenium salt may result in improved biological activity compared to the ferrocenyl 
compounds.1,2 Additionally, the variation of the counter ion of ferrocenium salts has been 
reported to have an effect on the anticancer activity of ferrocenium compounds.3 Therefore, 
an investigation of the effects of the counterion on the anticancer activity of the proposed 
trimeric ferrocenium salts may be a promising avenue to explore. Additionally, the 
introduction of a sulfonate group to the 5-positions of the benzimidazole rings to improve 
solubility may be an interesting avenue to explore. 
 
Figure 5.1:  The proposed general structure of the ferrocenium salts.  
The project has demonstrated a great scope in the development of trinuclear ruthenium-




Chapter 5                                    Conclusions and Future Outlook  
trinuclear complexes synthesized in this study to improve the cytotoxic activity and selectivity 
of these complexes.  
Firstly, the 1,3,5-triazine core could be incorporated into the trimeric organic ligand. The  
1,3,5-triazine core has been extensively studied due to its vast biological activity,4 thus making 
the core an interesting anchor for the development of new trimeric complexes. The 
introduction of a water-soluble ligand (for example the PTA ligand) may increase the overall 
aqueous solubility of the complexes and thus, may enhance the anticancer activity of the 
complexes. In addition, replacing the chloride ligand with the iodido ligand may significantly 
increase the selectivity and anticancer activity of the compounds.5 Therefore, investigating 
the effect of the halogen ligand on the cytotoxicity and selectivity of the complexes may yield 
interesting results. One most obvious alteration to the trinuclear ruthenium(II) moieties is 
varying the size of the arene ring. Thus, introducing the biphenyl and tetrahydroanthracene 
rings, which have been shown to enhance cytotoxicity relative to ruthenium complexes 
bearing the p-cymene functionality.6 A proposed general structure that incorporates the 
suggested changes to the complexes is shown in Figure 5.2. Exploring the synthesis, the 
anticancer evaluation and gaining mechanistic insights of such complexes could provide a 
fruitful extension of this study for future research. 
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6.1  General details 
All reactions were carried out under an inert argon atmosphere unless stated otherwise.  All 
reagents were purchased from commercial sources (Sigma-Aldrich or Combi-blocks) and used 
without further purification. The heat to reactions conducted above room temperature was 
supplied by a hot plate and silicone oil. All aqueous solutions were prepared using deionized 
water. The [Ru(p-cymene)Cl2]2 dimeric precursor was prepared following a literature 
method.1 Reactions were monitored by TLC using aluminium-backed Merck silica-gel F254 
plates, and compounds were visualized under UV-lamp. All column chromatography was 
carried out using Fulka Silica Gel 60, 40 – 63 microns.  
Nuclear Magnetic Resonance spectra were recorded on either a Bruker Top-spin GmbH 400 
plus spectrometer (1H: 399.95 MHz; 13C{1H}: 100.65 MHz; 31P{1H}: 162.01 MHz; 19F{1H}: 376.58 
MHz ) or a Varian Mercury 300 spectrometer (1H: 300.08 MHz; 13C{1H}: 75.46 MHz; 31P{1H}: 
121.47 MHz), with a Brucker Biospin GmbH casing and sample injector at 30 °C. Chemical 
shifts were reported using tetramethylsilane (TMS) as the internal standard. Chemical shifts 
and J-coupling values were reported in ppm and Hz, respectively.  Infrared (IR) spectroscopy 
was conducted on a Perkin-Elmer Spectrum 100 FT-IR spectrometer using Attenuated Total 
Reflectance (ATR) in the solid-state, with bond vibrations measured in reciprocal centimetres 
(cm-1). Mass Spectrometry (MS) determinations were carried out using Electron Impact (EI) 
on a JEOL GCmatell instrument or Electrospray Ionisation (ESI) on a Waters API Quattro Micro 
triple quadrupole mass spectrometer with data recorded using the positive mode. A Büchi 
Melting Point Apparatus B-540 machine was used to obtain the uncorrected melting points 
of each compound. The purity of the ligands was determined using an analytical Agilent HPLC 
1260 with an  Agilent infinity diode array detector (DAD) 1260 UV/ Vis detector which was set 
to wavelengths ranging from 210 – 640 nm. Two solvent mixtures were used to elute the 
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compounds, Solvent A (10 mM NH4OAc/ H2O) and Solvent B (10 mM NH4OAc/ MeOH), at a 
flow rate of 0.9 mL/min. The set gradients were as follows: 90% Solvent A from 0 – 1 min,  
90 – 5% Solvent A from 1 – 3 min and 5% Solvent B between 3 and 5 min. Determination of  
C/ H/ N was done using a 2400 CHN Elemental Analyzer by Perkin Elmer. 
6.2  The general procedure for the synthesis of the tris-nitrobenzenes (1 – 3) 
Tris(2-aminoethyl)amine (1 eq.) was dissolved in DMF (5 mL) at room temperature. 
Thereafter, the appropriate nitrobenzene (3 eq.) was added to the reaction vessel and the 
reaction was allowed to stir at room temperature for 24 hours, reaction progress was 
monitored by TLC analysis. Upon completion, the reaction mixture was diluted with a 
saturated brine solution (30 mL) and then extracted with two aliquots of ethyl acetate  
(2 x 30 mL). The organic extracts were collected and dried over anhydrous sodium sulfate, 
and excess solvent was reduced in vacuo. The resultant crude was purified using column 
chromatography to afford the desired tris-nitrobenzene product.  
6.2.1 The synthesis of N1-(2-nitrophenyl)-N2,N2-bis(2-
((2nitrophenyl)amino)ethyl)ethane-1,2-diamine2 (1)  
 
Tris(2-aminoethyl)amine (0.500 mL, 3.34 mmol) was reacted with 1-fluoro-2-nitrobenzene 
(1.06 mL, 10.1 mmol) at room temperature for 24 hours. The desired compound (1) was 
isolated as a bright yellow solid (1.11 g, 2.18 mmol). Rf (4:6 EtOAc:  Pet. Ether): 0.50. Yield: 
48.3%. 1H NMR (300 MHz, DMSO) δ (ppm): 8.21 (t, J = 5.1 Hz, 3H, H-g), 8.00 (dd, J = 8.6, 1.6 
Hz, 3H, H-b), 7.46 (ddd, J = 8.5, 7.0, 1.4 Hz, 3H, H-d), 6.98 (d, J = 8.0 Hz, 3H, H-e), 6.64 (ddd, 
 J = 8.3, 6.9, 1.1 Hz, 3H, H-c), 3.45 (q, J = 6.1 Hz, 6H, H-h), 2.90 (t, J = 6.3 Hz, 6H, H-i).  
13C{1H}-NMR (101 MHz, DMSO) δ (ppm): 145.50 (C-f), 136.87 (C-b), 131.53 (C-a), 126.64  
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6.2.2 Synthesis of N1-(2-nitro-4-(trifluoromethyl)phenyl)-N2,N2-bis(2-((2-nitro-4-
(trifluoromethyl)phenyl)amino)ethyl)ethane-1,2-diamine (2) 
 
Tris(2-aminoethyl)amine (0.500 mL, 3.34 mmol) and 4-chloro-3-nitrobenzotrifluoride  
(1.49 mL, 10.0 mmol) were dissolved in DMF and allowed to stir at room temperature for  
24 hours. The pure compound  (2) was isolated as a bright yellow solid (0.841 g, 1.18 mmol). 
Rf (2:1 Pet. Ether: EtOAc): 0.56. Yield: 35.3%. 1H NMR (300 MHz, DMSO) δ (ppm): 8.45 (t,  
J = 5.0 Hz, 3H, H-h), 8.15 (d, J = s1.6 Hz, 3H, H-b), 7.66 (dd, J = 9.1, 2.1 Hz, 3H, H-e), 7.15 (d, J 
= 9.1 Hz, 3H, H-f), 3.49 (dd, J = 11.0, 5.5 Hz, 6H, H-i), 2.92 (t, J = 5.9 Hz, 6H, H-j). 13C{1H}-NMR 
(101 MHz, DMSO) δ (ppm): 146.49 (C-g), 131.53 (C-f), 129.96 (C-a), 124.97 (C-d), 123.68  
(C-b), 115.60 (C-e), 114.70 (C-d), 52.17 (C-j), 40.80 (C-i). MP (°C): 170.6 – 172.1. 
6.2.3 The synthesis of N1-(4-methyl-2-nitrophenyl)-N2,N2-bis(2-((4-methyl-2-
nitrophenyl)amino)ethyl)ethane-1,2-diamine (3) 
 
Tris(2-aminoethyl)amine (0.500 mL, 3.34 mmol) and 4-fluoro-2-nitrotoluene (1.55 g, 
 10.0 mmol) were dissolved in DMF and allowed to stir at room temperature for 24 hours. The 
pure compound  (3) was isolated as a dark orange solid (0.887 g, 1.62 mmol). Rf (4:1 Pet. 
Ether: EtOAc): 0.51. Yield: 39.2%.1H NMR (300 MHz, DMSO) δ (ppm): 8.08  
(t, J = 5.0 Hz, 3H, H-h), 7.79 (d, J = 1.0 Hz, 3H, H-b), 7.29 (dd, J = 8.8, 1.9 Hz, 3H, H-e), 6.89  
(d, J = 8.8 Hz, 3H, H-f), 3.41 (dd, J = 11.5, 5.9 Hz, 6H, H-i), 2.87 (t, J = 6.2 Hz, 6H, H-j), 2.20 (s, 
9H, H-d).
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125.07 (C-b), 124.02 (C-c), 114.39 (C-f), 52.47 (C-j), 40.70 (C-i), 19.36 (C-d). MP (°C): 125.6 -
127.3. 
6.3  The synthesis of the tris-1,2-benzenediamines (4 – 6) 
 
The appropriate tris-nitrobenzene (1 eq.) was dissolved in dry methanol (10 mL) and allowed 
to stir for 5 minutes. Ammonium chloride (30 eq.) and zinc (60 eq.) were added to the reaction 
vessel. The reaction mixture was then stirred vigorously at room temperature for 1 hour. After 
1 hour, TLC analysis showed the complete conversion of the starting materials to a new 
product. The reaction mixture was filtered through Celite® and rinsed with copious methanol. 
The filtrate was subsequently collected, and the excess solvent was reduced by rotary 
evaporation. The resultant residue was redissolved in ethyl acetate (30 mL) and washed with 
two aliquots of a saturated sodium bicarbonate solution (2 x 30 mL), a 1M solution of sodium 
hydroxide (30 mL) and deionized water (30 mL). The organic extracts were collected, dried 
over anhydrous sodium sulfate and excess solvent was reduced under reduced pressure. The 
resultant crude was purified using column chromatography (100% ethyl acetate). 
 
6.3.1 Synthesis of N1-(2-(bis(2-((2-aminophenyl)amino)ethyl)amino)ethyl)benzene-
1,2-diamine2 (4)  
 
N1-(2-nitrophenyl)-N2,N2-bis(2-((2nitrophenyl)amino)ethyl)ethane-1,2-diamine (0.810 g,  
1.59 mmol) was reacted with ammonium chloride (2.52 g, 47.0 mmol) and zinc powder  
(6.16 g, 94.2 mmol) at room temperature for 24 hours. The desired product  (4) was isolated 
as a dark brown solid (0.778 g, 1.86 mmol). Rf (EtOAc): 0.45. Yield: 97.0%.  1H NMR (300 MHz, 
DMSO) δ (ppm): 6.57 (dd, 3JHH = 7.2 Hz, 4JHH = 1.5 Hz, 3H, H-d), 6.53 – 6.38 (m, 9H, H-c, H-e 
and H-f), 4.38 (s, 9H, H-a), 3.13 (dd, 3JHH = 4.7 Hz, 4JHH =11.8 Hz, 6H, H-h), 2.79 (t, 3JHH = 6.6 Hz, 
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117.48 (C-d), 114.98 (C-f), 110.67 (C-c), 53.61 (C-i), 42.18 (C-h). FT-IR (ATR) ν (cm-1): 3366 and 
3299 (1° amine). MP (°C): 121.7 – 123.8. 
 





(trifluoromethyl)phenyl)amino)ethyl)ethane-1,2-diamine (0.603 g, 0.842 mmol), ammonium 
chloride (1.35 g, 25.2 mmol) and zinc powder (3.32 g, 50.8 mmol) were reacted in anhydrous 
methanol at room temperature for 1 hour. The product  (5) was isolated as a beige solid (0.660 
g, 0.706 mmol). Rf (1:1 EtOAc: Pet. Ether): 0.97. Yield: 83.8%. 1H NMR (300 MHz, DMSO) δ 
(ppm): 6.83 (d, 3JHH = 2.0 Hz, 3H, H-c), 6.74 (d, 3JHH = 8.3 Hz, 3H, H-g), 6.45 (d, 3JHH = 8.2 Hz, 3H, 
H-f), 5.02 (t, 3JHH = 5.2 Hz, 3H, H-i), 4.84 (s, 6H, H-a), 3.19 (dd, 3JHH = 11.9 Hz, 4JHH = 6.0 Hz, 6H, 
H-j), 2.78 (t, 3JHH = 6.6 Hz, 6H, H-k). 13C{1H}-NMR (101 MHz, DMSO) δ (ppm): 139.03 (C-h), 
135.08 (C-b), 124.07 (C-d), 116.46 (q, J = 31.0 Hz, C-e), 114.70 (C-g), 109.69 (C-c), 108.28 (C-f), 
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diamine (1.11 g, 2.01 mmol) was reacted with ammonium chloride (3.17 g, 59.3 mmol) and 
zinc powder ( 6.76 g, 103 mmol) in anhydrous methanol for 1 hour. The desired product (6) 
was isolated as a brown solid (0.668 g, 1.45 mmol). Rf (EtOAc): 0.14. Yield: 75.1%.  
1H NMR (300 MHz, DMSO) δ (ppm):  6.40 (d, 3JHH = 1.1 Hz, 3H, H-b), 6.32 (m, 6H, H-e, H-f), 
4.32 (s, 6H, H-k), 4.25 (t, 3JHH = 5,0 Hz, 3H, H-h), 3.07 (d, 3JHH = 4.8 Hz, 6H, H-i), 2.74 (t,  
3JHH = 6.4 Hz, 6H, H-j), 2.08 (s, 9H, H-d). 13C{1H}-NMR (101 MHz, DMSO) δ (ppm): 135.96  
(C-g), 134.42 (C-a), 125.99 (C-c), 118.60 (C-e), 115.90 (C-f), 111.12 (C-b), 53.70 (C-i), 42.47  
(C-j), 20.91 (C-d). FT-IR (ATR) ν (cm-1): 3373  and 3318 (1° amine).  MP (°C): 128.3 – 130.2. 
 
6.4  The general synthetic procedure for the 2,5-disubstituted benzimidazole-based trimeric  
ligands (7 – 12) 
The appropriate tris-1,2-benzenediamine (1 eq.) was dissolved in anhydrous ethanol (6 mL), 
and allowed to stir for 5 minutes. Benzaldehyde or 2-pyridinecarboxaldehyde (3.6 eq.) was 
added to the reaction vessel. Thereafter, magnesium sulfate (18 eq.) and trifluoroacetic acid 
(0.3 eq.) were added to the reaction vessel. The reaction mixtures with benzaldehyde were 
refluxed at 80 °C for 24 hours and the reactions with 2-pyridinecarboxaldehyde were stirred 
at room temperature for 24 hours, open to air. TLC analysis confirmed the successful 
conversion of starting materials to a new product. The reaction mixture was subsequently 
filtered and the filtrate was collected, and excess solvent was removed by rotary evaporation. 
The resultant crude was redissolved in ethyl acetate (30 mL) and washed with a saturated 
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extract was collected and dried over anhydrous sodium sulfate, and the excess solvent was 
removed in vacuo. The resultant residue was purified using column chromatography. 








N1-(2-(bis(2-((2-aminophenyl)amino)ethyl)amino)ethyl)benzene-1,2-diamine (0.113 g,  
0.246 mmol) was dissolved in ethanol. Benzaldehyde (0.0876 mL, 0.859 mmol), TFA  
(0.00547 mL, 0.0715 mmol) and magnesium sulfate (0.523 g, 4.83 mmol) were added to the 
reaction vessel. The desired product was isolated as a pale yellow solid (7) (0.0740g,  
0.109 mmol). Rf (7:3 EtOAc: Pet. Ether): 0.21. Yield: 51.1%. 1H NMR (400 MHz, DMSO) δ 
(ppm): 7.68 – 7.62 (m, 3H, H-e), 7.59 – 7.53 (m, 6H, H-k), 7.48 – 7.40 (m, 9H, H-l and H-m), 
7.29 – 7.22 (m, 6H, H-d and H-g), 7.20 – 7.15 (m, 3H, H-f), 3.79 (t, 3JHH = 7.1 Hz, 6H, H-a), 2.41 
(t, 3JHH = 7.1 Hz, 6H, H-b). 13C{1H}-NMR (101 MHz, DMSO) δ (ppm): 153.59 (C-i), 143.01 (C-h), 
135.71 (C-c), 130.81 (C-m), 130.08 (C-i), 129.43 (C-l), 129.13 (C-k), 123.00 (C-f), 122.52 (C-e), 
119.70 (C-g), 110.91 (C-d), 52.91 (C-a), 42.75 (C-b). FT-IR (ATR) ν (cm-1): 1695 (imine C=N). MP 
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(trifluoromethyl)benzene-1,2-diamine (0.106 g, 0.165 mmol) was dissolved in ethanol. 
Benzaldehyde (0.0631 mL, 0.598 mmol), TFA (0.00371 mL, 0.0481 mmol) and magnesium 
sulfate (0.348 g, 2.88 mmol) were subsequently added to the reaction vessel. The pure 
product (8) was isolated as a cream solid  (0.0952 g, 0.108 mmol). Rf (1:1 EtOAc: Pet. Ether): 
0.18. Yield: 70.3%. 1H NMR (300 MHz, DMSO) δ (ppm): 8.01 (s, 3H, H-d), 7.61 – 7.54 (m, 6H, 
H-g, H-h), 7.52 (dd, 3JHH = 8.7 Hz, 4JHH  = 1.4 Hz, 3H, H-n), 7.48 – 7.39 (m, 12H, H-l, H-m), 3.88 
(t, 3JHH = 6.6 Hz, 6H, H-a), 2.36 (t, J = 6.6 Hz, 6H, H-b). 13C{1H}-NMR (101 MHz, DMSO) δ (ppm): 
155.87 (C-j), 142.41 (C-i), 138.00 (C-c), 130.51 (C-k), 130.11 (C-n), 129.49 (C-m), 129.21 (C-l), 
126.78 (C-e), 123.55 (q, J = 35.9 Hz, C-f), 119.47 (C-g), 117.06 (C-d), 112.01 (C-h), 52.43 (C-b), 
42.88 (C-a). 19F{1H}-NMR (377 MHz, DMSO) δ (ppm): -58.94 (d, JF-C  = 23.3 Hz). FT-IR (ATR) 
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diamine (0.0968 g, 0.198 mmol) was dissolve in ethanol. Thereafter, benzaldehyde  
(0.0796 mL, 0.780 mmol), TFA (0.00500 mL, 0.0650 mmol) and magnesium sulfate (0.469 g, 
3.91 mmol) were added to the reaction vessel. The desired product was isolated as a white 
solid (9) (0.0723 g, 0.100 mmol). Rf (1:1 Pet. Ether: EtOAc): 0.12. Yield: 46.4%. 1H NMR (300 
MHz, CDCl3) δ (ppm): 7.58 (s, 3H, H-h), 7.55 – 7.48 (m, 6H, H-l), 7.44 – 7.35 (m, 9H, H-m, H-n), 
7.07 (dd, 3JHH = 8.2 Hz, 4JHH = 1.1 Hz, 3H, H-d), 6.78 (d, 3JHH = 8.2 Hz, 3H, H-e), 3.69 (t, 3JHH = 7.0 
Hz, 6H, H-a), 2.50 (s, 9H, H-g), 2.37 (t, 3JHH = 7.0 Hz, 6H, H-b). 13C{1H}-NMR (101 MHz, CDCl3)  
δ (ppm): 153.41 (C-j), 143.07 (C-i), 133.17 (C-f), 132.53 (C-c), 130.37 (C-k), 129.92 (C-m), 
129.07 (C-n), 128.83 (C-l), 124.55 (C-d), 119.94 (C-h), 109.07 (C-e), 53.43 (C-b), 42.78 (C-a), 
21.56 (C-g). FT-IR (ATR) ν (cm-1): 1625 (imine C=N). MP (°C): 197.6 – 199.8. Purity: 97% by LC 
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6.4.4 Synthesis of tris(2-(2-(pyridin-2-yl)-1H-benzo[d]imidazol-1-yl)ethyl)amine (10) 
 
N1-(2-(bis(2-((2-aminophenyl)amino)ethyl)amino)ethyl)benzene-1,2-diamine (0.103 g, 0.238 
mmol) was dissolved in ethanol. Thereafter, 2-pyridinecarboxaldehyde (0.0817 mL,  
0.859 mmol), TFA (0.00547 mL, 0.0715 mmol) and magnesium sulfate (0.517 g, 4.29 mmol) 
were added to the reaction vessel. The desired product (10) was isolated as a pale brown solid  
(0.0300g, 0.0441 mmol). Rf (7:3 EtOAc: Pet. Ether): 0.22. Yield: 34.8%. 1H NMR (300 MHz, 
DMSO) δ (ppm): 8.30 (m, 6H, H-n and H-m), 7.92 (td, 3JHH = 7.8 Hz, 4JHH = 1.5 Hz, 3H, H-l), 7.76 
– 7.69 (m, 3H, H-e),7.41 – 7.23 (m, 12H, H-k, H-d, H-f and H-g), 4.60 (t, 3JHH = 6.8 Hz, 6H, H-a), 
2.97 (t, 3JHH = 6.9 Hz, 6H, H-b). 13C{1H}-NMR (101 MHz, DMSO) δ (ppm): 149.81 (C-j), 149.37 
(C-n), 148.39 (C-h), 142.04 (C-i), 137.26 (C-l), 136.22 (C-c), 124.17 (C-k), 124.02 (C-m), 123.13 
(C-f), 122.32 (C-g), 119.53 (C-e), 110.42 (C-d), 53.64 (C-a), 43.38 (C-b). FT-IR (ATR) ν (cm-1): 
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(trifluoromethyl)benzene-1,2-diamine (0.107 g, 0.169 mmol) was dissolved in ethanol. 
Thereafter, 2-pyridinecarboxaldehyde (0.0550 mL, 0.578 mmol), TFA (0.00371 mL, 0.0481 
mmol) and magnesium sulfate (0.351 g, 2.93 mmol) were added to the reaction vessel. The 
desired product was isolated as a white solid (11) (0.0203 g, 0.0229 mmol). Rf (2:1 Pet. Ether: 
EtOAc): 0.13. Yield: 40.3%. 1H NMR (300 MHz, DMSO) δ (ppm): 8.35 (d, J = 4.2 Hz, 3H, H-o), 
8.29 (d, 3JHH = 7.9 Hz, 3H, H-n), 8.10 (s, 3H, H-d), 7.95 (t, 3JHH = 7.4 Hz, 3H, H-l), 7.66 – 7.53 (m, 
6H, H-g, H-h), 7.42 – 7.33 (m, 3H, H-m), 4.65 (t, 3JHH = 6.5 Hz, 6H, H-a), 3.03 (t, 3JHH = 6.3 Hz, 
6H, H-b). 13C{1H}-NMR (151 MHz, DMSO) δ (ppm): 152.29 (C-k), 149.76 (C-j), 149.06 (C-o), 
142.03 (C-c), 139.03 (C-i), 137.96 (C-e), 125.12 (C-f), 125.06 (C-n), 120.03 (C-g), 117.48 (C-h), 
112.14 (C-d), 53.86 (C-b), 44.28 (C-a). 19F{1H}-NMR (377 MHz, DMSO) δ (ppm): -59.19 (s).  
FT-IR (ATR) ν (cm-1): 1620 (imine C=N), 1587 (pyridyl C=N). MP (°C): 201.3 – 202. Purity: 94% 
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diamine (0.102 g, 0.217 mmol) was dissolve in ethanol. Thereafter, 2-pyridinecarboxaldehyde 
(0.0741 mL, 0.781 mmol), TFA (0.00500 mL, 0.0650 mmol) and magnesium sulfate (0.471 g, 
4.01 mmol) were added to the reaction vessel. The desired product was isolated as a cream 
solid (12) (0.0530 g, 0.0733 mmol). Rf (7:3 EtOAc: Pet. Ether): 0.27. Yield: 33.8%.  
1H NMR (400 MHz, CDCl3) δ (ppm): 8.41 (d, 3JHH = 8.0 Hz, 3H, H-o), 8.30 (d, 3JHH = 4.5 Hz, 3H, 
H-l), 7.77 (td, 3JHH = 7.8 Hz, 4JHH = 1.8 Hz, 3H, H-m), 7.63 (s, 3H, H-h), 7.22 – 7.06 (m, 9H, H-d,  
H-e, H-n), 4.81 – 4.74 (m, 6H, H-a), 3.27 – 3.14 (m, 6H, H-b), 2.51 (s, 9H, H-g). 13C{1H}-NMR 
(101 MHz, CDCl3) δ (ppm): 150.50 (C-j), 149.65 (C-k), 148.52 (C-o), 142.86 (C-i), 136.77 (C-m), 
134.75 (C-f), 132.54 (C-c), 125.17 (C-e), 124.57 (C-d), 123.62 (C-l), 119.91 (C-h), 109.43 (C-n), 
54.66 (C-b), 44.38 (C-a), 21.60 (C-g). FT-IR (ATR) ν (cm-1): 1726 (imine C=N), 1590 (pyridyl C=N). 
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6.5  The general synthesis of the  2-ferrocenyl tris-benzimidazole compounds (13 – 15) 
The appropriate tris-1,2-benzenediamine (1 eq.) was dissolved in dry ethanol (6 mL), and 
allowed to stir for 5 minutes. Ferrocenecarboxaldehyde (3.6 eq.) was added to the reaction 
vessel. Thereafter, magnesium sulfate (18 eq.) and trifluoroacetic acid (0.3 eq.) were added 
to the reaction vessel. The reaction mixture was stirred at room temperature for 24 hours, 
open to air. Upon confirmation of reaction completion by TLC, the reaction mixture was 
subsequently filtered and the filtrate collected. The excess solvent was removed by rotary 
evaporation, and the resultant crude was redissolved in ethyl acetate (30 mL) and washed 
with a saturated sodium bicarbonate solution (30 mL) and a saturated brine solution (30 mL). 
The organic extracts were collected and dried over anhydrous sodium sulfate, and the excess 
solvent was removed under vacuum. The resultant residue was purified using column 
chromatography. 
6.5.1 The synthesis of tris(2-(2-ferrocenyl-1H-benzo[d]imidazol-1-yl)ethyl)amine (13) 
 
N1-(2-(bis(2-((2-aminophenyl)amino)ethyl)amino)ethyl)benzene-1,2-diamine (0.100 g, 0.230 
mmol) was dissolved in ethanol. Thereafter, ferrocenecarboxaldehyde (0.228 g, 1.06 mmol), 
TFA (0.00600 mL, 0.0725 mmol) and magnesium sulfate (0.635 g, 5.27 mmol) were added to 
the reaction vessel. The desired product was isolated as a dark red solid (13) (0.0312 g, 0.0312 
mmol). Rf (1:1 EtOAc: Pet. Ether): 0.32. Yield: 13.1%. 1H NMR (300 MHz, DMSO) δ (ppm): 
7.63 – 7.53 (m, 3H, H-d), 7.40 – 7.33 (m, 3H, H-g), 7.25 – 7.14 (m, 6H, H-e and H-f), 4.83 (br s, 
6H, H-k), 4.50 – 4.35 (m, 12H, H-l and H-a), 4.15 (s, 15H, H-Cp), 3.03 (t, J = 7.2 Hz, 6H, H-b). 
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and C-f), 118.88 (C-d), 110.39 (C-g), 74.58 (C-j), 70.31 (C-k), 69.96 (C-Cp), 69.43 (C-l), 54.43  
(C-b), 43.14 (C-a). FT-IR (ATR) ν (cm-1): 1611 (imine C=N).MP (°C): 168.3 – 170.1. MS (HR-ESI, 
m/z): Calculated: 1002.2327, Found: 1002.2359 (100%, [M+H]+). 




(trifluoromethyl)benzene-1,2-diamine (0.103 g, 0.160 mmol) was dissolved in ethanol. 
Ferrocenecarboxaldehyde (0.124 g, 0.578 mmol), TFA (0.00369 mL, 0.0418 mmol) and 
magnesium sulfate (0.348 g, 2.89 mmol) were added to the reaction vessel. The pure product 
(14) was isolated as a pale orange solid (0.0616 g, 0.0511 mmol). Rf (2:1 EtOAc: Pet. Ether): 
0.22. Yield: 31.8%. 1H NMR (600 MHz, DMSO) δ (ppm): 7.95 (s, 3H, H-d), 7.55 (d, J = 8.4 Hz, 
3H, H-g), 7.49 (d, J = 8.4 Hz, 3H, H-h), 4.87 (br s, 6H, H-l), 4.48 (br s, 6H, H-m), 4.45 (t,  
J = 6.8 Hz, 6H, H-a), 4.15 (s, 15H, H-Cp), 3.03 (t, J = 6.8 Hz, 6H, H-b). 13C{1H}-NMR (151 MHz, 
DMSO) δ (ppm): 155.80 (C-j), 142.67 (C-c), 138.65 (C-i), 126.42 (C-e), 124.62 (C-f), 118.70  
(C-g), 116.07 (C-d), 111.37 (C-h), 73.51 (C-k), 70.73 (C-m), 70.07 (C-Cp), 69.70 (C-l), 53.97  
(C-b), 43.24 (C-a). 19F{1H}-NMR (377 MHz, DMSO) δ (ppm): -58.86 (d, JF-C  = 30.6 Hz). FT-IR 
(ATR) ν (cm-1): 1623 (imine C=N). MP (°C): 216.5 – 218.2. MS (HR-ESI, m/z): Calculated: 
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diamine (0.112 g, 0.231 mmol) was dissolve in ethanol. Ferrocenecarboxaldehyde (0.167 g, 
0.701 mmol), TFA (0.00500 mL, 0.0650 mmol) and magnesium sulfate (0.483 g, 4.21mmol) 
were added to the reaction vessel. The desired product was isolated as a reddish-brown solid 
(15) (0.0480 g, 0.0460 mmol). Rf (1:1 EtOac: Pet. Ether): 0.36. Yield: 22.0%. 1H NMR (300 
MHz, DMSO) δ (ppm): 7.37 (s, 3H, H-d), 7.21 (d, J = 8.2 Hz, 3H, H-h), 7.02 (dd, J = 8.3, 1.2 Hz, 
3H, H-g),  4.80 (br s, 6H, H-l), 4.43 (br s, 6H, H-m), 4.34 (t, J = 6.5 Hz, 6H, H-a), 4.13 (s, 15H,  
H-Cp), 2.98 (t, J = 6.2 Hz, 6H, H-b), 2.40 (s, 9H, H-g). 13C{1H}-NMR (101 MHz, DMSO) δ(ppm): 
152.69 (C-j), 143.60 (C-i), 134.46 (C-c), 131.20 (C-e), 123.53 (C-h), 118.73 (C-d), 109.92 (C-g), 
74.78 (C-k), 70.22 (C-l), 69.93 (C-Cp), 69.37 (C-m), 54.48 (C-b), 43.18 (C-a), 21.66 (C-f). FT-IR 
(ATR) ν (cm-1): 1620 (imine C=N). MP (°C): 139.1 – 141.7. MS (HR-ESI, m/z): Calculated: 
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6.6  The synthesis of N-ethyl-2-nitroaniline3 (16)  
 
Ethylamine (0.630 mL, 9.48 mmol) was dissolved in DMF (5 mL) at room temperature. 
Thereafter, 1-fluoro-2-nitrobenzene (0.500 mL,  4.74 mmol)  was added to the reaction vessel 
and the reaction was stirred at room temperature for 24 hours. After reaction completion 
was noted on TLC,  the reaction mixture was diluted with a saturated brine solution (20 mL) 
and then extracted with two aliquots of ethyl acetate (2 x 20 mL). The organic extracts were 
collected and dried over anhydrous sodium sulfate, and excess solvent was reduced under 
vacuum. The resultant crude was purified using column chromatography (1: 19 EtOAc: 
Hexane) to afford the desired product (16) as a bright yellow oil (0.854 g, 5.14 mmol). Rf (1:19 
EtOAc: Hexane): 0.41. Yield: 90.1%. 1H NMR (300 MHz, CDCl3) δ (ppm): 8.15 (d,  J = 7.8 Hz, 
1H, H-b), 7.95 (s, 1H, H-g), 7.42 (t,  J = 7.5 Hz, 1H, H-d), 6.84 (d, J = 8.6 Hz, 1H, H-e), 6.62 (t, J = 
7.7 Hz, 1H, H-c), 3.44 – 3.25 (m, 3H, H-h), 1.37 (t, J = 7.2 Hz, 3H, H-i). 
6.7  Synthesis of N1-ethylbenzene-1,2-diamine3 (17) 
 
N-ethyl-2-nitroaniline (16) (0.800 g, 4.44 mmol) was added to a stirring solution of anhydrous 
methanol (10 mL). Ammonium chloride (2.37 g, 44.4 mmol) and zinc (5.81 g,  
88.8 mmol) were subsequently added to the reaction vessel. The reaction mixture was stirred 
vigorously at room temperature for 1 hour. After 1 hour, TLC analysis showed the complete 
conversion of the starting materials to a new product. The reaction mixture was filtered 
through Celite® and rinsed with copious methanol. The filtrate was subsequently collected, 
and the excess solvent was reduced by rotary evaporation. The resultant residue was 
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bicarbonate solution (2 x 30 mL) and thereafter deionized water (30 mL). The organic extract 
was collected, dried over anhydrous sodium sulfate and excess solvent was reduced in vacuo 
and the resultant crude was purified using column chromatography (100% ethyl acetate). The 
desired product (18) was isolated as a brown oil (0.541 g, 3.97 mmol). Rf (100% EtOAc): 0.81. 
Yield: 89.5%. 1H NMR (300 MHz, CDCl3) δ(ppm):  6.90 – 6.81 (m, 1H, H-d), 6.77 – 6.65 (m, 3H, 
H-c, H-e, H-f), 3.26 (s, J = 12.0 Hz, 2H, H-a), 3.17 (q, J = 7.1 Hz, 2H, H-h), 1.32 (t, J = 7.1 Hz, 3H, 
H-i). 
 
6.8  The synthesis of 1-ethyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole4 (18) 
 
 
N1-ethylbenzene-1,2-diamine (17) (0.400 g, 2.94 mmol) was dissolved in anhydrous ethanol 
(5 mL) and stirred for 5 minutes. Thereafter, 2-pyridinecarboxaldehyde  
(0.420 mL, 4.41 mmol), magnesium sulfate (2.12 g, 17.6 mmol) and trifluoroacetic acid  
(0.023 mL, 0.294 mmol) were chronologically added to the reaction vessel. The reaction 
mixture was allowed to stir, open to air, for 24 hours at room temperature. TLC analysis 
confirmed the successful conversion of starting materials to a new product after 24 hours. 
The reaction mixture was subsequently filtered and the filtrate collected. The excess solvent 
was removed by rotary evaporation, and the resultant crude was redissolved in ethyl acetate 
(30 mL) and washed with a saturated sodium bicarbonate solution (30 mL) and a saturated 
brine solution (30 mL). The organic extract was collected and dried over anhydrous sodium 
sulfate, and the excess solvent was removed in vacuo. The resultant residue was purified using 
column chromatography (1: 2 EtOAc: Pet. Ether) and the desired product (18) was obtained 
as a dark brown viscous oil (0.337 g, 1.51 mmol). Rf (1: 2 EtOAc: Pet. Ether): 0.33. Yield: 51.4%. 
1H NMR (300 MHz, CDCl3) δ(ppm): 8.73 – 8.66 (m, 1H, H-i), 8.41  
(d, J = 8.0 Hz, 1H, H-l), 7.88 – 7.76 (m, 2H, H-b, H-e), 7.50 – 7.40 (m, 1H, H-k), 7.38 – 7.28 (m, 
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6.9  The Synthesis of the cyclometallated C,N-Ru(II)-p-cymene metal complexes (19 – 21) 
6.9.1 Synthesis of cyclometallated Ru(II)-p-cymene metal complex (19) 
 
Tris(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl)amine (0.0353 g, 0.0516 mmol) was 
dissolved in 1: 1 DCM: Ethanol (30 mL). To this brown solution, the dichloro 
(p-cymene)ruthenium(II) dimer (0.0474 g, 0.0774 mmol), sodium acetate (0.00853 g, 0.103 
mmol) was added and the mixture was stirred at room temperature for 24 hours. After TLC 
analysis confirmed the conversion of the limiting reagent to a product spot, the reaction 
mixture was filtered through Celite®. The filtrate was collected, and excess solvent was 
reduced to ca. 1 mL, and this crude mixture was subjected to trituration in chloroform for 24 
hours. A dark green crude was isolated by suction filtration, and this was re-dissolved in DCM 
(1 mL) and precipitated in pentane. The desired product (19) was isolated as a light green 
powder (0.0704 g, 0.0473 mmol) by suction filtration. Yield: 84.9%. 1H NMR (300 MHz, DMSO) 
δ (ppm): 8.27 (d, 3JHH = 7.3 Hz, 3H, H-n), 7.97 (d, 3JHH = 8.0 Hz, 3H, H-g), 7.60 – 7.12 (m, 12H, H-
d, H-e, H-f, H-k), 7.06 (t, 3JHH = 7.4 Hz, 3H, H-l), 6.86 (m, 3H, H-m), 5.97 (dd, 3JHH = 13.7 Hz, 4JHH 
= 6.9 Hz, 3H, H-r), 5.75 – 5.63 (m, 3H, H-q), 5.37 (dt, 3JHH = 11.2, 5.7 Hz, 3H, H-t), 5.19 (t, 3JHH = 
5.8 Hz, 3H, H-s), 4.42 (s, 6H, H-a), 2.92 (br s, 6H, H-b), 1.63 (s, 9H, H-p), 0.70 – 0.54 (m, 9H, H-
u), 0.53 – 0.36 (m, 9H, H-v). 13C{1H}-NMR (101 MHz, DMSO) δ (ppm): 141.34 (C-n),  
124.11 (C-l), 123.63 (C-d, C-e, C-f), 122.54 (C-m), 117.91 (C-g), 111.05 (C-k), 89.75 (C-q), 89.88 
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18.84 (C-a). FT-IR (ATR) ν (cm-1): 1580 (imine C=N). MP (°C): 275.1 (decomp.). MS (HR-ESI, 
m/z): Calculated: 1488.2580, Found: 1488.2526 (100%, [M + H]+). 
 
6.9.2  Synthesis of the trifluoromethyl substituted Ru(II) cyclometallated complex (20) 
 
Tris(2-(2-phenyl-5-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)ethyl)amine (0.0210 g,  
0.0227 mmol) was dissolved in dry acetonitrile (10 mL). The dichloro(p-cymene)ruthenium(II) 
dimer (0.0222 g, 0.0363 mmol) and sodium acetate (0.0112 g, 0.136 mmol) were then added 
to the reaction vessel. The reaction mixture was then allowed to stir at room temperature for 
24 hours, after which the complete reaction of the limiting reagent was observed upon TLC 
analysis. The reaction mixture was then filtered through Celite ® and the filtrate was collected. 
Excess solvent was removed by rotary evaporation and the resulting crude was re-dissolved 
in DCM (ca. 1 mL). Hexane was subsequently added to the vessel, resulting in a dark yellow 
precipitate (20) which was isolated by suction filtration (0.0479 g, 0.0283 mmol). Yield: 83.3%. 
1H NMR (300 MHz, CDCl3) δ(ppm): 8.30 (d, J = 7.5 Hz, 3H, H-o), 7.99 (m, 3H, H-h), 7.59 – 7.23 
(m, 15H, H-g, H-d, H-l), 6.99 – 6.69 (m, 6H, H-m, H-n), 5.77 (t, 3JHH = 5.7 Hz, 3H, H-q), 5.66 (t, 
3JHH = 5.4 Hz, 3H, H-s), 5.36 – 5.16 (m, 3H, H-r), 5.02 (t, 3JHH = 5.3 Hz, 3H, H-t), 3.67 (s, 6H, H-a), 
2.33 – 2.08 (m, 9H, H-b, H-u), 1.98 (dd, J = 5.4, 2.4 Hz, 9H, H-y), 0.80 (dd, 3JHH = 13.8 Hz, 4JHH = 
8.4 Hz, 9H, H-x), 0.64 (dd, 3JHH = 12.6 Hz, 4JHH =  6.0 Hz, 9H, H-v). 13C{1H}-NMR (151 MHz, CDCl3) 
δ (ppm): 161.05, 142.17, 138.99, 135.47 – 133.80 , 131.85, 130.41, 126.40, 123.88, 121.63, 
116.83 – 114.65 (m), 113.66, 103.81 – 103.05 (m), 101.64 – 100.21 (m), 91.49, 90.30, 83.33, 
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ν (cm-1): 1581 (imine C=N). MS (HR-ESI, m/z): Calculated: 1156.9920, Found: 1157.3227 (40% 
[M + Na+ - C26H25ClF3N2Ru]+). Elemental Analysis for C78H75Cl3F9N7Ru3.3H2O (1745.098  
g.mol-1): Found (%) C, 53.95%; H, 4.31%; N, 6.12%; Calculated (%) C, 53.69%; H, 4.68%; N, 
5.62%. 
6.9.3 Synthesis of the methyl substituted Ru(II) cyclometallated complex (21) 
 
 
Tris(2-(5-methyl-2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl)amine (0.0291 g, 0.0405 mmol) 
was dissolved in anhydrous acetonitrile (8 mL). To this solution,  
dichloro(p-cymene)ruthenium(II) dimer (0.0384 g, 0.0627 mmol), sodium acetate (0.0350 g, 
0.427 mmol) was added and the mixture was stirred at room temperature for 24 hours. After 
TLC analysis (in 100% ethyl acetate) confirmed the complete conversion of the limiting 
reagent to a product spot, the reaction mixture was filtered through Celite®. The filtrate was 
collected, and excess solvent was removed, and the resultant crude was  
re-dissolved in ca. 1 mL DCM and hexane (12 mL) was subsequently added to the solution. 
This resulted in the precipitation of a dark yellow-brownish precipitate (21) which was 
isolated via suction filtration (0.0638 g, 0.0417 mmol). Yield: 88.3%. 1H NMR (300 MHz, 
DMSO) δ (ppm): 8.26 (t, 3JHH  = 6.7 Hz, 3H, H-o), 7.72 (d, 3JHH  = 4.4 Hz, 3H, H-h), 7.61 – 6.73 (m, 
18H, H-n, H-m, H-l, H-g, H-d), 6.11 – 5.88 (m, 3H, H-q), 5.68 (t, 3JHH = 6.0 Hz, 3H, H-s), 5.47 – 
5.27 (m, 3H, H-r), 5.23 – 5.12 (m, 3H, H-t), 4.54 – 4.23 (m, 6H, H-a), 2.84 – 2.74 (m, 6H, H-b), 
2.65 – 2.55 (m, 6H, H-f), 2.42 (d, 3JHH = 3.9 Hz, 3H, H-f), 1.95 – 1.62 (m, 12H, H-y, H-u), 0.72 – 
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146.16, 145.41, 141.62, 141.32, 135.00, 134.15, 134.05, 133.00, 129.25, 128.10, 126.53, 
124.91, 123.93, 122.46, 89.88, 88.88, 82.93, 80.84, 33.43, 30.78, 24.43, 22.38, 21.79, 21.01, 
18.94. FT-IR (ATR) ν (cm-1): 1578 (imine C=N).  MS (HR-ESI, m/z): Calculated: 1493.9860, 
Found: 1494.3296 (70% [M - Cl]+). Elemental Analysis for C78H84Cl3N7Ru3.3H2O 
(1583.184 g.mol-1): Found (%) C, 59.36%; H, 5.82%; N, 5.85%; Calculated (%) C, 59.18%;  
H, 5.73%; N, 6.19%. 
6.10 General synthetic procedure for the cationic N,N-Ru(II)-p-cymene metal complexes 
(22 – 24) 
The ruthenium dimer [Ru(η6-p-PriC6H4Me)Cl2]2 (1.5 eq.) was added to a stirring solution of the 
appropriate 2-pyridyl tris-benzimidazole ligand (1 eq.) in a 1: 1 v/v% solution of DCM: Ethanol. 
The reaction mixture was stirred at room temperature for 24 hours. After TLC analysis 
confirmed the complete reaction of the limiting reagent, the contents of the reaction flask 
were filtered through Celite® and the filtrate was collected. NH4PF6 (4 eq.) was added to the 
filtrate and was allowed to stir for at room temperature for 1 hour.  The DCM was removed 
from the reaction mixture under reduced pressure, which resulted in the precipitation of a 
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6.10.1 Synthesis of the cationic N,N-Ru(II)-p-cymene metal complex (22) 
 
Tris(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)ethyl)amine (0.0354 g, 0.0520 mmol) was reacted 
with dichloro(p-cymene)ruthenium(II) dimer (0.0478 g, 0.0780 mmol) at room temperature 
for 24 hours. Thereafter, NH4PF6 (0.0487 g, 0.299 mmol) was added to the reaction mixture  
and stirred for an additional hour. The desired product (22) was isolated by vacuum filtration 
as a dark yellow solid (0.0435 g, 0.0265 mmol). Yield: 51.1%. 1H NMR (300 MHz, DMSO) δ 
(ppm): 9.69 – 9.55 (m, 3H, H-n), 8.14 – 7.92 (m, 9H, H-m, H-l, H-e), 7.83 – 7.40 (m, 12H, H-k, 
H-d, H-f, H-g), 6.31 (d, 3JHH = 6.0 Hz, 3H, H-p), 6.27 (d, 3JHH = 6.0 Hz, 3H, H-q), 6.13 (d, 3JHH = 5.1 
Hz, 3H, H-r), 6.05 (d, J3JHH = 5.8 Hz, 3H, H-s), 4.60 – 4.23 (m, 6H, H-a), 3.11 – 2.80 (m, 6H, H-b), 
2.42 – 2.24 (m, 3H, H-u), 2.13 (s,9H, H-o), 0.91 – 0.73 (m, 9H, H-v, H-t). 13C{1H}-NMR (101 
MHz, DMSO) δ (ppm): 157.98 (C-n), 148.39 (C-j), 145.46 (C-h), 140.23 (C-i), 127.64 (C-l), 
126.90 (C-c), 126.18 (C-m), 124.69 (C-k), 119.46 (C-e), 119.31 (C-f) ,119.19 (C-g), 112.94 (C-d), 
84.53 (C-p), 83.16(C-q), 80.72 (C-r), 79.64 (C-s), 52.32 (C-b), 44.36 (C-a), 30.96 (C-u), 22.25 (C-
t), 22.13 (C-v), 19.09 (C-o). 31P{1H}-NMR (162 MHz, DMSO) δ (ppm): -144.13 (sep, J = 711.2 
Hz, PF6). FT-IR (ATR) ν (cm-1): 1599 (imine C=N), 1481 (pyridyl C=N).  MP (°C): 225.2 (decomp.). 




Chapter 6                                                  Experimental  
6.10.2 Synthesis of the cationic N,N-Ru(II)-p-cymene metal complex (23) 
 
 
The ruthenium dimer [Ru(η6-p-PriC6H4Me)Cl2]2 (0.0636 g, 0.104 mmol) was reacted with  
tris(2-(2-(pyridin-2-yl)-5-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl)ethyl)amine ( 0.0529 g, 
0.0735 mmol) at room temperature. NH4PF6 (0.0356 g, 0.434 mmol) was added to the 
reaction mixture  and stirred for an additional hour. The desired product (24) was isolated as 
a bright yellow solid (0.0523 g, 0.0293 mmol). Yield: 69.3%. 1H NMR (600 MHz, DMSO) δ 
(ppm): 9.68 – 9.60 (m, 3H, H-o), 8.17 – 7.99 (m, 9H, H-n, H-l and H-d),  7.94 – 7.83 (m, 6H, H-
g and H-h), 7.82 – 7.70 (m, 3H, H-m), 6.37 – 6.26 (m, 6H, H-q and H-s), 6.13 (dd, 3JHH = 13.1 Hz, 
4JHH = 6.5 Hz, 3H, H-r), 6.07 – 5.99 (m, 3H, H-t), 4.68 – 4.32 (m, 6H, H-a),  3.12 – 2.89 (m, 6H, 
H-b), 2.47 – 2.40 (m, 3H, H-u), 2.13 – 2.08 (m, 9H, H-p), 0.91 – 0.83 (m, 18H, H-x and H-v). 
13C{1H}-NMR (151 MHz, DMSO) δ (ppm): 158.13 (C-o), 150.88 (C-j), 144.84 (C-k), 140.91 (C-
d), 139.88 (C-i), 138.47 (C-c), 128.22 (C-m),125.76 (C-e), 123.38 (C-l), 116.14 (C-p-cye), 115.05 
(C-h), 104.51 (C-f), 87.20 (C-q), 84.96 (C-s), 83.41 (C-t), 81.69 (C-r), 52.48 (C-b), 45.20 (C-a), 
31.46 (C-u), 22.31 (C-x), 22.16 (C-v), 19.34 (C-p). 31P{1H}-NMR (162 MHz, DMSO) δ (ppm): -
144.10 (sep, J = 711.1 Hz, PF6). 19F NMR (377 MHz, DMSO) δ (ppm): -59.32 (s, J = 7.4 Hz), -
70.34 (dd, J = 711.0, 13.7 Hz). FT-IR (ATR) ν (cm-1): 1572 (imine C=N), 1490 (pyridyl C=N). MP 
(°C): 231.2 (decomp.). MS (HR-ESI, m/z): Calculated: 1823.0329, Found: 1823.1600 (80%,  
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6.10.3 Synthesis of the cationic N,N-Ru(II)-p-cymene metal complex (24) 
 
The ruthenium dimer [Ru(η6-p-PriC6H4Me)Cl2]2 (0.0382 g, 0.0624 mmol) was reacted with 
tris(2-(5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazol-1-yl)ethyl)amine (0.0292 g, 0.0404 
mmol)in a at room temperature. NH4PF6 (0.0487 g, 0.299 mmol) was addeds to the reaction 
mixture  and stirred for 1 hour. The desired product (23) was isolated as a bright yellow solid 
(0.0597 g, 0.0303 mmol). Yield: 75.0%. 1H NMR (400 MHz, DMSO) δ (ppm): 9.67 – 9.53 (m, 
3H, H-o), 8.10 – 7.87 (m, 6H, H-n and  H-d), 7.71 (ddd, 2JHH = 28.5 Hz, 3JHH = 16.6 Hz, 4JHH = 10.1 
Hz, 6H, H-m and H-l), 7.54 – 7.27 (m, 6H, H-g and H-h), 6.33 (t, 3JHH = 7.3 Hz, 3H, H-q), 6.25 (d, 
3JHH = 6.0 Hz, 3H, H-s), 6.15 (dd, 3JHH = 13.2 Hz, 4JHH = 6.5 Hz, 3H, H-r), 6.04 (d, 3JHH = 5.9 Hz, 3H, 
H-t), 4.53 – 4.17 (m, 6H, H-a), 2.95 (d, 3JHH = 22.9 Hz, 6H, H-b), 2.65 (s, 3H, H-f), 2.62 (s, 3H, H-
y), 2.57 (s, 3H, H-z), 2.39 – 2.26 (m, 3H, H-u), 2.13 (t, 3JHH = 7.1 Hz, 9H, H-p), 0.85 – 0.75 (m, 
18H, H-x and H-v). 13C{1H}-NMR (101 MHz, DMSO) δ (ppm): 157.85 (C-o), 148.01 (C-k), 145.52 
(C-j), 140.59 (C-i), 140.23 (C-n), 136.25 (C-c), 134.35 (C-e), 128.58 (C-h), 127.44 (C-l), 124.31 
(C-d), 118.31 (C-m), 112.51 (C-g), 87.07 (C-s), 84.72 (C-q), 82.96 (C-t), 80.27 (C-r), 55.35 (C-p-
cye), 53.07 (C-p-cye), 52.53 (C-b), 44.24 (C-a), 30.97 (C-u), 22.31 (C-x, C-v), 22.10 (C-f, C-y), 
21.64 (C-z), 19.13 (C-p). 31P{1H}-NMR (162 MHz, DMSO) δ (ppm): -144.16 (sep, J = 711.2 Hz, 
PF6). FT-IR (ATR) ν (cm-1): 1674 (imine C=N), 1464 (pyridyl C=N). MP (°C): 236.8 (decomp.). MS 
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6.10.4  Mononuclear cationic N,N-Ru(II)-p-cymene complex (25) 
 
 1-Ethyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole (0.0784 g, 0.352 mmol) was reacted with 
dichloro(p-cymene)ruthenium(II) dimer (0.107 g, 0.176 mmol) at room temperature for  
24 hours. NH4PF6 (0.0494 g, 0.301 mmol) was added to the reaction mixture  and stirred for  
1 hour. The desired product (22) was isolated by vacuum filtration as a yellow solid (0.0899 g, 
0.141 mmol). Yield: 81.3%. 1H NMR (300 MHz, DMSO) δ(ppm): 9.72 (d, J = 5.1 Hz, 1H, H-i), 
8.52 (d, J = 8.1 Hz, 1H, H-j), 8.36 (t, J = 7.4 Hz, 1H, H-l), 8.13 (dd, J = 6.9, 1.8 Hz, 1H, H-k), 8.09 
– 8.03 (m, 1H, H-b), 7.90 – 7.82 (m, 1H, H-e), 7.75 – 7.62 (m, 2H, H-c, H-d), 6.38 (d, J = 6.1 Hz, 
1H, H-t), 6.33 (d, J = 6.2 Hz, 1H, H-s), 6.21 (d, J = 6.1 Hz, 1H, H-u), 6.11 (d, J = 6.1 Hz, 1H, H-v), 
5.04 – 4.76 (m, 2H, H-m), 2.48 – 2.38 (m, 1H, H-q), 2.24 (s, 3H, H-o), 1.43 (t, J = 7.1 Hz, 3H, H-
n), 0.92 – 0.85 (m, 6H, H-p, H-r). 13C{1H}-NMR (151 MHz, DMSO) (ppm): 157.91 (C-i), 148.30 
(C-h), 145.64 (C-g), 140.86 (C-a), 140.45 (C-k), 135.78 (C-f), 127.70 (C-l), 126.81 (C-c), 126.02 
(C-d), 125.15 (C-j), 119.10 (C-b), 112.88 (C-e), 104.79 (C-x), 103.27 (C-w), 86.90 (C-u), 84.54 
(C-v), 83.16 (C-t), 80.57 (C-s), 40.93 (C-m), 30.97 (C-q), 22.13 (C-r), 22.10 (C-p), 19.10 (C-o), 
15.19 (C-n). MS (HR-ESI, m/z): Calculated: 494.0937, Found: 494.0948 (100% [M – PF6]+). FT-
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6.11 Single crystal X-ray crystallography 
Single crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II DUO 
diffractometer using graphite-monochromated Mo-K radiation ( = 0.71073 Å). Data 
collection was carried out at 173(2) K. Temperature was controlled by an Oxford Cryostream 
cooling system (Oxford Cryostat). Cell refinement and data reduction were performed using 
the program SAINT.5 The data were scaled, and absorption correction performed using 
SADABS.6 The structure was solved by direct methods using SHELXS-976 and refined by full-
matrix least-squares methods based on F2 using SHELXL-20146 and using the graphical 
interface program X-Seed.7 The programs X-Seed and POV-Ray8 were used to prepare 
molecular graphic images. All non-hydrogen atoms were refined anisotropically. All hydrogen 
atoms were placed in idealized positions and refined in riding models with Uiso assigned 1.2 
or 1.5 times Ueq of their parent atoms and the bond distances were constrained in the range 
from 0.95 Å to 0.99 Å. 
6.12 Cell culture  
The human breast adenocarcinoma cell line, MCF-7 (oestrogen-receptor positive, ER+) 
and the human melanoma cell line 501mel were maintained in Roswell Park Memorial 
Institute (RPMI) 1640 medium (Sigma Aldrich, USA). The human breast 
adenocarcinoma cell line, MDA-MB-231 (triple-negative, TNBC) was maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma Aldrich, USA). All culture 
medium was supplemented with 10% heat-inactivated foetal bovine serum (FBS),  
100 U/mL penicillin and 100 μg/mL streptomycin. The non-tumorigenic  human breast 
epithelial MCF-12A cells were maintained in complete media consisting of DMEM/ Ham's F12 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 0.1 
μg/ml cholera toxin (Sigma, St. Louis, MO, USA), 0.5 μg/ml hydrocortisone (Calbiochem, 
Billerica, MA), 10 μg/ml insulin (Novorapid; Novo Nordisk, Copenhagen, Denmark), 20 ng/ml 
epidermal growth factor (Gibco, Life Technologies, Carlsbad, CA), and 5% horse serum 
(Highveld Biological, Lyndhurst, South Africa). Cells were maintained at 37 °C in a 95% air 
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6.13 Cytotoxicity studies  
Cells (MCF-7, MDA-MB-231, 501mel and MCF-12A) were seeded in a 96-well plate at a density 
of 4500 cells/well, 3000 cells/well, 4000 cells/well and 6000 cells/well, respectively, and were 
incubated for either 48 hours (MCF-7, 501mel and MCF-12A cell lines) or  24 hours  
(MDA-MB-231 cell line), respectively, to allow adhesion. After adhesion, the cells were 
treated with either the vehicle (0.1% DMSO) or 10 μM or 20 μM of the test compounds for  
48 hours. The impact of the test compounds on cell viability of cancer cells was determined 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay as 
described in literature.9 The absorbance at 600 nm was determined for each well using a 
spectrophotometer (GloMax® Explorer Multimode Microplate Reader GM3500, Promega) 
and normalized to the RPMI medium (for the MCF-7 cell line) absorbance. For IC50 
(concentration required for 50% viability) determination of selected compounds, cells were 
treated using concentrations 5 – 35 μM. These experiments were performed twice in 
quadruplicate, and the mean cell viability determined using GraphPad Prism V.5.01 software. 
6.14 Solution stability and 5’-GMP binding study 
The solvent stability of the trimetallic complexes (22 – 24) was assessed using UV/ Vis 
spectroscopy, in which 5.00 mg of each complex was dissolved in 1 mL of DMSO. The samples 
were heated and maintained at 37 °C for the duration of sampling. UV/ Vis spectra were 
recorded at 0, 2.5, 5, 24, 26.5 29, 31.5 and 48 hours after the initial sample preparation. The 
UV/ Vis spectra were recorded on a Shimadzu UV-1800 spectrophotometer which was set to 
measure absorbance at wavelengths between 250 and 800 nm. The interaction of the 
complex 22 was investigated by 1H NMR experiments in which 3.00 mg of 22 and 3.00 mg of 
5’-GMP was dissolved in a mixture of 0.5 mL of H2O and 0.5 mL of DMSO (d6). The samples 
were heated and maintained at 37 °C for the duration of the experiment. The 1H NMR spectra 
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